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ABSTRACT 
This thesis is based around examination of three mainstream inhaled drugs 
Formoterol, Budesonide and Beclomethasone for treatment of asthma and 
COPD. 
The areas investigated are these which have been raised in reports and 
studies, where there are concern, for drug use and assessment of their use.
In reporting this work the literature study sets out a brief summary of the 
background and anatomy and physiology of the respiratory system and then 
discuses the mechanism of drug deposition in the lung, as well as the 
methods of studying deposition and pulmonary delivery devices. This section 
includes the basis of asthma and COPD and its treatment. In addition, a short 
section is presented on the role of the pharmacist in improving asthma and 
COPD patient’s care.  
Therefore the thesis is divided into 3 parts based around formoterol, 
budesonide and beclomethasone. 
In the first case the research determines the in-vitro performance of 
formoterol and budesonide in combination therapy. In the initial stage a new 
rapid, robust and sensitive HPLC method was developed and validated for 
the simultaneous assay of formoterol and the two epimers of budesonide
which are pharmacologically active. 
In the second section, the purpose was to evaluate the aerodynamic 
characteristics for a combination of formoterol and the two epimers of 
budesonide at inhalation flow rates of 28.3 and 60 L/min.  The aerodynamic 
characteristics of the emitted dose were measured by an Anderson cascade 
impactor (ACI) and the next generation cascade impactor (NGI). In all 
aerodynamic characterisations, the differences between flow rates 28.3 and 
60 were statistically significant in formoterol, budesonide R and budesonide 
S, while the differences between ACI and NGI at 60 were not statistically 
significant. 
Spacers are commonly used especially for paediatric and elderly patients. 
However, there is considerable discussion about their use and operation. In 
addition, the introduction of the HFAs propellants has led to many changes in 
the drug formulation characteristics. The purpose of the last section is to 
examine the  performance of different types of spacers with different 
beclomethasone pMDIs. Also, it was to examine the hypothesis of whether 
the result of a specific spacer with a given drug/ brand name can be 
extrapolated to other pMDIs or brand names for the same drug. 
The results show that there are different effects on aerodynamic 
characterisation and there are significant differences in the amount of drug 
available for inhalation when different spacers are used as inhalation aids. 
Thus, the study shows that the result from experiments with a combination of 
a spacer and a device cannot be extrapolated to other combination.
KEY WORDS
Dry powder inhalers (DPIs) turbuhaler®, pressurised-metered-dose-inhalers
(pMDIs), breath-operated devices,  hydrofluoroalkane (HFA), 
chlorofluorocarbon (CFC), formoterol, budesonide R, budesonide S, 
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1 LITERATURE REVIEW
ANATOMY AND PHYSIOLOGY OF THE RESPIRATORY SYSTEM
1.1.1 Introduction 
In order to understand the therapeutic application of drugs in this area, it is 
firstly important to discuss the respiratory system. The main function of a 
respiratory system is gas exchange and, at the same time, it plays a role in 
maintaining the acid-base balance by removing CO2. Also, the respiratory 
system participates in phonation by moving the air through the vocal cords 
(2007). The respiratory tract can be classified into two main divisions, the 
upper and lower airways, as shown in Figure 1.1 (Clarke et al., 1984). The 
upper airway consists of the nasal cavity, oral cavity and pharynx. The 
pharynx includes three parts: nasopharynx, oropharynx and laryngopharynx. 
The upper respiratory tract conducts, humidifies and warms air. Also, it takes 
part in swallowing, smelling and speaking. Furthermore, it helps to filter the 
air from large particles by impaction in the nose and oropharynx (Packet, 
2005).   
The lower airway includes the larynx, the trachea, the bronchi and the lungs. 
The main function of the lower airway is conduction of air. The majority of the 
respiratory tract is lined with ciliated cells which brush mucus and debris up 
and out of the tracts. 
1.1.2 Lung
The lungs are paired, cone-shaped organs which take up most of the space 
of the thorax. The right lung is larger than the left lung. The two lungs are 
each covered within a double membrane known as the pleura. The lungs are 
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divided into lobes by invaginations of the pleura, which for most of the time 
are incomplete. The right lung consists of three lobes, while the left lung 
Figure 1.1 Respiratory System: structure detail Source: (AHA, 2006)
consists of two lobes, (see Figure 1.2) (Clark et al., 2005). The upper lobe 
lies in front of the lower lobe. The lobes further separate into the
bronchopulmonary segments by fibrous septa that expand inwards from the 
pleural surface, each of which has a segmental bronchus. The 
bronchopulmonary segment is subdivided into lobules about 1 cm in diameter 
and has a pyramid shape, with the apex facing towards the bronchioles that, 
supply them. Within each lobule a terminal bronchus supplies an acinus, and 
within this structure further separation of the bronchioles finally gives rise to 
the alveoli (Clark et al., 2005).
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Figure 1.2 Anatomy of the lungs showing the different lobes on the right 
and left side Source: (YourSurgery.Com, 2009)
1.1.3 Trachea, bronchi and bronchioles 
The trachea is a tubular structure located close to the sixth cervical vertebra. 
Its length is 10 to 15 cm by 16 to 20 cm width, in a horseshoe shape. The 
trachea, under the junction of the manubrium sternum and the second right 
costal cartilage, branches at the carina into the right and left main bronchi 
(Figure 1.3). In the same way, the right main bronchus branches again into 
the upper lobe and the intermediate bronchus, then each lobe is separated 
into the middle and lower lobe bronchi. On the other hand, the left main 
bronchus is separated into upper and lower lobe bronchi only. Further 
additional divisions occur as each lobar bronchus divides into segmental and 
subsegmental bronchi.  At the end of the terminal bronchioles are the alveoli 
(Clark et al., 2005).
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Figure 1.3 The carina where the trachea branch to the left main and right 
main bronchi Source: Adapted from (Selby, 2002). 
In total, there are about 23 divisions between the trachea and the alveoli, with 
the structure of the tubes changing progressively from the trachea to the 
terminal bronchioles, as shown in Figure 1.4 (Levitzky, 2007).
The structures of the first seven divisions comprise walls of cartilage and 
smooth muscle. Also, the structure has an epithelial lining with cilia and 
goblet cells. In addition, it has mucus-secreting endocrine cells as either 
Kulchitsky or amine precursor and uptake decarboxylation (APUD) containing 
5-hydroxytryptamine (Levitzky, 2007).
The divisions from 16 to 18 have no cartilage. Compared to the first seven
divisions, there is a progressively thinner muscular layer, a single layer of 
ciliated cells, and fewer goblet cells, as well as granulated Clara cells that 
produce a surfactant-like substance.
Literature Review                                                                                           Chapter1
6
Figure 1.4 Schematic representation of airway branching in human lung 
with approximate dimensions Source: (Wiebel, 1984)
The ciliated epithelium is an important defence mechanism. Every cell 
contains around 200 cilia beating at 1000 beats per minute in well controlled 
waves of contraction (Clark et al., 2005). Furthermore the trachea has many 
mechanical and chemical receptors. The muscles of the posterior tracheal 
wall contain slowly adapting pulmonary stretch receptors (SARs) which are 
lung vagal afferents which play a role in controlling breathing pattern and 
airway smooth muscle tone. They also create dilation of the upper airway 
through reducing vagal efferent action. In addition, the rapidly adapting 
irritant receptors are around the tracheal circumference. These can be 
considered as cough receptors. Also, the tracheal circumference contains 
other reflex action such as bronchoconstriction (Rajagopal et al., 2005).
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1.1.4 Pleura
The intact visceral pleura is a thin translucent sheet of mesothelial tissue. It is 
the surface covering of the lung and lines the interlobar fissures. It is 
contiguous at the hilum with the parietal pleura. The parietal pleura is the 
surface which covers the chest wall. A small volume of fluid fills the pleural 
space, ranging from 1 to 20 mL. The factors controling the movement of fluid 
into and out of the pleural space are hydrostatic, colloid osmotic and tissue 
pressure in the parietal and visceral pleura.  The parietal pleura includes 
lymphatics that drain into the internal mammary artery, periaortic arteries, 
and diaphragmatic lymph nodes (Clark et al., 2005, Crapo, 2004). In order to 
prevent lung collapse, the pressure within the pleural space i.e. (between 
visceral and parietal pleural surfaces) is usually maintained at sub-
atmospheric pressure (Warrell, 2003)
1.1.5 Alveoli  
The alveoli are the final branching of the respiratory tree and perform gas 
exchange for the lung. Each lung contains about 300 million alveoli, 
representing a total surface area of approx. 40-80 m2. There are two types of 
alveolar epithelial cells. The predominant type I cells pneumocytes which 
have an extremely attenuated cytoplasm and provide a thin barrier to allow a 
rapid gas exchange. Furthermore, Type I cells are linked together by tight 
junctions that reduce the fluid movements in and out of the alveoli (Bourke, 
2003, Clark et al., 2005). The other is Type II pneumocytes which cover less 
of the epithelial lining and are at the borders of the alveolus and contain 
distinctive lamellar vacuoles, which produce the surfactant. The pores of 
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Kohn are apertures in the alveolar septum, which allow the communication of 
two adjacent alveoli (Clark et al., 2005).
1.1.6 Muscles of respiration 
The muscles of respiration can be classified into two categories. The first is 
the inspiratory muscles which include the diaphragm, t h e  external 
intercostals and the accessory muscles of inspiration. The second category is 
the expiratory muscles which include the abdominal muscles and internal 
intercostal muscles (Levitzky, 2007).  
1.1.6.1 Diaphragm  
This is considered as the primary inspiration muscles, which separate the 
abdominal and the thorax cavities. Nevertheless, its involvement in the 
expiratory is limited. It has a large surface area about 250 cm2 and is dome-
shaped (Levitzky, 2007).  The parietal pleura covers the upper part while the 
peritoneum covers the lower part. The muscle fibres begin from the lower ribs 
and insert into the central tendon (Clark et al., 2005).
1.1.6.2 External intercostals.
Their contraction leads to rib cage enlargement. 
1.1.6.3 Accessory muscles of inspiration
Usually, they do not participate in normal quiet breathing. However, they can 
be involved in high demand situations such as in exercise, in coughing or 
sneezing, or in asthma (Levitzky, 2007). 
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1.1.7 Pulmonary vasculature and lymphatics  
The right ventricle pumps deoxygenated blood to the pulmonary arteries, 
which branch into the pulmonary capillaries, which surround the alveoli, for 
gas and fluid exchange. The pulmonary venules drain into four main 
pulmonary veins carrying the blood back to the left side of the heart.
Lymphatic channels are located in the interstitial space between the alveolar 
cells and the capillary endothelium of the pulmonary arterioles (Clark et al., 
2005).
1.1.8 Physiology of areathing, coughing and sneezing 
During inspiration, the size of the thorax is enlarged by the movement of the 
diaphragm downward and the lower ribs upward and outward. As a 
consequence, the thoracic size will be increased and the pressure within the 
chest decreases. As a result, air moves into the lungs from the atmosphere. 
In contrast, the expiration is a passive process but becomes active during 
exercise, speech, sneezing or coughing and during bronchitis. During 
expiration, t h e  diaphragm and other respiratory muscles relax, thus
decreasing the size of the thorax, pressure then increases and air moves out 
of the chest into the atmosphere, as shown in Figure 1.5 (Selby, 2002)
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Figure 1.5 An illustration for inspiration and expiration Source: (Packet, 
2005). 
1.1.9 Regulation of ventilation
Breathing is spontaneously initiated in the brainstem in the central nervous 
system. It receives its information from mechanoreceptors and 
chemoreceptors. Mechanoreceptors include stretch, irritant and juxtacapillary 
(J) receptors.  Stretch receptors are sensitive to stretch and movement in the 
respiratory system. Irritant receptors react to stimulation of inhaled irritants by 
generating bronchoconstriction and hyperpnoea. These receptors are 
triggered by congestion of pulmonary capillaries and increases in interstitial 
fluid volume, which stimulate rapid, shallow breathing. Chemoreceptors are 
located centrally, peripherally and within the lung tissue. They are also 
sensitive to pH which decreases due to CO2 increase. While peripheral 
chemoreceptors are located in the aortic arch and carotid body, they respond
to hypoxemia (Selby, 2002, Levitzky, 2007). Breathing generally is 
involuntary, however, there is ability for voluntary control such as speech and 
exercise. There are many factors which can depress the respiratory muscle 
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function, including drugs such as benzodiazepines and opioids. Depression 
is also caused through ingestion of ethanol and electrolyte disturbance,
particularly potassium, magnesium and phosphate, systemic acidosis and 
neuromuscular disease (Figure 1.6) (Selby, 2002).
Figure 1.6 Chemical and neurogenic factors in control of ventilation 
Source: (Clark et al., 2005).
Coughing is a defence mechanism to protect the respiratory system by 
expelling secretions and foreign bodies from the lower respiratory tract. It is 
activated by stimulating the rapidly adapting irritant receptors. (Rajagopal et 
al., 2005, Selby, 2002). Cough can be triggered by many causes including 
asthma, postnasal drip, gastroesophageal reflux (GERD), an over-production 
of mucus due to many diseases or an adverse effect of drugs. A typical 
example is the pharmacological group of angiotensin II converting enzyme
inhibitors (ACE-I) (Levitzky, 2007). Another defence mechanism is sneezing, 
activated by stimulating receptors located in the nose and nasopharynx
(Levitzky, 2007).
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LUNG DEPOSITION
1.1.10 Introduction 
For the treatment of respiratory disorder, different types of inhaler are used. 
Drug particles are deposited in the respiratory system depending on the drug
physical and chemical properties and the host’s physiology. 
1.1.11 Aerosol
Stuart, (1973) defined an aerosol as “any system of solid particles or liquid 
droplets of sufficiently small diameter to maintain some stability as 
suspension in air”. It can be classified into monodisperse, where the particles 
have approximately the same size and heterodisperse or polydisperse when
different sizes are involved. But the perfect monodisperse system does not 
exist and it is widely accepted that if an RSD < 20% p/p, an aerosol can be 
called monodisperse (Newman et al., 1982). 
1.1.12 Mechanism of deposition
Although there are many mechanisms for lung deposition only three 
mechanisms are important: inertial impaction, gravitational sedimentation, 
and Brownian diffusion (Figure 1.7) (Newman et al., 1982, Bisgaard et al., 
2002).
1.1.12.1 Inertial Impaction.
The depositions of the majority of drug particles larger than a few μm occur
by inertial impaction. When the particles are heavy or travelling at high 
speed, this may lead to the particles being unable to follow a change in
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direction and as a result they will impact on the airway wall (Bisgaard et al., 
2002, Newman et al., 1982). 
Figure 1.7 Illustration of particle transport onto airway surfaces Source: 
(Bisgaard et al., 2002).
1.1.12.2 Gravitational sedimentation
Particle sedimentation is driven by the gravitational force which is balanced 
by air resistance. Particle sizes range from 0.5 µm to 5 µm and may travel to 
peripheral parts of the lung where they can settle onto smaller airways. This 
can occur during quiet breathing or breath holding (Newman et al., 1982, 
Bisgaard et al., 2002).
1.1.12.3 Brownian diffusion 
For particles smaller than 0.5 µm, Brownian diffusion is the most important 
mechanism of deposition. Here, particles inside the  airways may be 
displaced by the random bombardment of gas molecules which impact on the 
airway walls (Bisgaard et al., 2002, Newman et al., 1982). 
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1.1.12.4 Insignificant mechanisms 
These include electrical charge force, diffusophoresis, thermophoresis and 
simple contact. The particles are deposited by electrical force between the 
particles and the airway walls since pharmaceutical formulations are usually 
not strongly charged. As a result, this mechanism can play an insignificant 
role (Bisgaard et al., 2002). Diffusophoresis is the diffusion of gas from the 
area of high to low concentration. In the same way, thermophoresis is the 
movement of particles from regions of high to low temperature. When the 
particles are larger compared with the airway diameter, simple contact may 
result in deposition of the particle  (Newman et al., 1982, Bisgaard et al., 
2002).  
1.1.13 Summary of mechanism of deposition
In summary, the parameters which most affect particle transport into the 
respiratory tract are the particle size, density, velocity and time. It is a 
common practice to substitute the breathing cycle period for time and flow 
rate for velocity as shown in Table 1.1.   
Table 1.1 Summary of effects of four parameters on deposition 
mechanisms
Mechanism of 
deposition
Particle 
size
Particle 
density 
Breathing 
cycle period 
Flow rate 
Inertial Increase Increase Independent Increase
Gravitational Increase Increase Increase Independent
Brownian diffusion Decrease Independent Increase Independent
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1.1.14 Concept of aerodynamic particle diameter 
The particle size of an aerosol is a crucial physical property affecting the lung 
drug deposition. In addition, aerodynamic diameter rather than geometric 
diameter controls particle deposition in the lungs. The aerodynamic diameter 
is a product of geometric diameter and the square root of density as shown in 
this equation ( pd ), where p is the particle density and d the geometric 
diameter. Furthermore, particles with the same product of ( pd )will exhibit 
identical deposition. On the other hand as a particle becomes more porous, it 
becomes less dense and as result the aerodynamic diameter decreases. 
Accordingly, as density decreases, particles that are larger in geometric 
diameter can deposit deeper into the lung region, because they are smaller in 
aerodynamic diameter (Mandal, 2005)
Bisgaard and co-workers (2002) defined the aerodynamic diameter of 
particles as the diameter of a fictitious sphere of unit density which, under the 
action of gravity, settles with the same velocity as the particles in the
equation.
For spheres at the same velocity, they behave with aerodynamically the 
same deposition, although it should be noted that this concept is limited to 
particles transported by gravitational and inertial transport (Bisgaard et al., 
2002).      
METHODS OF STUDYING DEPOSITION
There are many methods to identify drug deposition in the lung two main 
types:  in-vivo, such as the pharmacokinetic and scintigraphic methods and
in-vitro, methods which have potential value in predicting lung deposition. In 
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addition, they have a major role in the quality control for inhaled formulations, 
examples are dose emission and particle size distribution
The information that is available from these in-vivo and in-vitro studies 
includes total lung dose, extrapulmonary delivery, drug distribution within the 
respiratory system, the relationship between lung dose and therapeutic effect
and the influence of factors such as disease, inhalation technique and intra-
and inter-patient variability (Bisgaard et al., 2002).   
1.1.15 In-vivo methods
1.1.15.1 Introduction 
In many devices, after inhalation, up to 20% of the inhaled dose is delivered 
to the lung and 80% is deposited in the oropharyngeal region and therefore is 
swallowed. The fraction delivered to the lung is cleared either by the 
mucociliary ladder and swallowed within 24 hours or by absorption through 
the very large surface area of the respiratory system into systemic circulation, 
as shown in Figure 1.8 (Chrystyn, 2001). 
Figure 1.8  Fate of inhaled drug
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The drug proportion which reaches the systemic circulation has the potential 
to cause extra-pulmonary adverse effects such as in the case of 
corticosteroid osteoporosis and Cushing's syndrome. However, when the 
corticosteroid is absorbed from the gut it undergoes first-pass metabolism 
and these adverse effects are minimised. Corticosteroids are generally highly 
affected by first-pass metabolism. As an example, budesonide is metabolised 
up to 89%, fluticasone > 99% and  mometasone >99% (O'Connell, 2003).  
In recent years, as the pharmaceutical development of new drugs through 
the inhalation route has evolved, interest in the in-vivo assessment of drug
delivery to the lung has increased. But the results from early studies have
been variable. The selection of subjects has had a major influence on the 
validity of the study results. Also, in the early studies, the number of subjects 
was often relatively low. Added to this, the studies were often conducted 
under well-controlled conditions and these generally do not fully reflect 
normal patient conditions. Therefore, it is possible to suggest that the results 
obtained using well trained, supervised healthy subjects and under ideal 
conditions, do not always reflect the real situation. With actual patients, many 
factors often have a greater impact on the results; these include  airflow 
obstruction and inhalation technique (Bisgaard et al., 2002). As a result, it is 
suggested that considerable caution should be taken when extrapolating data 
from healthy well trained subjects to real patients (Derendorf et al., 2001).
1.1.15.2 Imaging 
There are three main methods for imaging, planar gamma scintigraphy, 
single photon emission computed tomography (SPECT) and positron 
emission tomography (PET). The main advantage of these imaging 
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techniques over others is the ability to localise deposition within the body, 
including extrapulmonary, and the distribution throughout the airways. 
However, there are safety issues all imaging methods which use  
radionucleotides expose the subjects to health risks, more pronounced in 
children than in adults (Bisgaard et al., 2002).
A typical example is where the drug is labelled with a gamma ray-emitting 
isotope and a gamma camera is used to image radiation emitting from the 
radioisotopes. An illustration of the general process used in aerosol imaging 
is summarised in Figure 1.9.
Figure 1.9 Schematic illustration of application of gamma scintigraphy to 
estimate lung deposition Source: Adapted from (Bisgaard et al., 2002).
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In practice, imaging techniques are subject to a number of operational
challenges, including labelling of the drug formulation and interpretation of 
the images produced.
1.1.15.3 Relationship between drug delivery and effect (pharmaco-
dynamics).
It has been shown that a good relationship exists between lung deposition 
and the effects for both bronchodilators and steroids (Derendorf et al., 2001).
In addition, some research has shown a relationship between the pattern of 
deposition and the pharmacodynamic effect, especially for inhaled steroids. 
There has, however, been limited work in this area because the therapeutic 
effect of inhaled steroids needs weeks to be seen. For β2 agonists, the 
reason is that doses are usually administered at close to/or supermaximal 
level and for that reason the doses are close to the plateau of the dose 
response curve (Bisgaard et al., 2002).       
1.1.15.4 Pharmacokinetic methods in use
Pharmacokinetic methods are used to evaluate the lung deposition, although 
they do not generally provide information on the distribution of drug into 
different regions of the lungs (Derendorf et al., 2001). These methods 
estimate total systemic delivery via oral and inhaled routes by means of area 
under the curve (AUC) data or urinary excretion of the drug (Chrystyn, 2001). 
Historically, the pharmacokinetic methods have faced difficulties because of 
small amounts of drug present in the systemic circulation. Today, this 
problem has been overcome by using more sensitive analytical techniques. 
The pharmacokinetic techniques provide the advantage over imaging 
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techniques of avoiding the use of radiation and the drug formulation can be 
used without any modifications. 
As shown in Figure 1.8, in some inhaled drugs, a considerable amount may 
be absorbed from the  gastrointestinal route. Therefore, to distinguish 
between the inhaled and oral absorption routes, many methods have been 
suggested. One example is to block gastrointestinal absorption by activated 
charcoal. The second is to collect the serum or urine sample within a specific 
time, using the time lag between the pulmonary and gastrointestinal 
absorptions. Thirdly,  the amount of drug in serum can be measured directly 
when the gastrointestinal absorption is negligible, e.g. sodium cromoglycate, 
first-pass metabolism is very high, e.g. fluticasone, or by correction for drugs 
of known bioavailability (Derendorf et al., 2001, Bisgaard et al., 2002).
1.1.15.4.1 Identification of total systemic delivery 
In the case where the systemic availability through gastrointestinal absorption 
is negligible, e.g. fluticasone and sodium cromoglycate, all systemic drug 
concentrations represent the absorption from pulmonary routes (Derendorf et 
al., 2001).
1.1.15.4.2 Assessment of pulmonary deposition using activated charcoal.
For drugs where gastrointestinal absorption involvement is considerable, 
block of the absorption is necessary and a solution is to use activated 
charcoal administered together with the drug, as shown in Figure 1.10.
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Figure 1.10 Schematic illustration of the application of pharmacokinetic and 
the charcoal block methods to estimate the lung deposition Source: Adapted
from (Bisgaard et al., 2002)
1.1.15.4.3 Assessment of pulmonary deposition utilizing lag time.
The absorption of most drugs occurs in the small intestine which takes time.  
On the other hand, the absorption from the pulmonary system is rapid and 
this leads to a time lag between the absorptions from the two systems. As a 
result  samples for pulmonary deposition are collected in this lag time 
(Chrystyn, 2001).
1.1.15.4.4 Correction for drugs of known bioavailability 
However many methods have also used activated charcoal to measure 
pulmonary deposition. But as an alternative, some clinical studies have used 
oral bioavailability data. In practice this technique is limited to drugs whose 
oral bioavailability has been well established.    
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1.1.16 In-vitro methods
1.1.16.1 Introduction
In-vitro methods contribute in a major way to drug development in the 
pharmaceutical industry. Alongside this, researchers use in-vitro methods to 
predict the drug deposition in lung. The reason is that pharmacological 
effects of an inhaled drug have a good relation with the amount of drug 
depositing in the lower airways and the deposition pattern, as shown in 
Figure 1.11. In addition, in-vitro methods are used to determine the difference 
between different inhaled formulations (Van Oort, 1995). 
A number of methods have been reported to characterise the particle size of 
a drug. In practice, it is possible to broadly categorise these into two areas: 
optical and inertial methods.
Figure 1.11 Relation between Andersen 8-stage CI cut size at 28.3L/min 
and likely deposition in lung. Source: Adapted from (Mitchell et al., 2000)
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1.1.16.2 Optical methods
Optical methods include microscopy, time-of-flight aerodynamic particle size 
analyser (TOF), light interaction methods optical particle counters (OPCS), 
laser diffractometry (LD) and phase Doppler particle size analysis (PDA). 
These instruments provide rapid techniques and, in addition, the TOF 
instrument measures the aerodynamic particle size. But they do have the
weakness that they are not drug-specific and lack the capability of a direct 
assay for the active pharmaceutical ingredient (API), because they are 
unable to differentiate between drug particles and carrier particles.
1.1.16.3 Inertial impaction method
The inertial cascade impaction is the gold standard to determine the 
aerodynamic characteristic of emitted dose. Generally, it is the method most 
acceptable to the regulatory agencies as it is based on the inertial impaction 
concept. Since the inhaled formulations comprise a combination of API and 
other excipients, it is important to measure the API. The method also uses 
the entire dose as sample and is able to measure the aerodynamic size. The
disadvantage is that it is calibrated only at fixed flow rates. 
The principle of cascade impactor operation is based on inertial impaction. 
Each stage of the impactor contains one or more nozzles or jets through 
which the sample loaded air stream is drawn, directing any particles towards 
the surface of the collection plate for that specific stage, as shown in Figure 
1.12. The determining factor of whether a particular particle impacts on that 
stage is its aerodynamic size. Particles with sufficient inertia will impact on 
that particular stage collection plate, while smaller particles with insufficient 
inertia will remain in the air stream and pass to the next stage. As the jets get
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smaller, the air velocity increases and smaller particles are collected. Finally, 
the smallest particles are collected on an after-filter. However, the influence 
of gravity becomes more observable at low flow rates with impactors (Mitchell 
et al., 2000). 
Figure 1.12 Principle of operation of cascade impactors Source: (Copley, 
2007).
The collection efficiency curve is the most important characteristic of each 
stage of a cascade impactor which is a measure of the percentage of 
particles of a specific size collected at the impaction plate of that stage. In an 
ideal situation, this curve should have a sharp straight line between the size 
of particles collected and those which are not. In the real world, however, this 
curve has an `S' shape as shown in Figure 1.13 (Copley, 2008a). 
Inertial impaction methods are divided into cascade impactors and impingers.
The difference between the two methods is that the collection substrate is a 
solid surface, whereas impingers use a liquid to collect the particles. The 
impingers are calibrated at 60L/min and are easy to use (Van Oort, 1995).  
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Figure 1.13 Impactor stage efficiencies at 60 L/Min. Source: (Copley, 2007).
One of the main problems with cascade impactors is carry-over of particles to 
smaller collection stages. This can take place due to re-entrainment into the 
airstream or due to particle bounce at the collection stages. In order to 
minimise  these effects, suitable coating of the collection stages may be 
necessary, especially, in the case of DPIs and certain MDIs (Mitchell et al., 
2000). 
It is also important to note that particle size analysis by cascade impactor can 
be interrupted by many factors which can affect the accuracy of the results as 
summarised in Table 1.2.
The European Pharmacopoeia (PhEuro) lists the following apparatus for
aerodynamic assessment of fine particles in both MDIs and DPIs:
 Apparatus A: Single-Stage Glass Impinger (SSGI)
 Apparatus C: Multi-Stage Liquid Impinger (MSLI)
 Apparatus D: Andersen Cascade Impactor (ACI)
 Apparatus E: Next Generation Impactor (NGI)
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Methods for Apparatus A are also specified for nebulisers (PhEuro, 2007). 
On the other hand, the United States Pharmacopeia lists six impactors which 
can be used for aerodynamic size distribution (USP, 2005) :
 Apparatus 1 for MDIs: ACI.
 Apparatus 2 for DPIs: MMI.
 Apparatus 3 for DPIs: ACI + Preseparator.
 Apparatus 4 for DPIs: MSLI.
 Apparatus 5 for DPIs: NGI + Preseparator.
 Apparatus 6 for MDIs: NGI.
Table 1.2 Potential causes of error in Impactor-based particle size 
measurements Impactor-related issues Source: (Mitchell et al., 2000)
Factor Potential Influence on Particle Size 
Distribution Accuracy
Correct location of collection surfaces High
Proper accounting for collection surfaces 
and back-up filter
High
Assertion of stage order High
Air leakage into impactor Low, unless leak is massive
Poor seal and orientation between 
induction port/impactor or between
induction port/pre-separator/impactor
Low, unless leak is massive or 
components grossly out of
alignment
Inadequate liquid volume or liquid missing 
from collection surfaces MSLI
More data needed to quantify risk 
of error
Flow rate High
Timer operation of solenoid valve (DPI-
Testing)
High
Cleanliness of stage nozzles More data needed to quantify risk 
of bias
Worn/corroded stage nozzles More data needed to quantify risk 
of bias
Electrostatic effects High, when non-metallic 
components are used
Use of collection surface coating High
Environmental factors (barometric 
pressure, relative humidity)
Potentially high, depending more 
on formulation e.g. hygroscopic 
particles than impactor
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Only three impactors, the MSLI, ACI and NGI, appear in both the PhEuro and 
USP. Both Pharmacopoeias state test procedures for all three impactors for 
use with both MDIs and DPIs. Nevertheless, the MSLI is restricted to DPIs 
only in USP (2005). 
1.1.16.3.1 SSGI (Single-Stage Glass Impinger).
Because it is a simple, easy to use and assemble, and an inexpensive quality 
control tool, the SSGI has been retained as Apparatus A in the PhEuro and is 
particular recommended for routine quality control applications. One 
advantage is that it is made of glass and therefore not affected by corrosion 
in the same way as conventional metallic impactors. The SSGI operates on 
the principle of impingement to categorise the dose emitted into non-
respirable and respirable dose. Stage 1 represents the non-respirable 
fraction and consists of the back of the glass throat and the upper 
impingement chamber, as shown in Figure 1. 14. The respirable dose is 
collected in the lower impingement chamber known as Stage 2. Its usage is 
restricted to the evaluation of nebulisers, MDIs and DPIs 
The impinger is calibrated at a flow rate of 60 L/min. The particle cut-off size 
is 6.4 microns and particles < 6.4 um pass into the lower impingement 
chamber.
1.1.16.3.2 MSLI (multi-stage liquid impinger)
The MSLI is listed as Apparatus 4 in the USP and as Apparatus C in the 
PhEuro. It consists of 4 impaction stages and a final filter stage. The MSLI is 
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used for measuring the aerodynamic size distribution of DPIs, in the USP
(2005) and for MDIs, DPIs and nebulisers, in the PhEuro (2007).
Figure 1.14 Single-stage glass impinger and dimensions in mm tolerances 
± 1 mm unless otherwise prescribed. Source: adapted from (Copley, 2007).
The MSLI is manufactured in three different materials aluminium, 316 
stainless steel or titanium. One advantage is that it is designed to help 
reduce the  problem of re-entrainment of powder associated with the 
conventional impactors such as the ACI, NGI and the MMI. This is because 
the collection stages of the MSLI are kept moist (PhEuro, 2007).
The MSLI requires an induction port to connect it to the inhaler, as shown in 
Figure 1.15, but does not require a pre-separator to use it with DPIs. 
Nevertheless, when operating with a DPI, the configuration of the 8-stage 
impactor specified in the Pharmacopoeia should be followed. The MSLI can 
be used throughout the range 30-100 L/min
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Figure 1.15 A- Schematic of MSLI.  B- MSLI (Aluminium, 316 Stainless 
Steel and Titanium) Source: adapted from (Copley, 2007).
1.1.16.3.3 ACI (Andersen cascade impactor)
The ACI is one of t he  most commonly used impactors within the 
pharmaceutical industry for evaluating inhaled products. It was originally 
developed as a bacteriological air sampler and then adopted by the 
pharmaceutical industry for characterising size distributions of aerosol 
products. The ACI is listed as Apparatus 1 for testing MDI products and 
Apparatus 3 for testing DPI products in the USP and also listed as Apparatus 
D in the PhEuro.. The ACI consists of eight stages together with a final filter. 
The stages are clamped together and sealed with O-rings. It can be 
manufactured from aluminium, 316 stainless steel and also titanium (see 
Figure 1.16).
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Figure 1.16 A- ACI (Aluminium, 316 stainless steel and titanium) and B-
Schematic of ACI Source: Adapted from (Copley, 2007).
The ACI has many advantages which may be summarised as follows:
 Well established and accepted by the regulatory authorities.
 Total of 8 individual stages ranging between 0.4 and 9 m.
 Constructed from three different materials (aluminium, 316 stainless steel 
or titanium) which give a variety of choice of construction.
 Can be operated at different flow rates, 28.3, 60 and 90 L/min, using a 
conversion kit for high flow rate testing. 
 Low resistance at high flow rates when Stages 6 & 7 are removed.
 Small space needed for operation.
 Stacked design allows damaged stages to be removed and replaced if 
necessary.
In order to prevent stages overloading, such as in the case of DPI testing, it 
is  necessary to add a preseparator, shown in Figure 1.17, which traps the 
non-inhalable particles (Mitchell et al., 2003). 
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Figure 1.17 Pre-separator for Andersen Cascade Impactor. Source:
adapted from (Copley, 2007).
1.1.16.3.4 MMI (Marple Miller cascade impactor)
Figure 1.18 A-Marple Miller Impactor, B- Schematic of Marple Miller 
impactor Source: adapted from (Copley, 2007)
The MMI is listed as Apparatus 2 in the USP, but, is not listed in the PhEuro.
MMI is a five-stage cascade impactor used for testing DPIs, as shown in 
Figure 1.18. MMI consists of five impaction stages and is calibrated to work 
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in the range 60-90 L/min. Each stage has a detachable collection cup to help 
in the fast and easy recovery of the drug particles. A paper filter is also 
placed after Stage 5. It is possible to remove the collection cups after each 
test without dismantling the impactor. Since the MMI has very low inter-stage 
losses, it is not necessary to regularly clean the inter-stage passageways 
between tests (USP, 2005).
1.1.16.3.5 NGI (Next Generation Impactor)
The NGI was released in 2000 and its monographs were later incorporated 
into the USP as Apparatus 5 for DPIs and Apparatus 6 for MDIs; it is also 
incorporated in PhEuro as Apparatus E. The NGI was designed specifically 
for pharmaceutical inhalers. It consists of three main parts: the base frame 
holding the sampling cup tray, the seal body holding the nozzles and the lid 
containing the inter-stage passageways, as illustrated in Figure 1.19. It has 
seven stages and operates in the range between 30 and 100 L/min. The NGI 
has many areas in which it is better for inhaler testing. One of its features is
that particles are collected on cups held in a tray, which can be removed 
easily, facilitating quick sample handling. Another unique feature is the 
presence of a micro-orifice collector (MOC) because it captures extremely 
small particles and in most cases, this eliminates the need for a final filter. 
Also, as it has low inter-stage losses, the captured particles in the MOC cup 
can be analysed in the same manner as the particles collected in the other 
impactor stage cups. This aspect is important for automation and particles 
are more easily dissolved from the collecting surface than from the fibres 
network in a filter. In addition, the NGI is 50% more productive than the ACI 
(Marple et al., 2003). 
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Figure 1.19 A- Next Generation Impactor B- Schematic of Next Generation 
Impactor Source: adapted from (Copley, 2007, UK-DoH., 2008)
1.1.16.4 Summary
Beyond their value in predicting lung deposition, in-vitro studies have an 
important role in quality control and product development. 
Inertial impactors are devices commonly used for the testing of aerosol 
particles. Their principle of operation is simple: an aerosol stream passes
through a nozzle and impinges upon a collection plate. Particles in the 
aerosol stream with large enough inertia will impact upon the collection plate,
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while finer particles with less momentum follow the stream and pass the plate 
without impacting. 
Inertial impactors methods are, however, time consuming. In contrast, optical 
methods, including TOF analysis, offer rapid measurements, making them 
attractive. On the other hand, only inertial impactor methods provide direct 
measure of the mass of API. Furthermore, this technique provides a direct 
assay of the aerodynamic diameter of most significance in predicting likely 
deposition in the airways. TOF-analysis also determines aerodynamic size; 
however, it lacks specificity since it measures the total component of drug 
rather than API mass. 
Finally, it is important to keep in mind that the primary aim of in-vitro methods 
is a relative measure of product performance rather than an absolute 
measure, since the aim of these methods is to ensure that the product tested 
is equivalent to the product clinically tested and proven.  
PULMONARY DELIVERY DEVICES
1.1.17 Introduction
Inhaled drug products are very popular for drug delivery through the lung or 
nasal mucosa for local or systemic therapy.
Inhaled bronchodilators and corticosteroids are the mainstay for treatment of
asthma and COPD. The inhaled drug devices are classified into three main 
categories: nebuliser, pMDI or DPI. Most clinical evidence shows that any of 
these devices will work for most situations and this includes the patient case 
where the patient is exacerbated or stable (Geller, 2005). 
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1.1.18 pMDIs (pressurised metered dose inhalers)
1.1.18.1 Introduction
The pMDI was first introduced in the first half of the 20th century and has 
become the most popular dosage form for the delivery of drug to the 
respiratory tract. It consist of propellants, drug formulation, a metering valve 
and actuator, as illustrated in Figure 1.20, all of which play roles in particle 
size, spray formation and, as a result, in determining drug delivery to the 
lungs. At first, they were known as metered dose inhaler (MDI), but the term 
“pMDI” has become more popular, in order to differentiate them from other 
non-pressurised metered dose devices such as DPIs and other multi-dose 
devices (Crowder et al., 2001).
Figure 1.20 A- Schematic of the pMDI. B- The component parts of the 
pMDI. Source: adapted from (Newman, 2005).
1.1.18.2 Container 
Aluminium, stainless steel and glass are used to manufacture the pMDI 
container or canister. An aluminium canister is preferred, because it is light, 
robust, light-proof and inexpensive. However, occasionally, due to their 
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nature glass containers may be preferred for some solution formulations. 
Usually, the internal surfaces are coated to avoid adhesion of drug particles 
and chemical degradation of drug. Also, the container can withstand the high 
pressure generated by the propellants and It must be made of inert materials 
for drug delivery (Crowder et al., 2001).
1.1.18.3 Propellants
One of the most vital components of a pMDI is its propellant. The propellant 
creates the force to generate the aerosol cloud. In pMDIs, it is typically 
liquefied compressed gas, which is in gaseous form at atmospheric pressure, 
and becomes liquid when compressed. They have to be non-toxic, non-
flammable, chemically stable, with constant vapour pressures throughout the 
product’s life, and compatible with drugs.
Chlorofluorocarbons (CFCs) met these requirements and pMDIs have 
traditionally used CFC as the major propellant. A key property of CFCs was
that within a closed canister they formed a 2-phase liquid and saturated 
vapour system. As a result, a dynamic equilibrium existed between liquid and 
vapour phases, providing a constant vapour pressure regardless of whether 
the canister is full or nearly empty (Newman, 2005).
However, pMDIs containing CFCs have recently been replaced because of 
the effect of CFCs on the ozone layer in the stratosphere and the use of 
CFCs was banned under international agreement. 
As result, hydrofluoroalkanes (HFA) have replaced CFCs. Formulations 
containing HFAs, either tetrafluoroethane (HFA-134a) or heptafluoropropane
(HFA-227), are usually used in formulations. In practice, however, despite the 
similarities with the CFCs, many challenges in substituting HFAs for CFCs in 
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pMDIs have been recognised.  These include compatibility of the pMDI 
components, such as valves and container walls, with HFAs. 
In addition, it has been found that HFAs are not completely eco-friendly and 
are greenhouse gases. It is therefore predicted that this may lead to future 
restrictions on their use, even though their involvement in global warming is 
expected to be low. As a result, many alternatives have been suggested as 
propellants, such as dimethyl ether, propane or butane. But propane and 
butane are likely to be excluded because of their flammability.
Overall, pMDIs which use CFC-free propellants have continued to challenge
formulation scientists to develop efficient pMDI devices (Crowder et al., 
2001).
1.1.18.4 Drug formulation
Suspensions or solutions are usually used as vehicles for drugs. Since CFCs 
are non-polar liquids in which many drugs have low solubility and generally
good chemical stability, suspensions have often been used in CFC_pMDIs.
In order to reduce particle aggregation and lubricate the valve mechanism,
surfactants have regularly been used in them. But, with the change to the 
HFAs system, solubility has become a problem. As a result, co-solvents have
been used, such as ethanol, a low-volatility co-solvent in HFA formulations,
which initially solubilises surfactants which had previously been approved for 
use in CFC formulations. More recently, ethanol has been used to solubilise 
the drug itself in inhaled formulation (Crowder et al., 2001, Newman, 2005). 
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1.1.18.5 Metering valve
This is incorporated into the container as it is an important component of the 
pMDI as its main purpose is to ensure the uniformity of the delivered doses. 
Usually, the metering valve incorporates a metering chamber which holds a 
single dose, with a volume ranging from 25 uL to 100 uL. In some cases the 
valve is surrounded by a large reservoir which is able to hold the next dose. 
Figure 1.21 A. metering valve in resting state. B. compressed valve Source 
: adapted from (Bisgaard et al., 2002).
Figure 1.21A shows the metering valve in the resting state; the channel 
between the body of the canister and the metering tank is opened, as a result 
the metering tank fills from the canister. As the pMDI is activated by 
compressing the valve stem, this channel then closes and another channel 
connecting the metering chamber to the atmosphere opens and the content 
of the metering tank empties, as shown in Figure 1.21B. When the 
compression is relieved, the valve retains its position, allowing the metering 
tank to be refilled (Figure 1.21 A). 
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Compatibility of other pMDI components, such as propellants, excipients and 
solvents with the parts of the valve, significantly influences pMDI 
performance. However, because of solubility in CFCs, elastomeric seals can 
swell and this has been found to sometimes cause suboptimal operation of 
the device. In contrast, the seals are less soluble in HFAs, and new 
elastomeric systems have been developed for use with them. The minimum 
concentrations of extractable and leachable in the formulation should be 
borne in mind when the valve elastomers are selected. Many new valves 
show good performance without the surfactant to lubricate the valve stem 
(Crowder et al., 2001). 
1.1.18.6 Actuator
The actuator is usually made from plastic and its design is a factor in 
determining the aerosol particle size, particularly the nozzle diameter, which 
ranges between 0.14 mm and 0.6 mm (Newman, 2005). Its effect on particle 
size has been studied using gamma scintigraphy, with a formulation 
containing fenoterol and ipratropium bromide. Newman reported mean lung 
deposition measured and a step-wise increase from 12.8% of emitted dose to 
15.2% 18.0% as a resulted of decreasing the nozzle diameter from 0.3 mm to 
.25 mm to 0.2 mm. Nevertheless, the 0.2 mm nozzle produced the highest 
deposition in the mouthpiece. Also, the length of the actuator nozzle path has 
influence on particle size (Newman et al., 1999).
1.1.18.7 Breath-actuated pMDIs
Patient co-ordination of actuation with inhalation can be a problem with
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pMDIs, especially in certain groups of patients such as the young, elderly or 
chronically ill. One solution is to use breath-actuated pMDIs which may 
overcome this problem, since they are sensitive to patient inhalation through 
the device and fire the inhaler simultaneously with their inhalation. The 
Autohaler, Easibreathe, K-Haler, MD Turbo, Xcelovent, Smartmist are 
example of such devices and there are several more under development. 
Another mechanism to overcome this problem is the addition of a spacer 
device or integrated spacer mouthpiece, and example of these are the
Aerohaler, Azmacort pMDI, and Spacehaler (Crowder et al., 2001).
1.1.18.8 Summary
The pMDIs have been used for more than 50 years and are well accepted by 
most patients as a method of administering inhaled medications. 
Conventional pMDIs consist of a container, a metering valve, a drug 
formulation and a propellant. Because of these points, pMDIs provide many 
advantages for the patients and these are listed in Table 1.3, along with 
some of the disadvantages.
Table 1.3 Advantages and disadvantages of conventional pMDIs
Advantages Disadvantages
Convenience, availability to use Drug delivery significantly affected
by inhalation techniqueCost 
Number of doses may reach 100 Propellants  needs
High pressure protects contents 
against bacteria and moisture. 
High velocity of particles leads to 
high oropharyngeal deposition
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1.1.19 DPIs (dry powder inhalers)
1.1.19.1 Introduction
The DPIs can be defined as devices through which an active drug is 
delivered to produce a local or systemic action by the pulmonary route using 
a dry powder formulation (Islam et al., 2008). At the end of the 1960s, the 
first DPI was introduced. The major reason was linked to one drug and the 
need for an increased dose of sodium cromoglycate 20 mg, where the pMDI
system was not capable of delivering such a dose, The Spinhaler® (Aventis) 
was therefore developed to deliver the drug (Chrystyn, 2007).
Successful delivery of drugs deep into the airways relies on the integration 
between powder formulations and the device performance. Most DPI 
formulations comprise a micronised drug, mixed with larger carrier particles, 
which decrease aggregation, improve flow and assist in dispersion.  Apart 
from ability to deliver larger dose, the DPIs have the advantage that they 
require minimum or no coordination of actuation and inhalation as DPIs are 
only activated while the patient inhales. Also, because the formulation for 
DPIs is one-phase, as a solid particle mixture, they are more stable than 
pMDIs. But the emitted dose depends on the patient’s inspiratory airflow 
(Chrystyn, 2007).
1.1.19.2 Principle of Operation
As indicated above, the majority of DPIs are comprised of micronised drug 
blended with larger carrier particles; this stops aggregation and improves 
airflow through the device. When the patient inhales through the DPI, the 
airflow will create turbulence and shear; the introduction of air into the 
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powder bed causes the static powder blend to be fluidised to enter the 
patient’s airways. In the airways, the particles of drug separate from the 
carrier and continue to the smaller airways, while the larger carrier particles 
deposit in the oropharynx. However, one main disadvantage of DPIs is the 
low deposition efficiency. This may be partially explained by insufficient
drug/carrier separation phased with DPIs, as shown in Figure 1.22. Another 
concern is dose uniformity.  
Figure 1.22   Principle of dry powder inhaler design. Source: adapted from 
(Telko et al., 2005).
A variety of dispersion mechanisms have been used for DPIs. The 
dominating mechanism is breath-activated, where the aerosol is generated 
by the patient’s inhalation. On the other hand, quite a few power-assisted 
devices such as vibratory, impact force and pneumatic have recently been 
developed or are currently under development. In addition, it may be possible 
to increase the delivery efficiency and reproducibility, if the shear and 
turbulence could be standardised by using a dispersion mechanism which 
omits the influence of the patient’s breath (Telko et al., 2005). 
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1.1.19.3 Types of DPI delivery devices
DPI devices are classified by dose type into three categories single-unit 
dose, multi-unit dose and multi-dose reservoirs. Table 1.4 gives examples of 
DPIs in the three categories
1.1.19.3.1 Single-unit dose devices
In a single-unit dose device, the drug is supplied in single gelatine capsules, 
which are then loaded into the inhaler for a single dose and removed after 
use. 
1.1.19.3.2 Multi-unit dose devices
The multi-unit dose device which can hold multiple doses without needing to 
reload. Each single dose is pre-metered, individually sealed and discharged.  
Generally, the packaging consists of replaceable disks or cartridges or strips 
of foil-polymer blister packaging that might or might not be refilled. The multi-
unit dose device system has the advantage of the doses being protected 
from environmental conditions and dose uniformity is enhanced.  
1.1.19.3.3 Multi-dose reservoir devices
The multi-dose reservoir device stores the bulk supply of drug and has a built 
in meter to measure each single dose from the bulk with each actuation. The 
recently released devices of this type try to overcome the common issues
such as decreasing the effect of flow rate dependent on dose emission and 
the effect of moisture which enters into the device reservoir from the patient 
during exhalation or from environmental humidity.
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Table 1.4 Current DPI devices available in market Source: adapted from 
(Islam et al., 2008)
Device DPI 
type
Delivery 
method
Drugs Diseases
First generation: breath-actuated single unit dose
Spinhaler SD Capsule SC Asthma
Rotahaler SD Capsule SS BDP SS + BDP Asthma
Inhalator SD Capsule FN Asthma
Cyclohaler SD Capsule SS BDP IB BUD Asthma
Handihaler SD Capsule TT COPD
Aerolizer SD Capsule FR Asthma
FlowCaps SD Capsule NA Asthma
TwinCaps SD Capsule NI Influenza
Second generation: breath-actuated multi-unit, multiple dose
Turbohaler MD Reservoir SS TS BUD Asthma
Diskhaler MD Blister 
package
SX BDP FP ZN Asthma, Influenza
Diskus/
Accuhaler
MD Strip pack SS SX FP SX+ FP Asthma
Aerohaler MD NA IB Asthma
Easyhaler MD Reservoir SS BDP Asthma
Ultrahaler MD Reservoir NA NA
Pulvinal MD Reservoir SS BDP Asthma
Novolizer MD Reservoir 
cartridge
BUD Asthma, COPD
MAGhaler MD Reservoir SS Asthma
Taifun MD Reservoir SS Asthma
Eclipse MD Capsule SC Asthma
Clickhaler MD Reservoir SS BDP Asthma
Asmanex 
Twisthaler
MD Reservoir MF Asthma
Third generation: active device
Exubera SD Blister Insulin Diabetic
Airmax MD Reservoir FR BUD Asthma COPD
MF: mometasone furoate, SS: salbutamol sulphate, SX: salmeterol xinafoate, 
FP: fluticasone propionate, BUD: budesonide, TS: terbutaline sulphate, FN: 
fenoterol, FR: formoterol, IB: ipratopium bromide, SC: sodium cromoglycate, 
BDP: beclomethasone dipropinate.NI: Neuraminidase inhibitors, ZN: 
zanamivir, SC: sodium chromoglycate, TT: Tiotropium, SD: Single dose, MD: 
Multi-dose
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1.1.20 Nebulisers
Nebulisers are devices which can generate aerosol droplets from a liquid and
produce a  respirable cloud for inhalation (Crowder et al., 2001). Nebulisers 
fall into two categories: jet nebuliser and ultrasonic nebuliser. 
1.1.21 Spacer devices 
Due to the high speed of production of the aerosol cloud after actuation, the 
coordination of actuation and patient inhalation can be very hard. As a result, 
patient oro-pharyngeal deposition can be high and there is often a big 
variation in the lung dose. In order to ease the coordination problem and
reduce the oro-pharyngeal deposition and lung dose variation, which occurs 
especially in children and the elderly, spacers and holding chambers have 
been introduced, as shown in Figure 1.23.
Figure 1.23 Choice of delivery device in children of different ages Source: 
(Bisgaard et al., 2002).
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Spacers were designed to be used with pMDIs, although they have also been 
used with DPIs (Everard et al., 1996, Matida et al., 2004). The spacer
classifies the particles according to their size and large particles are
deposited within the spacer rather than in the patient’s mouth. This may 
become very useful in DPIs in which side effects may occur from the 
deposition of large particles and agglomerates in the mouth, as occurs in 
pMDIs (Daniher et al., 2008). In clinical practice, the term spacer and holding 
chamber are often used interchangeably. But the spacers are an extension of 
the pMDI actuator, allowing the aerosol to decelerate and mature, whereas 
holding chambers are valved spacers allowing the patient to breathe the 
cloud of aerosol in the chamber. There are various designs, including large 
and small volume spacers and tube extensions (see Table 1.5 and Figure 
1.25). Especially in young children, it is critical to know the requirement for 
optimal drug delivery from spacers, because their breathing can be shallow 
and irregular, although this may be true for many other groups of patients. 
Over the years, more knowledge and understanding of the technical 
specification for spacers has developed (Bisgaard et al., 2002).
Figure 1.24 Schematic of spacer Source: (ASC, 2008).
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Table 1.5 Spacers available in UK source (BNF, 2008)
: Spacer Description  
Able Spacer® Small-volume device
AeroChamber® Plus Universal medium-volume device.
Babyhaler®
For paediatric use only. To be used with Flixotide®,
Seretide®, Serevent®, and Ventolin® inhalers.
Nebuchamber® to used with Pulmicort®
Optichamber® Universal device.
PARI Vortex Spacer® Universal medium-volume device.
Pocket Chamber® Universal small-volume device.
Volumatic®
Large-volume device. To be used with Clenil 
Modulite®, Flixotide®, Seretide®, Serevent®, and 
Ventolin® inhalers.
Figure 1.25 Spacers available in UK.
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1.1.22 Summary 
Aerosol therapy was introduced in the 1950s and became the cornerstone of 
management of obstructive airway diseases. Large doses can be delivered 
by nebulisers and small doses by pMDI and DPIs. The main disadvantage of 
inhaler devices is that they are inefficient as delivery systems to the lung and 
2-30% of total emitted dose is delivered, as shown in Table 1.6.
pMDIs continue to be the most popular delivery system because of their 
safety and efficacy profile in delivering drugs to the airways, but they are 
associated with high oro-pharyngeal deposition and poor coordination of 
actuation and inhalation because the emitted dose leaves the canister at high 
velocity. 
However, pMDIs including a spacer have become as effective as nebulisers 
but are also more convenient for patients to use. The use of spacers may 
also help to increase the delivered dose to the lung and decrease oro-
pharyngeal deposition and eye and skin contact.
But in operation many patients prefer DPI devices to pMDIs because they are 
easier to use. However, in practice, as DPIs are flow-dependent and in cases 
where patients have severe airway disease, there can be frequent pulmonary 
exacerbations or, if used in children, difficulty in achieving suitable flow rate.
A variety of DPI devices are currently available for obstructive disease with 
an emphasis on optimised drug delivery with low variability. The DPIs also 
have an advantage of a solid-state phase which makes them more stable 
products. They also have the advantage of delivery as a single-use 
disposable unit or multiple-dose refillable systems. A further advantage is 
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that they are activated by the patient’s inspiration and therefore can require a 
minimum of or no coordination.
Table 1.6 Characteristics of aerosol inhalers. Source: (Khilnani et al., 
2008)
pMDI DPI Nebuliser
Technique of generation 
of aerosol
Propellant 
based
Patient 
driven
Bernoulli’s principle
piezoelectric crystal
Particle size 1-10 μ 1-10 μ Variable
Drug deposition 5-10% 9-30% 2-10%
Oro-pharyngeal 
deposition
Significant Variable Insignificant
Patient coordination Required Not 
applicable
Not required
Breath hold Required Not 
required
Not required
Patient generation of 
flow
Not 
required
Required Not required
Amount of drug Small 
doses 
Small 
doses
Large doses 
possible
Contamination No No Possible
Use for chronic therapy Yes Yes Rarely
Use for emergency 
management
No No Yes
Use for intubated 
patients
Preferred No Second choice
Cost Cheap Cheap Expensive
pMDI = pressurised metered dose inhaler, DPI = dry powder inhaler
If all these points are taken into account together, in hospital departments / 
health centres it is often the case that nebulisers are the preferred choice in 
emergency departments and intensive care units.
As regards the commercially produced inhalers, it is the case that many 
inhaled drugs may be presented in more than one inhaler system or 
formulation. So it is important that the health-caregiver is aware that the drug 
delivery and deposition may be influenced by the drug formulation, the 
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propellant or the device. It may also be the case that a familiar drug in a new 
formulation or device may not be equal to the old formulation.
Many reported clinical studies have examined the performance of inhaler 
devices and concluded that none of the devices shows any clinicaly 
superiority. Therefore it is suggested that the selection of a device should be 
guided by a number of other factors, including patient preference, cost and 
patient age (Telko et al., 2005). 
ASTHMA
On of the major uses of inhaled devices is to relieve and treat the asthmatic 
patients. For this reason, background information is given below to assist in 
the kind of issues associated with inhalers and disease states associated 
with drugs at the centre of this thesis.    
1.1.23 Introduction 
Asthma is defined as a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role. This inflammatory disorder is 
associated with hyper-responsiveness to a variety of stimuli which leads to 
recurrent episodes of wheezing, breathlessness, chest tightness and cough, 
particularly at night and in the early morning. These episodes are generally 
associated with widespread but variable airflow obstruction which is often 
reversible, either spontaneously or with treatment (Bryne et al., 2006). 
1.1.24 Aetiology / Pathophysiology
There are two predominant types of asthma: extrinsic, allergic or atopic 
asthma and intrinsic or non-allergic asthma (Koda-Kimble, 2008, Helms, 
2006).
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Several factors may contribute to increase the susceptibility of the 
development of the disease in liable patients. These include small size at 
birth, viral infections, diet, exposure to smoking (either passive or active), and 
environmental pollutants (see Figure 1.26).
Figure 1.26 Causes and triggers of asthma. RSV (respiratory syncytial 
virus), NSAIDs, (non-steroidal anti-inflammatory drugs) Source: (Clark et al., 
2005).
The pathophysiology of asthma is characterised by a complex interaction 
between inflammatory cells and mediators. Mast cells, eosinophils, 
neutrophils, T-lymphocytes and epithelial cells play important roles in the 
pathophysiology of asthma. Figure 1.27 illustrates the mechanism of cells 
and mediators associated with airway inflammation. 
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Figure 1.27 Pathophysiologic findings in asthmatic airway. MCP-1, 
monocyte chemotactic protein; MIP-1, macrophage inflammatory protein;
GM-CSF granulocyte-macrophage colony-stimulating factor Source: (Koda-
Kimble, 2008).
When an antigen is inhaled the mast cells and TH2 are activated. This leads 
to release of mediators of inflammation such as leukotrienes and histamine 
and cytokines, including interleukin-4 and interleukin-5; they later migrate to 
the bone marrow and enhance final differentiation of eosinophils. Circulating 
eosinophils in turn moves to the  allergic inflammation area. As the 
eosinophils penetrate the matrix of the airways, their survival is prolonged by 
interleukin-4 and granulocyte-macrophage colonystimulating factor (GM-
CSF).
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The eosinophils secrete inflammatory mediators, such as granule proteins 
and leukotrienes, which cause airways’ tissue injuries. Furthermore, 
eosinophils can secrete GM-CSF to increase their survival and contribute to 
persistent airway inflammation. However, it should be borne in mind that over 
20 cytokines have been reported that could be involved in the inflammation 
process. Therefore, it is not surprising that drugs which target the presence 
of one cytokine have not been successful in treating asthma (Koda-Kimble, 
2008, Helms, 2006).
More recently, remodelling of the airways is thought to be secondary of 
failure to control airway inflammation in asthmatic patients. Airway 
remodelling (Figure1.28) refers to structural changes causing irreversible 
narrowing of the airway lumen and airflow obstruction which can eventually 
decrease lung function (Helms, 2006).
Figure 1.28 Remodelling of airways of asthmatic patients
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1.1.24.1 Prevalence of asthma 
Asthma varies from 1% to 18% in the population in different countries (Figure
1.29).
   
Figure 1.29 Asthma prevalence and mortality. Source: adapted from (Bryne 
et al., 2006).
1.1.25 Symptoms
Usually, patients with asthma present with symptoms such as cough,
episodic breathlessness, wheezing, cough, and chest tightness (Bryne et al., 
2006). 
1.1.26 Diagnosis
An accurate diagnosis of asthma is essential for appropriate treatment to be 
started. However, the absence of a gold standard definition leads to making 
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clear evidence-based recommendations on a diagnosis of asthma not 
possible.  
1.1.26.1 History
The diagnosis of asthma is based primarily on taking a comprehensive 
history of the symptoms (DiPiro et al., 2008).  
1.1.26.2 Pulmonary function tests
1.1.26.2.1 Spirometry
The normal value for the forced expiratory volume in one second (FEV1) 
forced vital capacity (FVC), FEV1 / FVC ratio in healthy persons is generally 
75% to 80%. Age, gender, height, weight and race influence the lung volume 
The patient's spirometry result is compared with a predicted normal values
table for patients with similar physiological characteristics (BTS, 2008).
1.1.27 Asthma classification
Classification of asthma severity is important to establish the treatment plan. 
Patients are classified into three age groups, 0-4, 5-11 and >12 years,  
Expert Panel Report 3 (EPR-3) uses the following classifications of 
intermittent, mild persistent, moderate persistent and severe persistent 
asthma. Using the frequency of symptoms as essential components of 
asthma classification (Koda-Kimble, 2008) (see Appendix B). 
1.1.28 Non-pharmacological management
As mentioned before, there are various dietary, environmental and other 
factors which trigger asthma. Avoiding these triggers may help in reducing
the need for pharmacotherapy (BTS, 2008).
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There is also a major concern regarding asthmatic patients increasing use of
alternative and complementary therapies such as herbs, vitamins, massage, 
black tea, coffee, ephedra, marijuana, dried ivy leaf extract, acupuncture, 
meditation, homeopathy and yoga. As there are no established clinical 
studies to support the use of these alternatives there is considerable concern 
over the expanding use of these methods (BTS, 2008, Koda-Kimble, 2008).
In addition, other strategies have been tried, including smoking cessation and 
weight reduction (BTS, 2008).
1.1.29 Pharmacological management
1.1.29.1 Goals of therapy
The major goal of asthma therapy is to control the disease. The key of this 
control are:
 No daytime symptoms
 No night-time awakening due to asthma
 No need for reliever medication
 No exacerbations
 No limitations on activity, including exercise
 Normal lung function (in practical terms, FEV1 and/or Peak expiratory 
flow (PEF) >80% predicted or best).
 Minimal side effects. 
In practice, patients may have different aims and wish to balance the goals of 
asthma therapy and the possible side effects or inconvenience of taking 
medication required (BTS, 2008). Table 1.7 shows the level of asthma 
control.  
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A stepwise approach aims to control asthma as soon as possible and, to 
achieve this, patients should begin management at the step closest to the 
initial severity of their asthma. To maintain the control, stepping-up or 
stepping-down of treatment is often carried out to achieve control (BTS, 
2008) (see Appendix B).
Table 1.7 Levels of asthma control Source: (Bryne et al., 2006)
Characteristic
Controlled
(All of the 
following)
Partly Controlled
(Any measure 
present in any 
week)
Uncontrolled
Daytime symptoms None (twice or 
less/week)
More than 
twice/week
Three or 
more 
features
of partly 
controlled
asthma 
present in
any week
Limitations of 
activities
None Any
Nocturnal symptoms 
/awakening
None Any
Need for reliever/
rescue treatment
None (twice or 
less/week)
More than 
twice/week
Lung function (PEF 
or FEV1)**
Normal < 80% predicted or 
personal best
(if known)
Exacerbations None One or more/year* One in any 
week***
* Any exacerbation should prompt review of maintenance treatment to ensure 
adequacy.
** Lung function is not a reliable test for children 5 years and younger.
***By definition, an exacerbation in any week makes that an uncontrolled 
asthma week.
COPD 
1.1.30 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterised by airflow 
obstruction that is progressive and not fully reversible. It takes several 
months to change significantly. The main cause is smoking (NICE-Guideline, 
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2004a).The two main forms of COPD are chronic bronchitis and emphysema 
(Helms, 2006). 
1.1.31 Epidemiology and aetiology 
Long-term exposure to toxic gases and particles can cause COPD. In 
particular, cigarette smoke, which accounts for over 90% of cases of COPD. 
Fortunately, only 10-20% of heavy smokers develop COPD. 
It is also the case that the incidence of COPD is correlated to the number of 
cigarettes smoked per day; furthermore, the death risk from COPD in 
patients who smoke 30 cigarettes per day is 20 times more than for a non-
smoker (Figure 1.30).
Figure 1.30 Influence of smoking on airflow limitation Source: (Clark et al., 
2005).
The number of patients diagnosed with COPD has been falling steadily; also, 
the death rate has fallen in the previous 25 years from 200 to 70 per 100,000
(Figure 1.31). In addition, it is the forecast that COPD will become the third 
most common cause of death and the fifth most common cause of disability 
worldwide by 2020, as shown in Table 1.8.
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Table 1.8 Changes in ranking for most important causes of death from 
1990 to 2020 in baseline scenario Source: (Murray et al., 1997)
Disorder Ranking Change in 
ranking1990 2020 
baseline 
model
Within top 15
Ischaemic heart disease 1 1 0
Cerebrovascular disease 2 2 0
Lower respiratory infections 3 4 -1
Diarrhoeal diseases. 4 11 -7
Perinatal disorders. 5 16 -11
Chronic obstructive 
pulmonary disease. 
(COPD)
6 3 +3
Tuberculosis 7 7 0
Measles 8 27 -19
Road-traffic accidents 9 6 +3
Trachea bronchus and lung 
cancers
10 5 +5
Malaria 11 29 -18
Self-inflicted injuries 12 10 +2
Cirrhosis of liver 13 12 +1
Stomach cancer 14 8 +6
Diabetes mellitus 15 19 -4
Outside top 15
Violence 16 14 +2
War injuries 20 15 +5
Liver cancer 21 13 +8
HIV 30 9 +21
1.1.32 Pathophysiology 
Pathological changes are hypertrophy and increase in the number of mucus-
secreting goblet cells of the bronchial tree, consistently distributed throughout 
the lung but mainly in the larger bronchi. In advanced cases, the bronchi are 
significantly inflamed and pus can be seen in the lumen (Figure 1.32).
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Figure 1.31  Age-adjusted death rates for COPD by country and sex, ages 
35 to 74 Source: adapted from (Hurd, 2000).
Figure 1.32 Pathological changes in airways in chronic bronchitis and 
emphysema. Source: (Clark et al., 2005).
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Cigarette smoking plays an important role in the pathology of the COPD 
through the presence of neutrophils in the lumen of the bronchial tree. 
Additionally, granulocytes infiltrate the  small airways of smokers. The 
granulocytes release elastases and proteases, which may enhance the 
development of emphysema. α1-Antitrypsin inhibitor is an antiproteinase 
inhibitor produced in the liver, which then it travels into the blood and 
penetrates the lung. Its functions are to neutralise neutrophils elastase and 
α1-Antitrypsin is a main serum antiprotease which may be inactivated by 
cigarette smoke. Furthermore, hypertrophy of mucous glands in the larger 
airways may result from repeated irritation from the inhalation of cigarette 
smoke. Also, the smoke has a bad impact on lung surfactant (Clark et al., 
2005).
1.1.33 Diagnosing COPD
The diagnosis of COPD depends on the suspicion as the cause of 
breathlessness or cough. The diagnosis is based on  symptoms and signs 
and supported by spirometry (NICE-Guideline, 2004f).
1.1.33.1 Symptoms
At an early stage, they are not obvious or disappear and, as the COPD 
progresses, the symptoms vary among individuals (NICE-Guideline, 2004f). 
They include productive cough, wheezing and breathlessness. Often, the 
patient has been a smoker for a long time. As the disease develops severe 
breathlessness may occur even after mild effort such as dressing (Clark et 
al., 2005).
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1.1.33.2 Signs 
In the early stage the signs are limited to wheezing throughout the chest. In 
severe disease, they include the patient’s being tachypnoeic, with prolonged 
expiration, use of accessory muscles, hyperinflated chest, wheeze or quiet 
breath sounds,  pursed lip breathing, cyanosis, raised jugular venous 
pressure (JVP) and/or cachexia (NICE-Guideline, 2004f).
1.1.34 Assessment of severity
The assessment of severity is essential because it has implications for 
treatment and relates to prognosis. One of the tools of classification is 
spirometry, which can be used to assess the severity of airflow obstruction 
and to guide treatment and predict prognosis (Rabe et al., 2007). 
1.1.35 Complications 
During the later stages of COPD, the patient may develop respiratory failure. 
Also, at this stage, chronic hypoxemia and hypercapnia can cause persistent 
vasoconstriction in the lung vascular bed, particularly the small pulmonary 
arteries, subsequently pulmonary arterial hypertension. COPD patients may 
develop cor pulmonale at the advanced stage, defined as an alteration in the 
structure and function of the right ventricle secondary to disorder of the 
respiratory system. It is characterised by right ventricular hypertrophy, 
pulmonary hypertension and, finally, right heart failure (Helms, 2006). 
1.1.36 Managing stable COPD
COPD is a heterogeneous disease, and the therapy plan should be 
individualised, based on symptoms and disability of the targeted patient
(NICE-Guideline, 2004g). 
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1.1.36.1 Smoking cessation
A  smoking history should be documented and patients should be 
encouraged to stop (NICE-Guideline, 2004g).  
1.1.36.2 Inhaled bronchodilator therapy
COPD is characterised by considerably irreversible airflow obstruction; 
however, bronchodilators have been t h e  central component of 
pharmacotherapy (Figure 1.33). β2-agonists, anticholinergics and 
theophylline have all been used in COPD. Beside their direct bronchodilation, 
both β2-agonists and anticholinergics also  reduce static and dynamic 
hyperinflation (NICE-Guideline, 2004g).
Figure 1.33 Therapy at each stage of COPD. Post-bronchodilator FEV1 is 
recommended for diagnosis and assessment of the severity of COPD. 
Source: (Rabe et al., 2007)
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1.1.36.3 Theophylline
Theophylline has many advantages, such as an increase in diaphragmatic 
strength in COPD patients, an effect on mucociliary clearance, anti-
inflammatory effects and extra-pulmonary effects, mainly enhancement in 
cardiac output. But it has a potential toxicity and marked interactions with 
other drugs. As a result, theophylline is kept for patients who do not tolerate 
or fail to respond adequately to a combination of inhaled bronchodilators or in 
patients who are unable to use inhaled therapy. However, because of its 
different pharmacokinetic profile and interaction with other medications, it 
should be cautiously used in the elderly (NICE-Guideline, 2004g, Koda-
Kimble, 2008).
1.1.36.4 Corticosteroids
Unlike eosinophils, neutrophils are less sensitive to steroids, even if a high 
dose of inhaled steroid is used. Currently, not all of the inhaled 
corticosteroids are licensed to be used alone for therapy of COPD patients. 
Inhaled corticosteroids should be considered for patients with an FEV1 < 
50% predicted, who are having ≥ 2 exacerbations per year, which urges 
treatment with antimicrobials or systemic corticosteroids. The goal of therapy 
is to reduce exacerbation frequency and decrease the decline in health 
status and not to provide an improvement in lung function (NICE-Guideline, 
2004g).
1.1.36.5 Combination therapy
Bronchodilators work through different mechanisms, hence combining drugs 
of these classes may add some clinical benefits to patients. This approach 
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may provide an additional advantage of reduction of the potential side effects 
of the drugs by avoiding having to use individual drugs near to their 
maximum dose. In addition, the combination of bronchodilator with an inhaled 
steroid may produce additive or synergistic clinical benefits (NICE-Guideline, 
2004g).
1.1.36.6 Supplemental Oxygen Therapy 
In the advanced stage of COPD, patients frequently become hypoxaemic. 
Many patients develop a tolerance for mild hypoxaemia; however, once the 
PaO2 falls below 8 kPa, patients start to develop signs of cor pulmonale, 
mainly peripheral oedema. Oxygen is used to improve exercise capacity and 
decrease disability in these patients. In addition, oxygen is used to relieve the 
breathlessness symptom (NICE-Guideline, 2004g).
1.1.36.7 -1 antitrypsin replacement therapy
-1 antitrypsin deficiency  accounts for around 2% of cases of COPD 
Recombinant -1 antitrypsin is currently available and replacement
therapy has been proposed as a method of treating patients with -1 
antitrypsin deficiency. However, the national clinical guideline on 
management of COPD in adults in primary and secondary care does not 
recommend -1 antitrypsin replacement therapy in the management  of 
patients with -1 antitrypsin deficiency (NICE-Guideline, 2004g).
1.1.36.8 Anti-oxidant therapy
There is currently good evidence linking the oxidative stress and severity of 
disease. The national clinical guideline on management of  COPD in adults in 
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primary and secondary care does not recommend use of vitamin E and beta-
carotene supplements, alone or in combination (NICE-Guideline, 2004g).
1.1.36.9 Mucolytic therapy
Mucolytic agents should be considered in patients with a chronic productive 
cough. Some of these drugs, particularly N-acetylcysteine, may also have 
antioxidant effects which may contribute to their clinical effects. (NICE-
Guideline, 2004g).
ASTHMA AND COPD: DIFFERENCES AND SIMILARITIES
Asthma and COPD disorders cause obstructed airflow and the symptoms of 
cough, wheeze and breathlessness; moreover, both illnesses can coexist in 
the same patient. However, despite sharing some clinical features, they differ 
significantly in aetiology, pathology and management (Koda-Kimble, 2008). 
Asthma is usually completely reversible. Patients with asthma respond well to 
anti-inflammatory medication, including inhaled corticoids. In addition, unless 
an acute exacerbation is existing, significant gas exchange abnormalities are 
rare. COPD, on the other hand, is a progressive and often fatal disease. 
Although bronchodilators are useful in COPD, the degree of bronchodilator 
reversibility is clearly less than in asthma. Furthermore, the benefits of anti-
inflammatory drugs, including inhaled corticoids, are much lower than in
COPD.
Patients with COPD, especially those with emphysema, have considerable 
derangements in pulmonary gas exchange, even at baseline. They generally
have a chronic cough, typically productive, and varying degrees of exertional 
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dyspnoea. Tables 1.9 and 1.10 illustrate the difference between asthma and 
COPD.
Figure 1.34 Inflammatory cascade in COPD and Asthma. Source: adapted 
from (Rabe et al., 2007).
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Table 1.9 Differences in pulmonary inflammation between asthma and 
COPD Source: (Rabe et al., 2007)
COPD Asthma
Cells Neutrophils ++
Macrophages +++
CD8+ T cells (Tc1)
Eosinophils ++
Macrophages +
CD4+ T cells (TH2)
Key Mediators IL-8, TNF-α, IL-1β, IL-6, NO+ Eotaxin,IL-4, IL-5, IL-13, 
NO+++
Oxidative stress +++ +
Site of disease Peripheral airways
Lung parenchyma
Pulmonary vessels
Proximal airways
Consequences Squamous metaplasia
Mucous metaplasia
Small airway fibrosis
Parenchymal destruction
Pulmonary vascular 
remodeling
Fragile epithelium,
Mucous metaplasia
↑ Basement membrane
Bronchoconstriction
Response to 
therapy
Small bronchodilator 
response
Poor response to steroids
Large bronchodilator 
response
Good response to steroids
NO= nitric oxide, TNF= Tumour necrosis factor, IL= Interleukin
1.1.37 Managing patients with mixed asthma and COPD
Some patients may show lung function characteristics of asthma and of 
COPD and the safest option is to treat them as having asthma but to expect 
COPD outcomes.
Under-estimating the asthmatic component of mixed lung disease exposes 
the patient to being left without inhaled steroids and other preventive therapy 
with possibility of fatal consequences. Overestimating t h e  asthmatic 
component may cause an overtreatment of the patient and perhaps denial of 
access to respiratory rehabilitation and to less use of relievers (Crockett, 
2003).
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Table 1.10 asthma versus COPD Source: (Helms, 2006).
Feature Asthma COPD
Past or current history of cigarette smoking Maybe Usually
Symptoms present before age 40 years Common Rare
Spirometry improvement after bronchodilator ≥12% Minimal
Chronic productive cough present Uncommon Common
Breathlessness Intermittent Persistent
Night-time awakening with dyspnoea /wheeze Common Uncommon
Significant intra- and inter- day variability in 
symptoms Common Uncommon
ROLE OF PHARMACIST IN IMPROVING ASTHMA AND COPD PATIENT 
CARE
Whether they work in community pharmacies, hospitals or other health 
settings, pharmacists are in an essential position to contribute to overall 
management of patients with asthma and COPD and can educate patients by 
providing information on the type and purposes of their medication and by 
demonstrating how to use inhaled drugs and peak flow meters. Also
pharmacists can be a valuable source of drug information for all members of 
the health care team by monitoring medication use and refill periods and use 
this information to alert prescribers and help identify poorly controlled 
patients. 
The visits to the emergency department and the patient’s admission to 
hospital are the largest portion of the total cost of illnesses, which can be 
reduced by better control of disease (Lenfant, 1995).
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DRUGS STUDIED
This thesis is based around the examination of three mainstream inhaled 
drugs, formoterol, budesonide and beclomethasone, for the treatment of 
asthma and COPD.
1.1.38 Budesonide 
Budesonide is a corticosteroid, designated chemically as (RS)-
11ß,16,17,21 -Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal 
with butyraldehyde. Budesonide is provided as a mixture of two epimers 22R 
and 22S. The empirical formula of budesonide is C25H34O6 (Figure1.35) and 
its molecular weight is 430.5 (Martindale et al., 2006).
It is a glucocorticoid with a high ratio of local to systemic anti-inflammatory 
activity due to the absence of halogen atoms on the corticosteroid nucleus,
which contributes to t h e  optimal topical-to-systemic activity ratio of 
budesonide.
Figure 1.35 Budesonide structure
1.1.38.1 Physical properties
Budesonide is a white to off-white, tasteless, odourless powder practically 
insoluble in water and in heptane, sparingly soluble in ethanol and freely 
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soluble in chloroform (UK-DoH., 2008). Its partition coefficient between 
octanol and water at pH 7.4 is 1.6 x 103.
Its high lipophilicity is an advantageous property associated with a high 
receptor affinity.
1.1.38.2 Pharmacokinetics 
The highest concentration (tmax) is reached after 30 minutes of oral powder 
inhalation after administration of budesonide at 400 g, 800 g or 1600 g 
twice daily via the Turbuhaler which results in a highest concentration (Cmax)
of 1.43 nmol/L, 2.55 nmol/L, and 5.37 nmol/L after the first dose, respectively 
(SYMBICORT®_Product_Information, 2004).  Work by Kaiser and co-
workers (1999) have shown that administration of the above doses for 3 
weeks resulted in a Cmax of 2.03 nmol/L, 3.64 nmol/L and 5.37 nmol/L, 
respectively. In these studies, the tmax was achieved at between 10 and 20 
minutes for all doses except single-dose budesonide 800 g. When an oral 
suspension inhalation was used, the tmax  was reached after 10 to 30 minutes 
(Szefler, 1999). 
The oral bioavailability from the oral dosage form (capsule) is about 9% after 
a single dose and around 11% after repeated dosing (Klasco, 2005a). 
Budesonide is known to undergo extensive first pass metabolism of around 
85% and metabolises to give two inactive metabolites, 16-
hydroxyprednisolone (24%) and 6-β-hydroxybudesonide (5%) (Brunton et al., 
2006). For oral inhalation, the bioavailability was 73% (Ryrfeldt et al., 1982). 
The total protein binding is 85% to 90% (Klasco, 2005a), with a volume of 
distribution (Vd) of 3 L/kg(Klasco, 2005a).
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Budesonide is then excreted mainly through renal excretion (60%) as 
metabolites and not as unchanged drug (Ryrfeldt et al., 1982). 
Budesonide has a half-life for the parent drug of around 2 to 3 hours. 
Furthermore, esterification can lead to increases in the retention time of 
budesonide in the lung. It has been shown that lung deposition of budesonide 
is twice as high as when administered by DPI versus pMDI, because it
produces a higher proportion of fine particles compared to other devices 
(O'Connell, 2003).
The local adverse effects are lower when a DPI budesonide is used, rather 
than a pMDI, and the reported incidences are 5.8% vs 17% (O'Connell, 
2003).
1.1.38.3 Monitoring parameters 
The important parameters of drugs are therapeutic value and toxicity. 
1.1.38.3.1 Therapeutic
An initial study often completed is a pulmonary function test, especially peak 
expiratory flow (PEF) (DiPiro, 2005). Secondly, physical examination is 
regularly carried out, such as decreased wheezing, dyspnoea and respiratory 
rate, and decreased number of exercise-induced asthma attacks. (DiPiro, 
2005).
1.1.38.3.2 Toxicity
The toxic effect of budesonide can be reduced in the following way. For 
patients suspected of over-using inhaled corticosteroids or on chronic 
systemic, the hypothalamic-pituitary-adrenal axis should be monitored by the 
adrenocorticotropin stimulation test, morning plasma cortisol levels and 
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urinary free cortisol test. It may then be seen that blood glucose, cholesterol, 
triglycerides and low-density lipoproteins may be elevated in patients treated 
with corticosteroids (Klasco, 2005b). 
Secondly physical examinations should be carried out for common toxicity 
from corticosteroids, initially the endocrinal effect which is the most common
effect as the Cushing syndrome. Also, the effect on growth of children can be 
monitored by measuring the height velocity every 3 to 6 months .
Children should be screened annually for any ocular toxicity. Additionally, a
common adverse effect for inhaled corticosteroid is oropharyngeal 
candidiasis. The signs and symptoms are the appearance of white, milky 
plaques on the tongue which can be avoided by instructing patients to wash 
their mouths after inhaler use. As regards the effects of corticosteroid on 
bone, including osteoporosis (Ledford et al., 1998).
1.1.38.4 Place in therapy  
Current treatment guidelines, such as The British Guidelines on Asthma 
Management (BTS, 2008), emphasise the use of inhaled corticosteroids 
(ICS) as first-line therapy for managing persistent asthma symptoms in both 
children and adults. Compared to ‘as needed use’ of β-agonists alone, ICs
generally have been shown to increase FEV1, decrease airway hyper-
responsiveness, improve symptoms in term of severity and frequencies, and 
decrease β-agonists use and need for oral corticosteroids, which can reduce 
hospitalisations and urgent care visits (Klasco, 2005b).
Literature Review                                                                                           Chapter1
74
1.1.38.5 Mechanism of action 
Glucocorticoids inhibit the activity of a variety of inflammatory cell types. Also, 
oral inhaled corticosteroids suppress the late-phase allergic responses 
associated with chronic bronchial asthma (Brunton et al., 2006).
1.1.39 Formoterol
It is a long-acting β2 agonist, which has an extended duration of action (up to 
12 hrs) compared to short-acting β2 agonists such as salbutamol, which are 
effective for 4–6 hrs. It is used in the treatment of both asthma and COPD.
Formoterol is used as a symptom controller to supplement prophylactic 
corticosteroid therapy.
1.1.39.1 Physical properties
Formoterol is a white, almost white, or slightly yellow powder. It is slightly 
soluble in water and in isopropyl alcohol, practically insoluble in acetonitrile 
and soluble in methanol. A 0.1% solution in water has a pH of 5.5 to 6.5
(Sweetman et al., 2006).
It has t h e  chemical name (±)-2´-Hydroxy-5´-[(RS)-1-hydroxy-2-fethyl]
formanilide fumarate, and molecular formula (C19H24N2O4 )2 ,C4H4O4 =804.9 
Figure 1.36 (UK-DoH., 2008).
1.1.39.2 Pharmacokinetics 
The initial response of formoterol is 1-3 minutes after inhalation and the peak 
response is 1-3 hours while after oral administration it is 20 minutes 
(SYMBICORT®_Product_Information, 2004). 
It has a duration of 8-12 hrs for single inhaled dose and oral dose is 5-8 
hours (Klasco, 2005c).
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Figure 1.36 Formoterol structure
Formoterol is extensively metabolised in the liver (Brunton et al., 2006). The 
percentage of renal excretion is 60% and 16%-28% of a dose is excreted as 
unchanged drug (Klasco, 2005c). Its elimination half-life is 10 hours .
1.1.39.3 Monitoring parameters
The therapeutic efficacy can be monitored by pulmonary function test and 
reduction of mainly nocturnal symptoms. On the other hand, toxicity can be 
monitored using clinical signs such as heart rate, serum potassium level, 
blood pressure and blood glucose (Klasco, 2005c). 
1.1.40 Beclomethasone Dipropionate
Beclomethasone is a synthetic, halogenated inhaled corticoid. Its oral inhaler 
is used in treatment of asthma and COPD (Brunton et al., 2006). Its chemical 
name is 9α-Chloro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-
dione 17,21-dipropionate, with molecular formula C28H37ClO7, and its 
molecular weight is 521.0 (Figure 1-37). It is a white or almost white, 
crystalline powder, practically insoluble in water, sparingly soluble in alcohol 
and freely soluble in acetone (Martindale et al., 2006). 
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Figure 1.37 Chemical structure for beclomethasone. 
1.1.40.1 Pharmacokinetics 
The  initial response of beclomethasone in asthmatic patients, if given by oral 
inhalation, is 1 to 4 weeks (Klasco, 2008). Its tmax, after administration of 4 
puffs of hydrofluoroalkane-134a beclomethasone, (HFA-BDP), is 2103 pg/mL 
at 0.9 hours. Administration of the  same dose of chlorofluorocarbon 
beclomethasone (CFC-BDP) is 1107 pg/mL at 1.4 hours (Lipworth, 1999).
Administration of 4 puffs of HFA-BDP resulted in AUC of 8603 pg/mL, while 
administration of the same dose of CFC-BDP resulted in an AUC of 5755 
pg/mL. This study concluded that the two formulations of BDP may not be 
equivalent on a microgram per microgram basis (Lipworth, 1999).
When it is given by oral inhalation, around 25% to 60% of each dose enters 
the bronchial airways. The lung absorption is rapid, with concentrations of 10 
to 20 ng/g reached after 42 to 84 g doses (Klasco, 2008). The total protein 
binding of beclomethasone is  87%. Metabolism sites are partially in the liver 
and extensively in the lung. It is rapidly hydrolysed by the lung. The main 
metabolites are beclomethasone-17-monopropionate, which is active, and 
meclomethasone alcohol, which is inactive. Its renal excretion is 10% to 15%, 
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and around 36% to 67% in faeces. It has an elimination half life 3 hours 
(Klasco, 2008).
1.1.40.2 Monitoring parameters
Monitoring parameters are similar to those for budesonide (see section 
1.9.1.3) 
1.1.40.3 Place In Therapy
Inhaled corticosteroids are considered as first-line therapy for managing 
persistent asthma and COPD in both children and adults (see section 
1.9.1.4)
1.1.41 Beclomethasone vs Budesonide 
Short-term studies have shown that budesonide is as effective as 
beclomethasone in the treatment of asthma. A number of double-blind trials 
have compared their efficacy in the management of asthma in adults 
receiving usual doses 200 to 800 g/day (Rafferty et al., 1985, Keelan et al., 
1984, Field et al., 1982, Willey et al., 1982), adults receiving high doses 800 
to 1600 g/day (Boe et al., 1989, Ebden et al., 1986, Svendsen et al., 1992)
and children (Springer et al., 1987, Baran, 1987). These studies are however 
limited by short duration of therapy, between 2 and 8 weeks. But since there 
is a strong carry-over of anti-asthmatic effects with inhaled corticosteroids, it 
seems unlikely that such short-term trials could detect any treatment 
differences between t h e  two medications. However, some studies 
demonstrated superiority of budesonide using a spacer device in the 
budesonide group and a conventional inhaler in the beclomethasone group 
(Field et al., 1982).
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Reichel and co-workers (2001) compared an HFA-BDP breath-actuated 
inhaler (Qvar® Autohaler) with budesonide delivered by DPI, in patients with 
moderately severe, symptomatic asthma, incompletely controlled by on-going 
treatment with inhaled budesonide. The study demonstrated that HFA-BDP
was clinically equivalent to twice the dose of budesonide.
AIMS AND OBJECTIVES 
1.1.42 Background.
As has been shown in the literature review, drug delivery by the pulmonary 
route is a very important to give direct access of a drug to the targeted area. 
The inhalation route offers many advantages over systemic delivery. 
Currently, most drugs used in the treatment of asthma and COPD are 
delivered by inhalation.
However, there are still a number of questions and areas of concern. In these 
studies, some of these questions are investigated. As a first example 
Symbicort® Turbuhaler® is an inhaled drug, made up of a combination of 
budesonide and formoterol (SYMBICORT®_Product_Information, 2004)
which shows synergistic effects in terms of reduction of asthma and COPD 
exacerbations (Pauwels et al., 1997a). Combining the anti-inflammatory 
corticosteroid budesonide and the rapid and long-lasting bronchodilator 
formoterol in the same device is designed to provide a simple, convenient 
and effective treatment. Budesonide is a glucocorticosteroid with high local 
anti-inflammatory effect (Brunton et al., 2006) and formoterol is a long acting 
and selective β2- agonist (Brunton et al., 2006).
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A major issue in the formulation is that budesonide is provided as a mixture 
of two epimers, 22R and 22S. The budesonide epimer R is known to be 2 to 
3 times more potent than the budesonide epimer S (Ryrfeldt et al., 1982). As 
a result, it is essential to keep the epimeric ratio constant. In addition to this,
the rate flow of each epimer may be different and therefore the 
pharmacological ratio may vary in delivery to the patient. Alongside this, it 
may be the case that formoterol and budesonide give differences in delivered 
drug ratio with change in flow rate. 
The influence of flow rate on drug delivery by Turbuhaler® has been 
investigated in many studies (Jaegfeldt et al., 1987, Newman et al., 1991, 
Tarsin et al., 2004). However, these studies did not test the effect of flow rate 
on the two epimers and formoterol separately. 
The third drug is beclomethasone, which is a synthetic halogenated inhaled 
corticoid. Its oral inhaler is used in treatment of asthma and COPD (Brunton 
et al., 2006).
On the other hand, beclomethasone, used in these experiments, is delivered 
by pMDIs, which are a convenient way of administering medication. But they 
emit an aerosol at high velocity and to be used properly they require 
coordination of inhalation and pMDI actuation. But even with an optimum 
technique, only < 15% of the emitted dose reaches the airways. As a result,
spacers have been introduced. Spacer devices are intended to improve the 
efficacy of inhaled therapy by decreasing the need for coordination between 
actuation and inhalation by allowing deceleration and evaporation of 
propellant and by decreasing oropharyngeal deposition of therapy (Bisgaard 
et al., 2002). Many different spacers are currently available, some designed 
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to fit with one particular product, while others are intended for use with a 
variety of pMDIs. 
In addition, CFCs have traditionally served as the propellant of choice for use 
with pMDIs. However, they deplete the ozone layer as noted by Molina and 
Rowland (1974). This has prompted a change to alternatives.
HFA134a has been approved by the Committee for Proprietary Medicinal 
Products (CPMP) under t h e  European Medicines Evaluation Agency 
(EMEA), as an alternative to CFCs used in medicinal products (Cripps et al., 
2000). As a result of the introduction of new propellants, many properties of 
the final products have changed. These changes may include extra-
pulmonary deposition, taste and/ or lung deposition (Bisgaard et al., 2002).
1.1.43 Aim
In the case of oral inhalers, it is commonly recognised that particle size plays 
an important role in defining where the particles will deposit (Bisgaard et al., 
2002). The main aim of the thesis is to examine the effect of the following 
factors: flow rate, spacers and drug formulation, on pulmonary delivery to the 
patient. In addition, a secondary aim is to examine the hypothesis of whether 
the result of a specific spacer with a given drug/ brand name can be 
extrapolated to other pMDIs or brand names for the same drug.       
1.1.44 Objectives
 To determine the in-vitro performance of formoterol and the two 
epimers of budesonide under different flow rate conditions from a 
Turbuhaler® by determining the fine particle dose (FPD) and the mass 
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median aerodynamic diameter (MMAD) of Symbicort turbuhaler, using 
28.3L/min and 60 L/min flow rate.
 To develop a sensitive and a simultaneous HPLC method for the 
analysis of formoterol and the two epimers of budesonide. Especially, 
it is required by the PhEuro (2007) that ratio of the two epimers (R/S) 
has to be within the range of 60-49/40-51%. 
 To examine the  effect of different type of spacers and drug 
formulations on the dose of beclomethasone delivered to the lungs 
and the throat deposition. Also, to measure the dose emitted from
different brand names of beclomethasone formulations alone and 
attached to spacers using different parameters, including washed 
versus unwashed and the number of actuated doses. 
 To compare the in-vitro aerosol deposition characteristics from 
different beclomethasone pMDIs with three common spacers using 
FPD and MMAD as parameters. 
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2 MATERIALS AND METHODS
APPARATUS AND INSTRUMENTATION
2.1.1 HPLC System
The HPLC SYSTEM was a 1050 Hewlett Packard series instrument which 
consisted of a HP 1050 UV-detector, autosampler pumping system (Hewlett 
Packard, Waldbronn, Germany). 
2.1.2 Integrator
Prime integration software was used. (HPLC Technology, Ltd, Welwyn Garden 
City, UK)
2.1.3 Scanning UV detector
The UV spectrophotometer was a Hewlett Packard diode-array 
spectrophotometer 8452A (Hewlett Packard, Palo Alto, California, USA)
2.1.4 HPLC column
HPLC column was a C18 ODS2 Spherisorb 5 µm column 250mm X 4.6mm id. 
(Capital Analytical Ltd, Leeds, UK)
2.1.5 General laboratory apparatus
pH meter was Accumet® AB10, (Fisher Scientific, Pittsburgh, PA,USA).
The microbalance was Thermo CAH C-35 capable of weighing to 6 figures 
(Scientific and medical Products Ltd, Cheadle, UK)
The electronic balance was a Mettler AE240 (Mettler Toledo Ltd, Greifensee, 
Switzerland) 
Ultrasonic bath (Telsonic Ltd, Basel, Switzerland).
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Water purification system was PURELAB® Ultra (Vivendi Water Systems, 
Bucks, UK)
2.1.6 Apparatus used to determine dose emission and the particles 
size.
A GAST 1023 Pump, 0-100L/min (GAST, Brook Hampton, Doncaster, UK).
Electronic digital flow meter Model DFM (Copley Scientific Ltd. Nottingham 
UK).
Andersen MKII cascade impactor (Copley Scientific Ltd.).
Critical Flow Controller Model TPK. (Copley Scientific Ltd.).
Sampling Apparatus for DPIs.and MDIs (Copley Scientific Ltd.).
Next Generation Pharmaceutical Impactor (NGI) (Copley Scientific Ltd.).
Copley Inhaler Testing Data Analysis Software (CITDAS) (Copley Scientific 
Ltd).
MATERIALS
2.1.7 Organic modifiers for HPLC
Acetonitrile (Fisher Scientific, Loughborough, UK)
Methanol (Fisher Scientific)
Ethanol (Fisher Scientific)
2.1.8 Buffer salts
Potassium dihydrogen orthophosphate (BDH Laboratories, Poole,UK)
Sodium hydroxide (BDH Laboratories) 
Orthophosphoric acid (BDH Laboratories)
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2.1.9 Analytes and general chemicals used
Budesonide (Sigma, Gillingham UK).
Formoterol (Cipla Ltd, Kurkumbh, India).
Beclomethasone (Sigma).
Releasil Silicone spray (Dow Corning Ltd, Barry Glamorgan, UK.)
2.1.10 Filters
Glass microfibre filter grade GF/A 81mm (Whatman international Ltd, Kent, uk)
Glass microfibre filter grade GF/A 47mm (Whatman International Ltd)
Galss fiber filter type A/E 25 mm (Pall Corporation, Michigan, USA)
2.1.11 Pharmaceutical preparations.
A Symbicort 400/12 Turbohaler® containing budesonide 400 µg and formoterol 
fumarate 12 µg /metered inhalation, were obtained from (AstraZeneca UK Ltd 
Luton, UK)  
A Clenil 250 Modulite® containing beclomethasone 250 µg /metered inhalation 
was obtained from (Trinity-Chiesi Pharmaceuticals Ltd, Highfield, UK).
A Clenil 100 Modulite® containing beclomethasone 100 µg /metered inhalation 
was obtained from (Trinity-Chiesi Pharmaceuticals Ltd,).
A Qvar100  Easi-Breathe® containing beclomethasone 100 µg /metered 
inhalation was obtained from (IVAX, Harlow, UK)
Qvar® 100 aerosol inhalation, containing beclomethasone 100 µg /metered 
inhalation was obtained from (IVAX)
Beclazone 250 Easi-Breathe®  containing beclomethasone 250 µg /metered 
inhalation was obtained from (IVAX,)
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Beclazone 100 Easi-Breathe® containing beclomethasone 100 µg /metered 
inhalation was obtained from (IVAX )
Becloforte aerosol inhalation, containing beclomethasone 250 µg /metered 
inhalation was obtained from (GlaxoSmithKline Uxbridge, UK) 
Becotide 100 aerosol inhalation, containing beclomethasone 250 µg /metered 
inhalation was obtained from (GlaxoSmithKline) 
2.1.12 Spacer devices
AeroChamber® Plus AeroChamber® Max were obtained from 
(GlaxoSmithKline) 
Optimizer® was obtained from (IVAX)
ANALYTICAL METHOD VALIDATION
The aim of validation of analytical methods is to display that the methods are 
appropriate for their intended function. Furthermore, the validation of the 
analytical methods demonstrates the reliability and performance in different 
conditions. Method validation for pharmaceuticals in the developed countries 
is now controlled by guidelines set out by the International Conference on 
Harmonization (ICH) guideline 2005  (HT Guideline, 2005). The explanations 
of these measurements are indicated below.  
2.1.13 Specificity
Specificity is the capacity of an analytical procedure to assess unequivocally 
the analyte in the presence of other components, which may include 
impurities, degradation or any substance which may interfere with the 
analyte. 
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2.1.14 Linearity  
In analytical science, the most easily used relationship is where a change is 
measured with respect to a primary variable, e.g. concentration, and the 
result is a predictable linear response. A linear relationship should be 
examined throughout the range of the analytical method. At the initial stage,
a relation should be elicited from the test results from standards that are 
directly obtained, or by other means obtained from a well defined 
mathematical equation, t hus  reflecting the relationship between the 
concentration of an analyte in samples and signal height or peak area as a 
function of analyte concentration. According to the ICH guidelines, the 
linearity should be determined by at least a series of five different 
concentrations with at least replicate measurement (HT Guideline, 2005). 
It is very common for the linearity to be evaluated graphically with or without 
mathematical evaluation. The evaluation is often made by visual inspection of 
a plot of the response, such as a signal height or peak area as a function of 
analyte concentration. If a relation is required, more mathematical tests can
be preformed and a linear relationship established, such as correlation 
coefficient, y-intercept and slope of the line.  
If the equation of the line is ideal, it should have an intercept close to zero. If 
the intercept is far from zero, then the effect of a non-zero intercept should be 
reconsidered in the method.
2.1.15 Accuracy
The accuracy of an analytical procedure expresses the degree of agreement 
between the test result generated and the true value. 
Materials and Methods                                                                                    Chapter2
88
2.1.16 Precision 
The precision is defined by the ICH Harmonised Tripartite Guideline (HT 
Guideline, 2005) as “the closeness of agreement (degree of scatter) between 
a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions”. The precision should 
be tested under the same working conditions. The relative standard deviation 
(RSD) is usually used to express the precision, although variance or 
coefficient of variation has been used in the past. 
Many terms are used to express precision, such as intermediate precision 
and reproducibility. 
2.1.16.1 Intermediate precision
Intermediate precision is a secondary term used to describe precision of the 
analytical procedure which is repeated on different days. It is also used to 
indicate the robustness of the assay over time.
2.1.16.2 Reproducibility
Reproducibility expresses the precision in terms of the closeness between 
different laboratories or different columns or instruments on the same or 
different sites. 
2.1.17 Limit of detection
It is the lowest amount of analyte which can be detected within a certain 
criteria. One of the simple ways to obtained this is by measuring the 
response against the noise and 3 to 1 signal to noise. An alternative is to use  
the standard deviation to determine the limit of detection (LOD) (Guideline, 
1996). 
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LOD= 
S
3.3 ………………………..Equation 2-1
where  = standard deviation of Y-intercept
            S= slope of calibration curve. 
             σ was calculated using the following equation:
2-n 
yi)-iy( 2
^
 ………….… Equation 2-2
where 
^
y i is the average,  yi  is (number1,number2,…) and n is the sample 
size
2.1.18 Limit of quantitation 
The limit of quantitation (LOQ) is the lowest concentration of analyte in the 
injected sample that can be detected and precisely quantified. There are 
many methods to express the LOQ. The simplest is to find the concentration 
which give 10 time of the signal to the noise. The other method is 
represented by the following equation:
LOQ= 
S
10 ……………………….Equation 2-3
Where  = standard deviation of Y-intercept
            S= slope of calibration curve.
2.1.19 Robustness 
Robustness examines the reliability of the analytical procedure when small 
changes in the method parameters are carried out, such as pH, variation in 
mobile phase composition, column temperature and flow rate. 
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METHODS 
2.1.20 Preparation of buffer
The suitable amount of buffer salt was accurately weighted, then transferred 
to a volumetric flask and Mili-Q water was added to made up to the desired 
volume. 
2.1.21 Preparation of HPLC mobile phase
In order to avoid the volume contraction of the mobile phase which is 
associated with addition of aqueous solution to organic solution, the two 
phases were accurately measured separately then mixed together. The pH of 
buffer was adjusted to the apparent pH, using the appropriate acid. The 
mobile phase was filtered through a 0.45 μm filter under vacuum to remove 
any unwanted particles which may block the HPLC system. The mobile 
phase was degassed using an ultrasonic bath under vacuum for 10 min 
before use. The pH meter was calibrated regularly using a commercial 
product to avoid inaccurate pH reading. 
2.1.22 Preparation of washing solution for inhalation sampling 
apparatus
In order to extract the drug from the apparatus, the washing solution was 
chosen to be compatible with the HPLC condition. The washing solution was 
prepared by mixing acetonitrile and water in the ratio of 70:30 v/v. The two 
phases were measured separately, then mixed together. 
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BUDESONIDE AND FORMOTEROL ANALYTICAL METHOD 
DEVELOPMENT AND VALIDATION
2.1.23 Objective of HPLC method development
The main objective of this study was to develop a sensitive and simultaneous 
HPLC method for the analysis of formoterol and the two epimers of 
budesonide. The budesonide  epimer R is known to be 2 to 3 times more 
potent than the budesonide epimer S (Ryrfeldt et al., 1982). Furthermore,  as 
required by the PhEuro, the ratio of the two epimers (R/S) has to be within 
the range of 60-49/40-51 (PhEuro, 2007). Therefore the analyst is required to 
have methods for these assays resulting in 2 methods being used. It would 
be a considerable advantage if an HPLC method could be found to replace 
the two separate methods from both a saving viewpoint and this an objective 
of a part of the research programme.
2.1.24 Method development for budesonide and formoterol
A literature review was carried out prior to method development. This is
summarised for formoterol in Table 2.1 and budesonide in Table 2.2. As the 
tables show, there is only one method which has separated formoterol and 
budesonide in one single method, developed by Assi et al (2006). However, it
does not separate the two budesonide epimers. Consequently, there is a 
need for a single method to separate formoterol and its two epimers, as this
is required by the PhEuro to give a fixed ratio between the two epimers. 
2.1.25 Determination of optimal detection wavelengths 
Before carrying out the HPLC separation, the UV spectrometer was used to 
determine the optimal wavelength for formoterol and budesonide.
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Table 2.1 The chromatographic conditions and parameters of the three 
HPLC formoterol assay methods
Parameters Method (Akapo et al., 2003) Methodb for formoterol and 
budesonide (Assi et al., 2006)
Column Alltech Alltima C18 5 mm 
silica column (15 cm x 4.6 
mm)
250mm×4.6mm i.d. (5 µm 
particle size) Spherisorb C18
column (Waters, UK)
Mobile 
phase
ammonium acetate (50 mM; 
pH 5.0) and methanol in the 
ratio 65:35 v/v
acetonitrile–5mM sodium 
dihydrogen orthophosphate, 
pH 3 (60:40%, v/v).
Flow rate 
(ml/min)
1.0 1.5
Wavelength 
(nm)
242 214
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2.1.26 HPLC method optimisation 
In the optimisation of the HPLC method for the detection of budesonide and 
formoterol, a trial and error strategy was used. Variable pH, organic modifier 
and buffer capacities were examined in order to reach the optimal retention 
time and the best separation for the two epimers. 
2.1.27 Result 
2.1.27.1 Determination of the optimal detection wavelengths
By using the UV-spectrometers, two wavelengths were selected (Figures 
2.1a and 2.1b). The best wavelengths were 214 nm for formoterol and 242 
nm for budesonide. From the UV scan, it was clear that to obtain maximum 
sensitivity from assay and to use only one assay procedure, ,the optimum 
method would be to have one HPLC procedure but to use two detection 
wavelengths. In many cases, the change of wavelength within method is not 
possible, because of large shift in the base line between the changes. 
However, the wavelength change in this case resulted in a minor shift which 
did not affect the detection and quantitation assay. In addition, the assay 
procedure provided very good resolution between the components and 
therefore there was no interference at the wavelength changeover, as shown 
in Figure 2.5.
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Figure 2.1   A- UV-spectrometers for budesonide 40µg/ml  (Acetonitrile: 
water 70:30 v/v) B- UV-spectrometers for formoterol 1.17 µg/ml (Acetonitrile: 
water 70:30 v/v)
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2.1.27.2 HPLC methods development. 
As mentioned, a method has been used previously to detect budesonide and
formoterol simultaneously. But it detects the budesonide and formoterol 
without separation of the two epimers (Assi et al., 2006). PhEuro (2007)
requirs keeping a fixed ratio between the two epimers.
In order to find a suitable method for the separation of the drug and epimers 
different organic modifier concentrations were tested, as shown in Figure 2.2. 
The two factors which had the largest effect on resolution were organic 
modifier concentration and buffer capacity. The best concentration was found
to be 40:60 v/v of Acetonitrile: buffer and the best buffer capacity was 7.5 
mM, as shown in Figure 2.3, which allowed separation. 
Table 2.3 The chromatographic conditions for budesonide and formoterol
Parameters HPLC budesonide and formoterol
Column reversed-phase  5 µm hypersil  C18 column, 250 X 
5 mm 
Mobile phase acetonitrile, and buffer 7.5 mM  Potassium 
dihydrogen phosphate (40:60 v/v) pH 3 
Flow rate (ml:min) 1 mL/min, isocratically. 
Wavelength (nm) 214/ 240
Temperature Room temperature 
Injection volume 100 µL
   
The two epimers were very sensitive to any change in the organic modifier 
but formoterol was not. On the other hand, budesonide epimers were less 
sensitive to buffer capacity change. Table 2.3 shows the final HPLC 
conditions. 
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Figure 2.2   Effect of organic modifier on retention time
Figure 2.3   Effect of buffer capacity on retention time 
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2.1.27.3 Analytical method validation.
In this study, the HT Guideline 2005 (HT Guideline, 2005) was followed to 
validate the method. 
2.1.27.3.1 Selectivity
The method developed was shown to be selective for formoterol and both 
budesonide epimers, as shown in Figure 2.4.  Figure 2.5 confirmed that there 
were no interfering peaks due to the blank Acetonitrile: water (70:30 v/v).
Figure 2.4 Chromatographic profiles of blank (Acetonitrile: water 70:30 v/v).
For full HPLC conditions (see Table 2.3).
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Figure 2.5  Chromatographic profiles of formoterol and the two epimers of 
budesonide. For full HPLC conditions (see Table 2.3)
2.1.27.3.2 Linearity
Peak heights and peak areas were linear over the range of 20.46 – 272.5 
µg/ml and 0.88 – 11.72 µg/ml for both budesonide and formoterol, 
respectively. The calibration solutions were diluted with a solution of 
acetonitrile: water 70:30 v/v. The linear response for formoterol yielded a 
regression equation of (y = 179.3 x - 28.88) with a correlation coefficient (R2
= 0.998 n=10) and (y = 8.879 x + 1.041) (R2 = 0.9998 n=10) for peak area 
and peak height, respectively. A linear response for the two epimers was also 
given and budesonide R gave a regression equation of (y = 49.86 x - 110.9) 
with a correlation coefficient (R2 = 0.999 n=10) for peak area and (y = 1.684 x 
+ 13.86) (R2 = 0.9965 n=10) for peak height. Secondly, budesonide S 
yielded a regression equation (y =42.84 x -125.93) (R2=0.9983 n=10) for 
peak area and (y =1.28X +12.43) (R2=0.99 n=10) for peak height (Figure
2.6).
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Figure 2.6   Linearity plot for budesonide epimers and formoterol. For full HPLC 
conditions (see Table 2.3).
Materials and Methods                                                                                    Chapter2
101
2.1.27.3.3 Accuracy
The data in Table 2.4 show very good recoveries at all levels. The average 
recoveries for three concentrations, low, medium and high in the linear range 
0.9-11.5 ug/ml, 50–250 ug/ml and 50–250 ug/ml for formoterol, budesonide 
R, and budesonide S, respectively, were used to examine the accuracy (n = 
5 for each level). The resultant statistic shows that the method has good 
accuracy. The method was therefore suitably accurate for use in the assay of 
formoterol, budesonide R and budesonide S
Table 2.4 Accuracy data for budesonide R, budesonide S and formoterol 
content (n= 5) 
Budesonide R
Concentrations levels (ug/ml) Accuracy (%)
Mean RSD
High 250 98.2 0.04
Medium  125 97.9 0.08
Low  50 98.1 0.2
Budesonide S
Concentrations levels (ug/ml) Accuracy (%)
Mean RSD
High 250 98.7 0.1
Medium  125 98.5 0.08
Low  50 97.9 0.02
Formoterol
Concentrations levels (ug/ml) Accuracy (%)
Mean RSD
High 11.5 98.2 0.08
Medium 6 97.8 0.09
Low  0.9 97.5 0.2
RSD: Relative standard deviation
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2.1.27.3.4 Precision 
The RSD of peak area responses for five standard injections was 0.257%, 
0.084%, 0.212% for formoterol, budesonide R and budesonide S,
respectively and these results meet the ICH Guideline. Furthermore, the 
retention time and peak height were tested and the results are shown in 
Table 2.5.
Table 2.5 Precision of assay method. For full HPLC conditions (see Table 
2.3).  
Run Substance Retention time (min) Area (mv)
Height 
(mv)
First run
Formoterol 7.808 150.4 8.600
Budesonide R 15.22 1,002 40.86
Budesonide S 16.38 849.2 32.01
Second run
Formoterol 7.804 150.5 8.626
Budesonide R 15.213 1,003 40.89
Budesonide S 16.37 852.2 32.05
Third run
Formoterol 7.804 151.3 8.665
Budesonide R 15.21 1,003. 40.93
Budesonide S 16.37 849.0 32.06
Forth run 
Formoterol 7.796 151.09 8.657
Budesonide R 15.21 1,003. 40.95
Budesonide S 16.37 851.9 32.09
Fifth run
Formoterol 7.804 150.7 8.662
Budesonide R 15.22 1,004 40.96
Budesonide S 16.38 852.9 32.09
Formoterol
AVG 7.803 150.8 8.642
STDEV 0.004 0.387 0.028
RSD 0.056 0.257 0.326
Budesonide R
AVG 15.22 1,003 40.92
STDEV 0.002 0.847 0.042
RSD 0.014 0.084 0.103
Budesonide S
AVG 16.37 851.0 32.06
STDEV 0.004 1.806 0.033
RSD 0.027 0.212 0.103
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2.1.27.3.5 Intra-day precision.
The Intra-day precision was tested. A series of five runs have been done at 
five different times on the same day. The results are summarised in the Table 
2.6.
Table 2.6  Repeatability of assay method. For full HPLC conditions (see 
Table 2.3).
Run
Substance Retention Time (min)
Peak  Area 
(mv)
Peak  
Height (mv) 
First run
FORMOTEROL 7.830 621.1 34.24
BUDESONIDE R 15.23 4133 164.0
BUDESONIDE S 16.41 3508 128.0
Second run
FORMOTEROL 7.830 622.8 34.10
BUDESONIDE R 15.23 4134 164.4
BUDESONIDE S 16.41 3509 128.3
Third run
FORMOTEROL 7.830 623.1 34.14
BUDESONIDE R 15.23 4139 164.5
BUDESONIDE S 16.41 3511 128.4
Forth run 
FORMOTEROL 7.830 621.9 34.12
BUDESONIDE R 15.24 4141 164.7
BUDESONIDE S 16.42 3512 128.5
Fifth run
FORMOTEROL 7.830 622.8 34.20
BUDESONIDE R 15.23 4141 164.9
BUDESONIDE S 16.41 3514 128.7
FORMOTEROL
Average 7.830 622.4 34.16
SD 0.00 0.84 0.06
RSD 0.02 0.13 0.17
BUDESONIDE R
AVERAGE 15.23 4138 164.5
SD 0.00 3.57 0.32
RSD 0.02 0.09 0.19
BUDESONIDE S
AVERAGE 16.41 3511 128.4
SD 0.00 2.54 0.26
RSD 0.02 0.07 0.20
SD: Standard DEVIATION, RSD: Relative standard deviation
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2.1.27.3.6 Intermediate precision
The RSD value for intermediate precision performed on different days is 
summarised in Table 2.7.
Table 2.7 Intermediate precision of assay method 
Run Substance 
Retention 
time (min)
Area 
(mv)
Height 
(mv)
First run
FORMOTEROL 7.630 2126 104.9
BUDESONIDE R 15.14 13739. 459.1
BUDESONIDE S 16.29 11822. 351.1
Second run
FORMOTEROL 7.620 2125 105.3
BUDESONIDE R 15.13 13748 459.0
BUDESONIDE S 16.28 11830 350.96
Third run
FORMOTEROL 7.610 2126 105.5
BUDESONIDE R 15.12 13744 458.7
BUDESONIDE S 16.27 11830 350.8
Forth run 
FORMOTEROL 7.600 2128 106.2
BUDESONIDE R 15.11 13740 455.0
BUDESONIDE S 16.26 11846 347.6
Fifth run
FORMOTEROL 7.580 2130 106.2
BUDESONIDE R 15.10 13755 457.3
BUDESONIDE S 16.25 11853 349.4
FORMOTEROL 
AVG 7.610 2127 105.6
STDEV 0.02 1.70 0.59
RSD 0.25 0.08 0.56
BUDESONIDE R
AVG 15.12 13745 457.8
STDEV 0.01 6.69 1.73
RSD 0.08 0.05 0.38
BUDESONIDE S
AVG 16.27 11836 350.0
STDEV 0.01 12.62 1.50
RSD 0.09 0.11 0.43
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2.1.27.3.7 Robustness 
From these results, the method was found to be robust and, as expected, the 
retention time decreased with increasing mobile phase flow rate. Finally, 
changes in pH of the buffer solution had little effect on the chromatographic 
profile of budesonide epimers. On the other hand, changes in pH of the 
buffer solution had a detrimental effect on formoterol retention time and peak 
area.
Table 2.8 Effect of flow rate on retention time
Flow rate ml/minute Formoterol (min)
Budesonide R 
(min)
Budesonide S 
(min)
0.80 10.66 22.53 24.31
1 8.13 16.45 17.78
1.20 6.57 13.59 14.65
Table 2.9 Effect of pH on retention time and peak area
Formoterol Budesonide R Budesonide S
pH
Retention 
time (min)
Area
Retention 
time (min)
Area
Retention 
time (min)
Area
3 8.13 203.60 16.45 1702.58 17.78 1337.38
5 11.61 43.24 16.75 1464.31 18.05 1159.13
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Figure 2.7   Effect of flow rate on retention time. For full HPLC conditions 
(see Table 2.3).
Effect of wavelength on peak area
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Figure 2.8   Effect of wavelength on peak area. For full HPLC conditions (see 
Table 2.3).
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Figure 2.9   Effect of pH on peak area. For full HPLC conditions (see Table 2.3)
2.1.27.3.8 Limit of quantitation and limit of detection  
The limit of detection (LOD) and the limit of quantitation (LOQ) were 
calculated from the average of the slopes and S.D. of the intercept of five 
calibration curves. The LOD and LOQ for the formoterol assay method were 
5.401 ng/ml and 18 ng/ml, respectively. In addition, the LOD and LOQ for 
budesonide R assay method were 134.5 ng/ml and 448.4 ng/ml, respectively. 
Finally, the LOD and LOQ for the budesonide S assay method were 62.27 
ng/ml and 207.57 ng/ml, respectively
2.1.28 Conclusion
An isocratic liquid chromatographic method has been described, which was 
optimised and validated for simultaneous qualitative and quantitative 
determination of formoterol fumarate and budesonide epimers. Acceptable 
assay precision and accuracy and excellent linearity were achieved  In 
addition to its high sensitivity, and robustness, the proposed HPLC method 
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proved reliable in the determination of the budesonide and formoterol 
delivered from the Symbicort® Turbuhaler, as shown in Chapter 3. As a 
result, it has been shown that previously reported separated methods can be 
replaced by one only.
BECLOMETHASONE ANALYTICAL METHOD VALIDATION
An HPLC method was published by Elaraud (1997) has been adopted to 
analyse beclomethasone. Table 2.10 summarises the HPLC conditions. The 
HT Guidelines 2005 were followed to validate the analytical method (HT 
Guideline, 2005). 
2.1.29 Result
2.1.29.1 Selectivity
The developed method demonstrates selectivity for beclomethasone. The 
blank (Acetonitrile: water 70:30 v/v) did not produce any peaks that interfered 
with the beclomethasone as shown in Figure 2.10.
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Figure 2.10 A- Chromatographic profiles of blank (Acetonitrile: water 70:30 
v/v) B- Chromatographic profiles of beclomethasone. For full HPLC 
conditions see Table 2.10
Table 2.10 Chromatographic conditions for beclomethasone.
Parameters HPLC beclomethasone
Column reversed-phase  5 µm hypersil  C18  250 x 5 mm id
Mobile phase 50 mM  Potassium dihydrogen phosphate pH 7 and 
acetonitrile (40:60 v/v) 
Flow rate (ml/min) 1 mL/min, isocratically at room temp. 
Wavelength (nm) 240
Temperature Room temperature 
Injection volume 100 µL
Limit of detection 9.20 ng/ml
limit of quantitation 28.0 ng/ml.
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2.1.29.2 Linearity
Linear responses were obtained for beclomethasone over the concentration 
range 0.013 – 12.5 µg/ml, with a regression equation of (y = 66.93x + 0.6716) 
and a correlation coefficient R2 = 0.9998 n=10 for peak Area Figure 2.10.
Figure 2.11   Linearity plot for beclomethasone. For full HPLC conditions (see 
Table 2.10).
2.1.29.3 Accuracy
The accuracy of the method was tested at three levels high 10 µg/ml, 
medium 6 µg/ml, and low 0.5 µg/ml (n = 5 for each level). The accuracy was 
estimated by the percent difference of the mean concentration determined 
from the known concentration. using the following equation 
Accuracy=1- 100
ionconcentratnominal
|ionconcentratnominal-ionconcentratmeasured| X Equation 2-4
Values in Table 2.11 show that the method is suitable for determining the 
potency of beclomethasone.
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Table 2.11 Accuracy data of Beclomethasone. For full HPLC conditions
see Table 2.10
Beclomethasone
Concentrations levels (ug/ml) Accuracy (%)
Mean RSD
High 10 99.1 0.02
Medium  6 98.7 0.06
Low  0.5 97.6 0.09
RSD: Relative Standard Deviation
2.1.29.4 Precision 
The intra-day variation of the assay method was determined by replicate 
analysis of one concentration. The inter-day precision was evaluated by 
measuring replicates of the same samples over a period of 2 weeks (n=5). 
The precision was expressed as a percentage by calculating the intra- and 
inter-day RSD. All intra- and inter-day data are summarised in Table 2.12 
and 2.13.
Table 2.12 Intra-day result of the Beclomethasone assay method
Retention time Peak Area
Run one 11.56 520.5
Run two 11.56 520.4
Run three 11.56 521.1
Run four 11.48 520.5
Run five 11.56 521.8
Average 11.55 520.9
Standard deviation 0.04 0.59
Relative standard deviation 0.32 0.11
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Table 2.13 Result of inter-day of the Beclomethasone assay method
Retention time Peak Area
1st day 11.64 217.7
4th  day 11.64 217.5
7th day 11.64 217.7
10th day 11.64 217.8
13th day 11.63 217.3
Average 11.64 217.6
Standard deviation 0.00 0.19
Relative standard deviation 0.04 0.09
2.1.29.5 Limit of quantitation and limit of detection  
The LOD (S/N ≥ 3) was 9.2ng/ml and the (LOQ S/N ≥ 10) was 28ng/ml,
where S is signal and N is noise.
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CHAPTER 3
IN-VITRO AERODYNAMIC PARTICLE SIZE
DISTRIBUTION OF THE SYMBICORT® TURBUHALER®
AT DIFFERENT INHALATION FLOWS USING AN 
ANDERSON CASCADE IMPACTOR AND THE NEXT 
GENERATION CASCADE IMPACTOR.
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3 IN-VITRO AERODYNAMIC PARTICLE  SIZE DISTRIBUTION OF 
THE SYMBICORT® TURBUHALER® AT DIFFERENT INHALATION 
FLOWS USING AN ANDERSON CASCADE IMPACTOR AND THE NEXT 
GENERATION CASCADE IMPACTOR
OBJECTIVE 
The objective of this section of the work  was to determine the in-vitro
performance of the formoterol and the two epimers of budesonide under 
different flow rate conditions. The fine particle dose (FPD) and the mass 
median aerodynamic diameter (MMAD) of 400/12 g budesonide/formoterol) 
Symbicort® Turbuhaler® has been determined using 28.3L/min and 60 L/min 
flow rate.
INTRODUCTION.
Drug delivery via the pulmonary route is an important and rapidly rising area. 
Inhalation offers many advantages over the systemic delivery route.
Currently, most drugs used in the treatment of asthma and airflow obstruction 
are delivered by inhalation. In the case of oral inhalers, it is commonly 
recognised that particle size plays an important role in defining where the 
particles will deposit in the lung (Bisgaard et al., 2002).
The regulators state that, all pharmaceutical dosage forms should guarantee 
that the drug is delivered in a safe and efficacious manner. Dose delivery is 
an important part of this because it is connected to both the safety and 
efficacy of the dosage form.  For an inhaled dosage form, the amount of drug 
emitted from the device as well as the aerodynamic particle size, needs to be 
tested. In addition, it is essential that the in-vitro tests should be designed to 
mimic the patient’s use as much as possible. 
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Table 3.1 Stage cut size (µm) for ACI for 28.3 and 60 L/min (UK., 2008)
(USP, 2005)
    Flow
Stage 
28.3 L/min 60 L/min
Stage -1 Omitted 9.0 µm
Stage -0 Omitted 5.8 µm
Stage 0 9.0  µm Omitted
Stage 1 5.8 µm 4.7 µm
Stage 2 4.7 µm 3.3 µm
Stage 3 3.3 µm 2.1 µm
Stage 4 2.1 µm 1.1 µm
Stage 5 1.1 µm 0.7 µm
Stage 6 0.7 µm 0.4 µm
Stage 7 0.4 µm Omitted
As indicated previously one key analytical method which is used to assess 
inhalation, is cascade impaction, these impactors, including but not limited to 
the ACI and MSLIs, are widely used for particle size analysis and are 
recommended by both the USP and the Euro_Ph. (Mitchell et al., 2003). The 
ACI is manufactured by Copley Scientific in the UK and is an eight-stage 
cascade system intended for measuring the particle size distribution 
produced by pMDIs and DPIs. In order to test the effect of flow rate on 
particles size distribution, The ACI can be operated at different flow rates. 
However, it is essential to consider a modification in cut-points for each stage 
since the flow rate has an effect on the cut-points at each stage (see section 
1.3.2.3.3.3). As an example the USP indicates that at 60 L/min, stages 0 and 
7 are removed and replaced with two different stages, -0 and -1. 
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In the case of commercial inhaler, the Symbicort® Turbuhaler® shows flow–
dependency for aerodynamic characteristics (Tarsin et al., 2004). Furthermore, many 
studies have demonstrated the effect of flow rate on the fine particles dose (Chrystyn, 
2003, Al-fadhl, 2007). 
Methods and instrumentation.
3.1.1 Equipment and Inhalation device 
The device and the equipment used in this study are listed in Sections 2.1 
and 2.2.   
3.1.2 Instrumentation. 
3.1.2.1 Procedure to set up Anderson Cascade Impactor for flow rate 
28.3L/min.
The initial work was to prepare the ACI for measurement of the symbicort 
sample. All parts of the ACI and its stages including pre-separator were 
washed with acetone and dried. Furthermore, to ensure efficient capture of 
the particles and prevent bouncing the collection plates were sprayed with 
silicone (USP, 2005) which was allowed to air dry. The ACI stages were then 
assembled as described in the manufacture’s manual which incorporates an 
after filter below the final stage to capture any fine particles that otherwise 
would escape from the apparatus Figure 3.1. A washing solution of 10 ml 
(acetonitrile: water 70:30, v/v) was placed into the preseparator to avoid re-
entrainment of impacted particles larger than 10 µm which may interfere with 
other particle size groups. Figure 3.1 shows the positioning of the ACI, critical 
flow controller, and the vacuum pump. The mouthpiece adapter was attached 
to the end of induction port and the system was checked for airtightness. The 
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flow control valve was adjusted to achieve a steady flow through the system 
at the required rate 28.3L/min (±5%), which was measured by an electronic 
digital flow meter [ Model DFM Copley Scientific Ltd]. According to the 
Pharmacopea method 4 L of air should be drawn through the inhaler for each 
determination and the sonic flow,  the absolute pressure ratio P3/P2 < 0.5 
was confirmed. The dry-powder inhaler was then prepared according to the 
patient leaflet instructions (see appendix A) and was discharged into the 
apparatus by opening the valve for the required time, 8.4 sec (±5%). The 
time was calculated according to the equation 4.1. Groups of five doses were 
selected randomly using random schedules, and each of these five doses 
was separately discharged into the apparatus from the device. Doses not 
used were discharged to waste using a flow rate of 90 L/min. The apparatus 
was then dismantled carefully to avoid any loss of material. The active 
ingredient was washed from the inner walls and the collection plate of each 
of the stages of the apparatus into an appropriate volume of the washing 
solution Table 3.2. The drug under test was extracted from the filter into the 
washing solution. In order to ensure complete extraction the filter was 
sonicated for three minutes in the washing solution. Also, the washing 
solution from the filter was further filtered through a 0.45 μm filter in order to 
remove any unwanted particles which may block the HPLC system.
3.1.2.2 Procedure to set up Anderson Cascade Impactor for flow rate 
60L/min.
The procedure is identical to that above in section 3.3.2.1 except that, a 
manual procedure was used to replace stages 0 and 7 by -1 and -0. As a 
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result the cut-point would not be altered by using high flow rate. Furthermore, 
the valve closing time was decreased to 4 seconds using equation 4.1.
Table 3.2 Washing volume of 70% acetonitrile for ACI stages.
         Flow
Stage 
28.3 L/min 60 L/min
Induction port  20 ml 20 ml
pre-separator 10 10 ml
Stage -1 Omitted 5 ml
Stage -0 Omitted 10 ml
Stage 0 5 ml Omitted
Stage 1 10 ml 10 ml
Stage 2 10 ml 10 ml
Stage 3 10 ml 10 ml
Stage 4 10 ml 10 ml
Stage 5 10 ml 5 ml
Stage 6 5 ml 5 ml
Stage 7 5 ml Omitted
Filter 10 ml 10 ml
3.1.2.3 Procedure to set up Next Generation Cascade Impactor for flow 
rate 60L/min.
The apparatus was assembled with the pre-separator as shown in Figure 3.2. 
Then cups were placed into the apparatus.  In addition all cups were sprayed 
with silicone in order to reduce the re-entrainment of impacted particle. Then 
the cups were placed in the bottom frame and the impactor lid was closed 
with the seal body attached, and the handle was operated to lock the 
impactor together so the system was airtight. 
Aero-characterisation of Symbicort® Turbuhaler®                                                             Chapter3 
119
Fi
gu
re
 3
.1
  
Th
e 
se
tti
ng
 o
f A
C
I, 
C
rit
ic
al
 F
lo
w
 C
on
tro
lle
r,
an
d 
th
e 
va
cu
um
 p
um
p.
Aero-characterisation of Symbicort® Turbuhaler®                                                             Chapter3 
120
The pre-separator was assembled as follows: 15 ml of washing solution was 
added to the central cup of the pre-separator base Figure 3.3. Next the pre-
separator body was placed on top of the pre-separator base and the two 
catches were closed. The induction port was then connected to the pre-
separator Figure 3.2 a suitable mouthpiece adapter was connected from this 
point onwards the assembly is similar to previous procedure in section 
3.3.2.1
Figure 3.2 Next generation with pre-separator for dry powder particles
analysis Source: (Copley, 2007)
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Table 3.3  Washing volume of 70% acetonitrile for NGI stages.
Stage Volume
Induction port 20 ml
Pre-separator 10 ml
Stage 1 10 ml
Stage 2 10 ml
Stage 3 10 ml
Stage 4 10 ml
Stage 5 10 ml
Stage 6 10 ml
Stage 7 5 ml
MOC 5 ml
.  
Figure 3.3 Next generation pre-separator configuration Source (USP, 
2005)
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3.1.3 High-performance liquid chromatography (HPLC) analysis
The amount of drug deposited in each stage was measured using the HPLC 
method of analysis which was developed and explained in section 2.5, 
3.1.4 Fine particle analysis 
All the aerodynamic calculation were conducted using the Copley software 
(CITDAS version 2) 
The measured parameters were 
 Total Dose Per Shot (TDPS) or ∑A which is the total mass of drug 
delivered from the mouthpiece of the inhaler into apparatus (USP, 
2005). 
 Fine Particles Dose (FPD) or R is the total mass of drug found on the 
stages of the apparatus below a defined size e.g 5 µm and the filter. 
 Fine Particle Fraction (FPF) is calculated by the following formula 
(USP, 2005)
FPF =  A
R ……………………… Equation 3-1
 In the same way Fine Particle Fraction of Nominal dose is calculated 
by the following formula 
FPN= 
doseNominal
R
…………... Equation 3-2
 Cumulative Percentage of Drug Mass less than Stated Aerodynamic 
Diameter is calculated as shown in Table 3.4
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 Throat deposition is summation of pre-separator and induction port. 
 to calculate the Geometric Standard Deviation (GSD) the percentage 
of mass less than stated aerodynamic is plotted versus D50 diameter 
on log probability paper. Then the GSD can be calculated using the 
following equation
GSD =
SizeY
SizeX ………………. Equation 3-3
Where Y equal to cumulative percentage of mass less than 15.87% 
and X equal to cumulative percentage of mass less than 84.13%.
 The Mass Median Aerodynamic Diameter (MMAD) can be calculated 
as shown in Figure 3.4. which corresponding to cumulative percentage 
of mass less than 50% 
Table 3.4    Calculation of cumulative percentage of mass less than stated 
aerodynamic diameter 
Stage Cumulative%
Filter 0
Stage7 A= (Drug Mass deposited on the filter)/I  X 100
Stage 6 B= (A + Drug Mass deposited on Stage 7)/I X 100
Stage 5 C= (B + Drug Mass deposited on Stage 6)/I X 100
Stage 4 D= (C + Drug Mass deposited on Stage 5)/I X 100
Stage 3 E= (D + Drug Mass deposited on Stage 4)/I X 100
Stage 2 F= (E + Drug Mass deposited on Stage 3)/I X 100
Stage 1 H= (F + Drug Mass deposited on Stage 2)/I X 100
Stage 0 I = (H + Drug Mass deposited on Stage 1)/I X 100
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3.1.5 Statistical analysis
The one-way ANOVA with the Bonferroni effect test was used to compare the 
aerodynamic particle size characterization of the different flow rate using 
SPSS V15.0 (SPSS Inc., Chicago, USA).
Figure 3.4 Plot of cumulative percentage of mass less than the stated 
aerodynamic diameter versus aerodynamic diameter. Source (USP, 2005)
RESULT
There are statistically significant differences for formoterol, budesonide R and 
budesonide S between 28.3L/min and 60 L/min in total emitted dose Tables 
3.5 to 3.7. The aerodynamic particles size distribution of formoterol, 
budesonide R, and budesonide S from the Symbicort® Turbuhaler® device is 
shown in Table 3.8 to Table 3.19 and Figure 3.5 to Figure 3.11. The 
comparison of aerodynamic particles size characterization results from the 
Symbicort® Turbuhaler® device shows that the FPD increases as the flow rate 
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is increased, this difference was statistically significant p < 0.001. Also, there 
is a statistical difference between flow rate 28.3L/min and 60 L/min in the 
MMAD. Where it decreases with increasing the flow rate. On the other hand, 
the effect of flow rate on FPF was statistically significant p < 0.001 and the 
high flow rate increases the FPF. Table 3.8 and Figure 3.6 shows a similarity 
in the fine particles distribution between the cascade impactors’ stages for 
formoterol, budesonide R, and budesonide S.  Furthermore, the STDEV of 
fine particles distribution reduced as the flow rate was increased which 
indicates an improvement in dosage form uniformity. On the other hand, as 
the flow increased, there was a decrease in the amount of formoterol, 
budesonide R, and budesonide S deposited in the throat induction (port and 
the pre-separator). Figure 3.11 clearly shows the decrease in the amounts 
deposited in the throat as the flow increases from 28.3 to 60 L/min. The 
results of ACI and NGCI  at 60 l/min showed an equal result in means of 
MMAD, FPF, FPFN, FPD, TDPS, GSD, In contrast, there is some differences 
in STDEV results which showed a higher STDEV with ACI. 
The abbreviation used in these tables and figures are as follow:
FPF= Fine Particle Fraction [%]
FPFN  = Fine Particle Fraction Nominal dose [%] 
TDPS= Total Dose Per Shot [ug] 
FPD= Fine Particle Dose [ug]
GSD= Geometric Standard Deviation 
MMAD = Mass Median Aerodynamic Diameter.  
STDEV= Standard Deviation
AVG= AVERAGE
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ACI 28.3 L/min = Andersen Cascade Impactor at flow rate 28.3L/min
ACI 60 L/min = Andersen Cascade Impactor at flow rate 60 L/min
NGI 60 L/min = Next Generation Impactors at 60 L/min
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Table 3.5 Mean difference for formoterol  (95% confidence interval) compared to formoterol, budesonide R and 
budesonide S at different flow rate, using ACI and NGI. (* p<0.05, ** < 0.01, ***<0.001 otherwise no significant difference)
Throat Deposition Emitted Dose FPD FPF MMAD
ACI 
28.3
L/min
Formoterol 60A 20.3**5.9- 34.8
-10.1*
-25.5- 5.2
-36.9***
-50.9- -22.9
-33.3***
-43.1- -23.5
1.3***
0.9 -1.8
Formoterol 60N 21.8**8.7- 35.0
-20.0**
-34.0- -6.1
-36.9***
-49.8- -24.0
-30.6***
-39.6- -21.7
1.0***
0.5- 1.4
BudisonideR28.3A 6.5-5.6- 18.7
5.6
-7.3- 18.6
0.1
-12.0- 12.2
-1.6
-10.1- 6.9
0.1
-0.3- 0.6
BudisonideS28.3A 0.9-11.3- 13.0
-2.3
-15.3- 10.6
-1.8
-13.9- 10.4
-2.8
-11.3- 5.7
0.0
-0.4- 0.4
ACI 60
L/min
Formoterol 28.3A -20.3**-34.8- -5.9
10.1*
-5.2- 25.5
36.9***
22.9- 50.9
33.3***
23.5- 43.1
-1.3***
-1.8- -0.9
Formoterol60N 1.4-13.4-16.4
-9.9
-25.7- 5.9
0.0
-14.7- 14.6
2.7
-7.6- 12.9
-0.4
-0.8- 0.1
BudisonideR60A -2.6-18.3- 13.1
2.1
-14.6- 18.8
3.5
-12.1- 19.2
2.3
-8.6- 13.3
-0.1
-0.6- 0.5
BudisonideS60A 3.8-11.9- 19.6
4.7
-12.0- 21.4
-0.2
-15.9- 15.4
-2.9
-13.8- 8.1
0.0
-0.5- 0.5
NGI 60
L/min
Formoterol 28.3A -21.8**-35.0- -8.7
20.0**
6.1- 34.0
36.9***
24.0- 49.8
30.6***
21.7- 39.6
-1.0***
-1.4- -0.5
Formoterol60A -1.4-16.4- 13.4
9.9
-5.9- 25.7
0.0
-14.6- 14.7
-2.7
-12.9- 7.6
0.4
-0.1- 0.8
BudisonideR60N 8.4-5.2- 22.0
12.9
-1.5- 27.4
3.4
-10.2- 16.9
-3.2
-12.7- 6.3
-0.2
-0.6- 0.3
BudisonideS60N 7.8-5.9- 21.4
3.5
-11.0- 17.9
-7.9
-21.5- 5.6
-7.3
-16.8- 2.2
-0.2
-0.6- 0.3
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Table 3.6 Mean difference for Budisonide R (95% confidence interval) compared to formoterol, budesonide R and 
budesonide S at different flow rate, using ACI and NGI. (* p<0.05, ** < 0.01, ***<0.001 otherwise no significant difference)
Throat Deposition Emitted Dose FPD FPF MMAD
ACI 
28.3
L/min
Formoterol 28.3A -6.5-18.7- 5.6
-5.6
-18.6- 7.3
-0.1
-12.2- 12.0
1.6
-6.9- 10.1
-0.1
-0.6- 0.3
BudisonideR60A 11.2-3.3- 25.6
-13.7*
-29.0- 1.7
-33.4***
-47.4- -19.4
-29.4***
-39.2- -19.6
1.1***
0.7- 1.6
BudisonideR60N 23.6**10.5- 36.8
-12.8*
-26.7-1.2
-33.6***
-46.5- -20.8
-32.2***
-41.2- -23.3
0.7**
0.2- 1.1
BudisonideS28.3A -5.7-17.8- 6.5
-8.0
-20.9-4.9
-1.9
-14.0- 10.2
-1.2
-9.67- 7.27
-0.1
-0.5- 0.3
ACI 
60
L/min
Formoterol60A 2.6-13.1- 18.3
-2.1
-18.8- 14.6
-3.5
-19.2- 12.1
-2.3
-13.3- 8.6
0.1
-0.5- 0.6
BudisonideR28.3A -11.2-25.6- 3.3
13.7*
-1.7- 29.0
33.4***
19.4- 47.4
29.4***
19.6- 39.2
-1.1***
-1.6- -0.7
BudisonideR60N 12.5-2.4- 27.3
0.9
-14.9- 16.7
-0.2
-14.8- 14.4
-2.9
-13.1- 7.4
-0.5
-1.0- 0.0
BudisonideS60A 6.4-9.3- 22.2
2.6
-14.1- 19.3
-3.7
-19.4- 11.9
-5.2
-16.1- 5.8
0.0
-0.5- 0.6
NGI 
60
L/min
Formoterol60N -8.4-22.0- 5.2
-12.9
-27.4- 1.5
-3.4
-16.9- 10.2
3.2
-6.3- 12.7
0.2
-0.3- 0.6
BudisonideR28.3A -23.6**-36.8- -10.5
12.8*
-1.2- 26.7
33.6***
20.8- 46.5
32.2***
23.3- 41.2
-0.7**
-1.1- -0.2
BudisonideR60A -12.5-27.3- 2.4
-0.9
-16.7-  14.9
0.2
-14.4- 14.8
2.9
-7.4- 13.1
0.5
0.0- 1.0
BudisonideS60N -0.6-14.2- 13.0
-9.4
-23.9- 5.0
-11.3
-24.8- 2.3
-4.1
-13.6- 5.4
0.0
-0.4- 0.5
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Table 3.7 Mean difference for Budisonide S (95% confidence interval) compared to formoterol, budesonide R and 
budesonide S at different flow rate, using ACI and NGI. (* p<0.05, ** < 0.01, ***<0.001 otherwise no significant difference)
Throat Deposition Emitted Dose FPD FPF MMAD
ACI 
28.3
L/min
Formoterol 28.3-A -0.9-13.0- 11.3
2.3
-10.6- 15.3
1.8
-10.4- 13.9
2.8
-5.7- 11.3
0.0
-0.4- 0.4
BudisonideR28.3A 5.7-6.5- 17.8
8.0
-4.9- 20.9
1.9
-10.2- 14.0
1.2
-7.3- 9.7
0.1
-0.3- 0.5
BudisonideS60A 23.3**8.8- 37.8
-3.1*
-18.4- 12.3
-35.3***
-49.3- -21.3
-33.4***
-43.1- -23.6
1.3***
0.8- 1.8
BudisonideS60N 28.7***15.6- 41.9
-14.2*
-28.2- -0.3
-43.0***
-55.9- -30.2
-35.1***
-44.1- -26.1
0.8**
0.4- 1.2
ACI 
60
L/min
Formoterol60A -3.8-19.6- 11.9
-4.7
-21.4- 12.0
0.2
-15.4- 15.9
2.9
-8.1- 13.8
0.0
-0.5- 0.5
BudisonideR60A -6.5-22.2- 9.3
-2.6
-19.3- 14.1
3.7
-11.9- 19.4
5.2
-5.8- 16.1
0.0
-0.6- 0.5
BudisonideS28.3A -23.3**-37.8- -8.8
3.1*
-12.3- 18.4
35.3***
21.3- 49.3
33.4***
23.6- 43.1
-1.3***
-1.8- -0.8
BudisonideS60N 5.4-9.5- 20.3
-11.1
-26.9- 4.7
-7.8
-22.4- 6.9
-1.8
-12.0- 8.5
-0.5
-1.0- 0.0
NGI 
60
L/min
Formoterol60N -7.8-21.4- 5.9
-3.5
-17.9- 11.0
7.9
-5.6- 21.5
7.3
-2.2- 16.8
0.2
-0.3- 0.6
BudisonideR60N 0.6-13.0- 14.2
9.4
-5.0- 23.9
11.3
-2.3- 24.8
4.1
-5.4- 13.6
0.0
-0.5- 0.4
BudisonideS28.3A -28.7***-41.9- -15.6
14.2*
0.3- 28.2
43.0***
30.2- 55.9
35.1***
26.1- 44.1
-0.8**
-1.2- -0.4
BudisonideS60A -5.4-20.3- 9.5
11.1
-4.7- 26.9
7.8
-6.9- 22.4
1.8
-8.5- 12.0
0.5
0.0- 1.0
Aero-characterisation of Symbicort® Turbuhaler®                                                             Chapter3 
130
Table 3.8 A comparison of amount of formoterol, budesonide R and 
budesonide S using five doses, deposited on each stage of ACI at 28.3 L/min 
from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port  [g] 3.54 0.62 105.23 22.25 112.33 36.64
Pre-separator [g] 4.72 1.34 143.97 38.50 159.56 61.87
Stage 0 [g] 0.06 0.05 1.61 2.11 2.82 3.84
Stage 1 [g] 0.16 0.08 5.25 3.92 5.24 3.85
Stage 2 [g] 0.31 0.18 13.18 9.28 13.86 9.21
Stage 3 [g] 0.84 0.54 26.87 11.20 29.89 11.58
Stage 4 [g] 0.55 0.27 22.86 8.49 25.45 8.64
Stage 5 [g] 0.44 0.33 15.14 10.76 16.71 11.27
Stage 6 [g] 0.00 0.00 0.17 0.04 0.22 0.06
Stage 7 [g] 0.00 0.00 0.17 0.04 0.22 0.06
Filter [g] 0.00 0.00 0.17 0.04 0.22 0.06
Nominal Dose [g] 12 400 400
Percentage [%] 88.5 20 83.6 14.19 91.63 15.02
TDPS  [g] 10.71 2.37 334.62 56.78 370.19 63.47
FPD  [g] 2.13 1.00 70.48 31.72 77.98 32.19
FPFN [%] 17.73 8.36 17.62 7.93 19.49 8.05
FPF [%] 19.16 5.6 20.77 8.03 21.98 10.68
MMAD [um] 3.62 0.14 3.48 0.16 3.61 0.22
GSD 1.43 0.03 1.44 0.08 1.51 0.14
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Table 3.9 A comparison of percentage of formoterol, budesonide R and 
budesonide S using five doses, deposited on each stage of ACI at 28.3 L/min 
from Symbicort® Turbuhaler® device.
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port   [%] 33.05 5.86 31.45 7.09 30.34 12.00   
Pre-separator [%] 44.05 12.71 43.03 12.27 43.10 20.25   
Stage 0  [%] 0.54 0.50 0.48 0.67 0.76 1.26   
Stage 1  [%] 1.47 0.71 1.57 1.25 1.41 1.26   
Stage 2  [%] 2.85 1.74 3.94 2.96 3.74 3.02   
Stage 3  [%] 7.88 5.13 8.03 3.57 8.08 3.79   
Stage 4  [%] 5.16 2.59 6.83 2.71 6.87 2.83   
Stage 5  [%] 4.13 3.08 4.52 3.43 4.51 3.69   
Stage 6  [%] 0.03 0.00 0.05 0.01 0.06 0.02   
Stage 7  [%] 0.03 0.00 0.05 0.01 0.06 0.02   
Filter  [%] 0.03 0.00 0.05 0.01 0.06 0.02   
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Ind
uc
t io
n  p
ort
pr e
-s e
pa
rat
or 
s ta
g e
 0
s ta
g e
1
s ta
g e
 2
s ta
g e
 3
s ta
g e
 4
s ta
g e
 5
s ta
g e
 6
s ta
g e
 7
F il
te r
form otero l
B udes onide R
B udes onide S
Figure 3.5 A comparison of percentage of formoterol, budesonide R and 
budesonide S deposited on each stage of ACI, at 28.3 L/min from Symbicort® 
Turbuhaler® device.
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Table 3.10 A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
ACI at 28.3 L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
Stage 0 [%} 100.0 100.0 100.0
Stage 1 [%} 100.0 100.0 100.0
Stage 2 [%} 93.20 93.74 94.30
Stage 3 [%} 79.98 78.01 79.20
Stage 4 [%} 43.47 45.95 46.64
Stage 5 [%} 19.55 18.67 18.92
Stage 6 [%} 0.42 0.61 0.71
Stage 7 [%} 0.28 0.41 0.48
Filter [%} 0.14 0.20 0.24
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Figure 3.6 A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
ACI at 28.3 L/min from Symbicort® Turbuhaler® device
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Table 3.11 A comparison of the amount of formoterol, budesonide R and 
budesonide S using five doses, deposited on each stage of the ACI at 60 
L/min from Symbicort® Turbuhaler® device. 
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port  [g] 4.57 0.62 161.25 25.77 135.52 11.87
Pre-separator [g] 0.92 0.41 31.97 13.63 31.90 15.76
Stage -1 [g] 0.11 0.06 1.65 2.55 1.54 2.65
Stage - 0 [g] 0.27 0.08 6.06 4.00 6.76 4.62
Stage 1 [g] 0.51 0.30 16.26 10.73 17.88 11.44
Stage 2 [g] 0.99 0.17 33.81 4.22 35.82 8.49
Stage 3 [g] 1.81 0.24 60.51 8.22 63.59 15.88
Stage 4 [g] 1.99 0.99 62.55 30.70 67.20 28.00
Stage 5 [g] 0.95 0.78 24.09 21.45 28.69 27.69
Stage 6 [g] 0.30 0.40 6.68 11.14 5.95 10.29
Filter [g] 0.01 0.01 0.49 0.56 0.01 0.00
Nominal Dose [g] 12 400 400
Percentage [%] 103.51 9.36 101.33 17.22 98.71 10.76
TDPS [g] 12.41 1.12 405.19 68.84 394.85 43.03
FPD [g] 6.55 1.50 204.27 46.08 219.13 34.87
FPFN [%] 54.58 12.46 51.07 11.52 54.78 8.72
FPF [%] 52.48 8.32 50.15 3.79 55.34 3.90
MMAD [m] 2.30 0.62 2.35 0.56 2.31 0.63
GSD 1.93 0.23 1.83 0.26 1.86 0.30
Table 3.12 A comparison of the percentage of formoterol, budesonide R 
and budesonide S using five doses, deposited on each stage of the ACI at 60 
L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port [%] 34.33 4.68 34.92 5.58 32.06 2.81
Pre-separator [%] 6.88 3.05 6.92 2.95 7.55 3.73
Stage -1 [%] 0.82 0.43 0.36 0.55 0.36 0.63
Stage - 0 [%] 2.05 0.60 1.31 0.87 1.60 1.09
Stage 1 [%] 3.85 2.27 3.52 2.32 4.23 2.71
Stage 2 [%] 7.42 1.28 7.32 0.91 8.47 2.01
Stage 3 [%] 13.62 1.78 13.10 1.78 15.04 3.76
Stage 4 [%] 14.96 7.45 13.54 6.65 15.90 6.62
Stage 5 [%] 7.13 5.83 5.22 4.64 6.79 6.55
Stage 6 [%] 2.23 3.04 1.45 2.41 1.41 2.43
Filter [%] 0.07 0.05 0.11 0.12 0.00 0.00
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Figure 3.7 A comparison of the percentage of formoterol, budesonide R 
and budesonide S using five doses, deposited on each stage of the ACI at 60 
L/min from Symbicort® Turbuhaler® device
Table 3.13 A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
ACI at 60 L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
Stage – 1 [%] 100.00 100.00 100.00
Stage -0 [%] 98.49 99.36 99.43
Stage 1 [%] 94.59 96.67 96.64
Stage 2 [%] 86.38 88.31 88.18
Stage 3 [%] 71.32 71.43 71.68
Stage 4 [%] 43.86 41.44 42.50
Stage 5 [%] 16.28 13.09 13.76
Stage 6 [%] 3.75 2.83 2.21
Filter [%] 0.15 0.28 0.00
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Figure 3.8 A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
ACI at 60 L/min from Symbicort® Turbuhaler® device
Table 3.14    A comparison of the percentage of formoterol, budesonide R 
and budesonide S using five doses, deposited on each stage of the NGI 60 
L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port [%] 36.34 6.73 37.46 3.11 35.01 4.29
Pre-separator [%] 4.68 1.4 0.47 0.23 0.13 0.24
Stage 1 [%] 1.87 0.25 0.68 0.51 0.47 0.56
Stage 2 [%] 10.17 1.27 12.41 1.64 12.28 1.53
Stage 3 [%] 15.34 1.93 17.88 1.43 19.18 1.57
Stage 4 [%] 17.9 1.97 20.26 0.63 21.45 1.04
Stage 5 [%] 10.11 1.07 9.47 0.29 10.57 0.83
Stage 6 [%] 3.07 0.17 0.79 0.58 0.92 0.62
Stage 7 [%] 0.5 0.14 0.27 0.19 0 0
MOC [%] 0.03 0.03 0.3 0.19 0 0
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Figure 3.9 A comparison of the percentage of formoterol, budesonide R 
and budesonide S using five doses, deposited on each stage of the NGI at 60 
L/min from Symbicort® Turbuhaler® device
Table 3.15   A comparison of the amount of formoterol, budesonide R and 
budesonide S using five doses, deposited on each stage of the NGI at 60 
L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
AVG STDEV AVG STDEV AVG STDEV
Induction port  [g] 4.75 1.00 143.3 22.22 146.8 5.98
Pre-separator [g] 0.60 0.13 1.72 0.56 0.60 1.15
Stage 1 [g] 0.25 0.06 2.90 2.58 2.14 2.66
Stage 2 [g] 1.35 0.32 48.59 14.82 52.50 11.69
Stage 3 [g] 2.03 0.46 69.50 17.92 81.65 15.18
Stage 4 [g] 2.35 0.44 78.03 14.89 91.10 13.71
Stage 5 [g] 1.32 0.21 36.46 6.71 44.66 4.83
Stage 6 [g] 0.40 0.06 3.36 2.82 4.08 2.82
Stage 7 [g] 0.07 0.02 0.93 0.49 0.01 0.00
MOC [g] 0.00 0.00 1.05 0.45 0.01 0.00
Nominal Dose 12 400 400
Percentage [%] 109.4 13.84 96.46 19.11 105.9 11.63
TDPS  [g] 13.13 1.66 385.8 76.43 437.5 29.32
FPD [g] 6.56 1.27 205.0 44.7 250.2 25.8
FPFN [%] 54.63 10.61 51.27 11.19 62.56 6.45
FPF[%] 49.80 5.36 53.03 1.80 57.10 2.10
MMAD [m] 2.65 0.09 2.82 0.13 2.80 0.07
GSD 1.88 0.02 1.74 0.04 1.72 0.05
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Table 3.16   A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
NGI at 60 L/min from Symbicort® Turbuhaler® device
Stage Formoterol Budesonide R Budesonide S
Stage 1 [%] 100.0 100.0 100.0
Stage 2 [%] 96.81 98.92 99.31
Stage 3 [%] 79.57 78.98 80.42
Stage 4 [%] 53.59 50.20 50.86
Stage 5 [%] 23.25 17.50 17.76
Stage 6 [%] 6.10 2.19 1.39
Stage 7 [%] 0.88 0.93 0.01
MOC [%] 0.04 0.49 0.00
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Figure 3.10   A comparison of cumulative mass percentages under size for 
formoterol, budesonide R and budesonide S deposited on each stage of the 
NGI at 60 L/min from Symbicort® Turbuhaler® device
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Table 3.17   Percentage of formoterol using five doses, deposited on each 
stage of ACI at two different flow rate  28.3 L/min and 60 L/min and NGI at 
60L/min. from Symbicort® Turbuhaler® device diveded by number of doses
ACI 28.3 ACI  60 NGI 60
AVI STDEV AVI STDEV AVI STDEV
Induction port [%] 33.48 5.86 34.33 4.68 36.34 6.73
Pre-separator [%] 44.63 12.71 6.88 3.05 4.68 1.4
Percentage [%] 88.58 20 103.5 9.36 109.4 13.84
TDPS  [g] 10.71 2.37 12.41 1.12 13.13 1.66
FPD  [g] 2.13 1 6.55 1.5 6.56 1.27
FPFN [%] 17.73 8.36 54.58 12.46 54.63 10.61
FPF [%] 19.16 5.6 52.48 8.32 49.8 5.36
MMAD [m] 3.62 0.14 2.3 0.62 2.65 0.09
GSD 1.43 0.03 1.93 0.23 1.88 0.02
Flow Rate [L/min] 28.3 60 60
Table 3.18   Amount (ug) of budesonide R using five doses, deposited on 
each stage of the ACI at two different flow rate  28.3 L/min and 60 L/min and 
NGI at 60L/min. from Symbicort® Turbuhaler® device 
ACI 28.3 ACI  60 NGI 60
AVG STDEV AVG STDEV AVG STDEV
Induction port  [%] 33.54 7.09 34.92 5.58 36.34 6.73
Pre-separator [%] 45.90 12.27 6.92 2.95 4.68 1.40
Percentage [%] 78.42 14.19 101.33 17.22 96.46 19.11
TDPS  [g] 334.62 56.78 405.19 68.84 385.84 76.43
FPD  [g] 70.48 31.72 204.27 46.08 205.06 44.7
FPFN [%] 17.62 7.93 51.07 11.52 51.27 11.19
FPF [%] 20.77 8.03 50.15 3.79 53.03 1.80
MMAD [m] 3.48 0.16 2.35 0.56 2.82 0.13
GSD 1.44 0.08 1.83 0.26 1.74 0.04
Flow Rate [L/min] 28.3 60 60
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Table 3.19   Amount (ug) of budesonide S using five doses, deposited on 
each stage of the Andersons Cascade impactor at two different flow rate  28.3 
L/min and 60 L/min and Next generation Cascade impactor at 60L/min. from 
Symbicort® Turbuhaler® device diveded by number of doses
ACI 28.3 ACI  60 NGI 60
AVG STDEV AVG STDEV AVI STDEV
Induction port [%] 36.77   12.00 32.06 2.81 35.01 4.29
Pre-separator [%] 52.23   20.25 7.55 3.73 0.13 0.24
Nominal Dose 400 0.00 400 00 400 0.00
Percentage [%] 76.37 15.02 98.71 10.76 105.90 11.63
TDPS  [g] 305.48 63.47 394.85 43.03 437.50 29.32
FPD  [g] 112.40 32.19 219.13 34.87 250.23 25.8
FPFN [%] 28.10 8.05 54.78 8.72 62.56 6.45
FPF [%] 36.79 10.68 55.34 3.90 57.10 2.10
MMAD [um] 3.46 0.22 2.31 0.63 2.80 0.07
GSD 1.55 0.14 1.86 0.30 1.72 0.05
Flow Rate [L/min] 28.3 60 60
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Figure 3.11   Percentage of formoterol, budesonide R, and budesonide S 
using five doses, deposited on pre-separator stage + induction port (throat 
deposition) of the ACI at 28.3L/min and 60 L/min from Symbicort® Turbuhaler® 
device.
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DISCUSSION
The influence of flow rate on drug delivery via the Turbuhaler® has been 
investigated in this study. The results showed that a direct relationship exists 
between flow rate through the Turbuhaler® and the deposition on the stages. 
The literatures  suggested similar data were reported for terbutaline sulphate
in an in-vivo study (Newman et al., 1991). Equally in-vitro results suggested 
that a high flow rate through the Turbuhaler® eases deaggregation of drug 
particles, it reduces particle impaction in the oropharynx, and therefore 
enhances lung deposition (Jaegfeldt et al., 1987). Other studies on dry 
powder inhalers when operated at 28 L/min revealed lower value for drug lung 
deposition. For instance the value for Spinhaler® was 12% (Auty et al., 1987),
and for Rotahaler® and Diskhaler® were close to 10% (Vidgren et al., 1988, 
Biddiscombe M, 1991, Biddiscombe et al., 1993). 
Tarsin and co-workers (2006) demonstrate that adult patients with severe 
asthma achieved a high inspiratory flow rate through the Turbuhaler®. On the 
other hand it has been reported that, the most preferred inhalation rate for 
Turbhaler was 60 L/min (Borgstrom et al., 1996). In addition, Engel co-
workers (1989) measured the flow through the Turbuhaler device for a variety 
of patients with different severities of asthma using the FEV,% of predicted as 
the severity marker they found the mean peak inspiratory flow rate was 59 
L/min with a range from 25 to 93 L/min.
The results of the MMAD and FPF showed a decrease in value as the flow 
was increased. The Symicort® formulation consists of formoterol, budesonide 
and lactose monohydrate as carrier (SYMBICORT®_Product_Information, 
2008). The carrier plays an important factor for the fine particle size 
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dispersion. It has been recognized earlier that separation of drugs and carrier 
particles occurs easer when the carrier crystals are smaller (Engel et al., 
1992). Engel and co-workers (1992) examined a mixture of small drug 
crystals and large carrier particles, and they found the drug particles larger 
than 5 µm are separated at flows of 60 L/min while particles in the size range 
5 – 7 µm needed a higher inhalation flow to be separated. As a consequence, 
the efficiency of the penetration and deposition within the airways is 
dependant upon both the inhalation flow rate and the aerodynamic size 
distribution of the inhaled aerosol. At a specific flow rate, the higher pressure 
drop devices such as Turbuhaler produced a higher FPF compared with the 
lower pressure drop devices that used capsule reservoirs. The high specific 
resistance devices would be expected to generate higher turbulence, and thus 
the high turbulence will generate a higher FPF (Engel et al., 1990).
For a patient reaching high inhalation flows it will be more likely that lung 
deposition will be increased and hypothetically more doses would be 
deposited in the central zone of the lungs. 
Amounts of budesonide and formoterol emitted from the same dose were 
similar. The inter-inhaler variability for the combination product is similar to 
that previously shown in a study (Tarsin et al., 2004). Nevertheless, Zanen 
and co-workers (1992) demonstrated that the high availability of salbutamol 
mass due to increasing the flow rate was not expressed as a stronger 
bronchodilator. Also they concluded that the impactor is able to detect minor 
differences but these are too small to make clinical differences. 
Figure 1.11 shows that at a 60 L/min flow rate the particles deposition in the 
throat the pre-separator and the induction port) has reduced compared to a 
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flow rate of 28.3L/min. An explanation for this change can be linked to the 
change in flow rate. Since the high flow rate enhances particle de-aggregation 
and reduces the MMAD as result less large particles will be available to 
deposit in the pre-separator (Jaegfeldt et al., 1987). 
The cumulative mass percentages under size 3 µm have increased for 
formoterol and two epimers of budesonide. Zanen and co-workers (1996)
conducted a study to determine the optimal particle size for a bronchodilator 
and their results demonstrated that the 3 µm has an optimum clinical effect. 
The study also showed that particles having a diameter greater than 5 µm 
have a tendency to either deposit in the throat or the mouth and therefore, 
they show significantly lower clinical effect. 
CONCLUSION
This chapter has helped in the understanding of the effect of flow on the 
particle size deposition into various regions of the lung. In-vitro flow–
dependency for particle deposition among cascade impactors has been 
demonstrated for a combination of budesonide and formoterol. The effect of 
this was more obvious for the FPD and the throat deposition. From the data 
obtained it can be expected that at a lower flow rate the drug particles might 
be deposited on the oropharyngeal. In addition the low fine particle dose 
indicated that lung deposition would be low.
Since, most of the DPIs such as the Turbuhaler®, devices depend on the 
patient's inspiratory influence to emit and deaggregate the drug, device design 
should minimize patient factors such as flow rate effects, environmental 
effects, and complexity in operation this will ensure that   the patient receive a 
safe and efficacious dose. The design of different dry powder inhaler devices 
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results in different resistances. A higher air velocity is more likely to induce 
turbulent air than a low velocity. The higher the turbulence generated by the 
device, the greater the FPF that is likely to be obtained. It is a principle in the 
formulation of a dry powder that the device should give a high FPF of drug 
whilst the carrier such as lactose, in the formulation should remain only in the 
upper airways. 
The flow-dependent particle deposition results emphasize the need for the 
Pharmacopoeias to use a variety of inhalation flow rates for in-vitro tests 
rather than one that is determined according to the resistance of the dry 
powder inhaler.
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CHAPTER 4
Performance of a small-volume valved holding 
chamber and small spacer with several 
beclomethasone brand-name preparations delivered 
by pressurised metered dose inhalers.
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4 PERFORMANCE OF SMALL-VOLUME VALVED HOLDING 
CHAMBER AND SMALL SPACER WITH SEVERAL BECLOMETHASONE 
BRAND-NAME PREPARATIONS DELIVERED BY PRESSURISED 
METERED DOSE INHALERS.
OBJECTIVE
The main objective of this study is to examine the dose emission of different 
brand names of beclomethasone formulations alone and attached to spacers. 
Many parameters have been compared including washed versus unwashed 
and the number of actuated doses. A secondary aim is to examine the 
hypothesis of whether the result of a specific spacer with a given drug/ brand 
name can be extrapolated to other pMDIs or brand names for the same drug.   
INTRODUCTION
As shown in the  literatures review pMDIs are a convenient way of 
administering medication which includes bronchodilators and corticosteroids,
for patients with asthma and COPD. As indicated they emit an aerosol at high 
velocity and to be used properly they require coordination of inhalation and 
pMDI actuation. But, even with an optimum technique, only < 15% of the 
emitted dose regularly reaches the airways. Spacer devices were introduced 
to try to improve the efficacy of inhaled therapy with pMDIs by decreasing the 
need for coordination between actuation and inhalation and by allowing 
deceleration and evaporation of propellant, so decreasing oropharyngeal 
deposition of therapy. In operation however, part of the inhaled drug is lost 
within the spacer. The major cause of the loss is impaction due to inertia, 
sedimentation due to reduced speed of the aerosol particles and adsorption 
due to electrical charge Figure 4.1. The loss by impaction occurs immediately 
after actuation, and loss due to sedimentation and adsorption is time-
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dependent (Bisgaard et al., 2002). Many different spacer devices are 
currently available, some designed to fit with one particular product, while 
others are intended for use with a variety of pMDIs. 
During these early devices, CFCs have traditionally served as the propellant 
of choice for use with pMDIs. But as discussed, they deplete the Ozone Layer 
as initially noted by Molina and Rowland (Molina et al., 1974). This 
discoverery and the introduction of legislation prompted a change.
Figure 4.1 Mechanism of aerosol loss within a spacer.
Example was DPIs which were recognised as a suitable alternative; however,
not all inhaled drug were available in DPIs. Furthermore, they are not always 
suitable for all patients, for example, those with low inspiratory flow rate 
(young, asthmatic, elderly and COPD patients) and low cognitive capability 
patients. Also DPIs may not be suitable in certain humid climates. In some 
situations, their extra expense would also deprive many of necessary therapy. 
As the same time as the development of DPIs alternative propellants were 
being investigated in pMDIs, HFAs were identified as suitable, non-ozone-
depleting alternatives (Terzano, 2001). In addition, HFA134a was approved 
by the Committee for Proprietary Medicinal Products (CPMP) under the 
European Medicines Evaluation Agency (EMEA), As a result of the 
introduction of these new propellants, many formulation changes were 
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needed. And the incorporation of co-solvents such as ethanol, was used in 
either suspension or solution formulations (Cripps et al., 2000). This 
reformulation however led to discernible changes in some properties of the 
final products, which included extra-pulmonary deposition, taste and/ or lung 
deposition (Bisgaard et al., 2002).
In this work the following formulations are examined:
 Qvar® is a CFC-free pMDI designed for oral inhalation. Each unit 
contains a solution of beclomethasone dipropionate in HFA-134a 
(1,1,1,2 tetrafluoroethane) propellant and ethanol. In operation the 
Qvar should be actuated twice prior to use of the first dose from a new 
canister or when the inhaler has not been used for more than 10 days
(Qavr®_Product-information, 2006). 
 Beclazone® is a CFC formulation, which provides beclomethasone in a
suspension form. The Beclazone list of excipients comprises oleic acid, 
dichlorodifluoromethane and trichlorofluoromethane
(Beclazone_Product-information, 2004). 
 The third inhaler used in this work, Clenil® also uses HFA 134a as the 
propellant. The formulation is a solution as opposed to the suspension 
formulations which were formerly used in pMDIs containing CFC. This 
pMDI is formulated from glycerol as non-volatile co-solvent, anhydrous 
ethanol as co-solvent and HFA-134 as propellant (CLENIL®_Product-
information, 2007b). 
 Becloforte ® and Becotide ® are CFC formulations, with the same 
formulation consisting of oleic acid, dichlorodifluoromethane and 
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trichlorofluoromethane (Becotide™_Product-information, 2007, 
Becloforte_Product-information, 2003).
Table 4.1 summarises the list of excipients of inhalers used in the 
experiments. And the spacers are indicated below:
 AeroChamber MAX® (AMAX) is VHC. The volume of AMAX is 198 mL. 
It is manufactured from a shatter-resistant, clear, anti-static polymer 
blend. The chamber has been completely redesigned for use with 
HFAs formulations. Furthermore, it is a universal pMDI VHC. It 
incorporates a Flow-Vu™ the Inspiratory Flow Indicator to provide the 
caregiver with reassurance of medication delivery to the lungs. Also it 
has a one-way, low resistance duckbill valve system
(Aerochamber_Max_Product-Monograph, 2006). 
 In contrast with the AMAX, the Aerochamber PLUS® VHC (APLUS) is 
prone to static and the volume is 149 mL. But it can be used with 
various pMDIs (Aerochamber_Plus_Product-Monograph, 2005). 
 The Optimizer® is a spacer with 50 mL volume. It comprises a plastic 
tube with a cross section of 2.5 x 3.5 cm. and has an overall length of 
10 cm (Hardy et al., 1996).
METHODOLOGY  
4.1.1 Instrumentation 
4.1.1.1 Equipment and inhalation device
The equipment used for the dose emission study is described in section 2.1 
2.2. 
The analytical HPLC method is detailed in section 2.6.
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Table 4.1 List of excipients. 
Inhaler CFC Alcohol 
content 
/ actuation
Excipients
Becotide Yesa Nilb Oleic acid, 
dichlorodifluoromethane  
trichlorofluoromethanec
Becloforte Yesa Nilb Oleic acid, 
dichlorodifluoromethane 
trichlorofluoromethaned
Beclazone
Easi-Breathe
Yesa Nilb Oleic acid, 
dichlorodifluoromethane 
trichlorofluoromethanee
Beclazone pMDI Yesa Nilb Oleic acid, 
dichlorodifluoromethane 
trichlorofluoromethanee
Qvar pMDI Noa 8.35  mgb HFA-134a, ethanolf
Qvar Easi-Breathe Noa 8.35  mgb HFA-134a, ethanolf
Qvar pMDI 50 µg Noa 8.35  mgb HFA-134a, ethanolf
Clenil modulite Noa 9mgb Glycerol,
ethanol anhydrous 
HFA-134g
a- (BNF, 2008). b- (Alrasbi et al., 2008), c- (Becotide™_Product-information, 
2007), d- (Becloforte_Product-information, 2003), e- (Beclazone_Product-
information, 2004), f- (Qavr®_Product-information, 2006),g-
(CLENIL®_Product-information, 2007b)
4.1.1.2 Instrumentation set up
The dose emission method described in the British Pharmacopeia (BP) for 
pMDIs was used. The initial work was to prepare the sampling apparatus for 
pMDIs Figure 4-2. All parts of the sampling apparatus for pMDIs were washed 
with acetone and dried and the apparatus was then assembled as described 
in the manufacture’s manual, which incorporates an after filter to capture any 
particles which would otherwise escape from the apparatus.
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Figure 4.2 Sampling Apparatus for pMDIs Source: (Copley, 2007).
Figure 4.3 illustrates the positioning of the sampling apparatus for pMDIs, the 
critical flow controller and the vacuum pump. The mouthpiece adapter was 
attached to the end of the sampling apparatus for the pMDIs/spacer. The flow 
control valve was adjusted to achieve a steady flow through the system at the 
required rate, 28.3L/min (±5%) which was measured by an electronic digital 
flow meter Model (DFM). According to the pharmacopeia method, 4 L of air 
was drawn through the inhaler for each determination and the absolute 
pressure ratio P3/P2 < 0.5 was confirmed. 
Each pMDI/spacer was prepared according to the patient leaflet instructions
(see appendix A) and was actuated into the collecting tube by opening the 
valve if the device was breath-actuated, otherwise it was operated by pressing 
down on the inhaler to release its contents (n=10). When 2 doses were
required the patient leaflet instructions were followed (see appendix A).
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The time 8.4 sec (±5%) was calculated according to equation 4-1.
T = 
Q
X x sec60
…………………………………… Equation 4-1
where T = Time duration consistent for withdrawal of X litres of air from the 
inhaler
Q = Flow rate required 
X = Volume L to be drawn through inhaler
The mean content of drug per actuation was tested at different points between 
the first and final actuation. Randomised sampling tables were used for 
studying the dose emission over the entire set of inhalers. 
Determinations were made for each pMDI and for attached to each of the 
three different spacers. The spacers were the Optimizer® spacer, the AMAX 
and the APLUS. Table 4.2 summarise the experiments. In these experiments, 
the Becotide actuator was washed with water and was compared with 
unwashed Becotide.   
Once used the apparatus was dismantled carefully to avoid any loss of 
material. And the emitted dose was washed from the collection tube/spacer 
into 50 mls of a washing solution (acetonitrile: water 70:30, v/v).
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Table 4.2   List of dose emission experiments conducted
Experiment  n=10 
Beclazone 100 µg 2 doses  Easi-Breathe® 
Beclazone100 µg 2 doses AMAX
Beclazone100 µg 2 doses APLUS
Beclazone 250 µg  1 dose Easi-Breathe®  Optimiser ®
Beclazone 250 µg 2 doses Easi-Breathe® 
Beclazone 250 µg  2 doses Easi-Breathe®  Optimiser
Becloforte 1 dose
Becloforte 1 dose  AMAX
Becloforte 1 dose APLUS
Becloforte 2 doses
Becloforte 2 doses APLUS
Becotide 100 µg  2 doses unwashed
Becotide 100 µg  2 doses washed
Becotide100 µg 2 doses  AMAX
Becotide 100 µg 2 doses Optimiser
Clenil 100 µg 2 doses 
Clenil 100 µg 2 doses AMAX
Clenil 100 µg 2 doses APLUS
Clenil 250 µg 1 dose 
Clenil 250 µg 1 dose AMAX
Clenil 250 µg 1 dose APLUS
Qvar 50 µg 1 dose  Aerosol
Qvar 50 µg  1 dose Aerosol APLUS
Qvar 50 µg 2 doses Aerosol
Qvar 50 µg  2 doses Aerosol AMAX
Qvar 50 µg  2 doses Aerosol APLUS
Qvar 100 µg 1 dose Aerosol Optimiser
Qvar 100 µg 2 doses Aerosol Optimiser
Qvar 100 µg 2 doses Easi-Breathe® 
Qvar 100 µg 1 dose Easi-Breathe AMAX
Qvar 100 µg 1 dose  Easi-Breathe APLUS
Qvar 100 µg 1 dose Easi-Breathe Optimizer
Qvar 100 µg 1 dose Easi-Breathe 
Both the collecting tube and spacer content is reported separately.  The drug 
under test was extracted from the filter into the washing solution.
In order to ensure complete extraction, the filter was sonicated for three 
minutes in the washing solution. Also, the washing solution from the filter was 
further filtered through a 0.45 μm filter in order to remove any unwanted 
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particles which might block the HPLC system. The amount of drug was 
determined by HPLC using the previously validated method described in 
section 2.6.
STATISTICAL ANALYSIS
One-way ANOVA with Bonferroni effect test was used to compare the emitted 
dose with different brands using SPSS V15.0 (SPSS Inc., Chicago, USA).
RESULTS AND DISCUSSION
4.1.2 Dosage uniformity
Table 4.3 shows the measured reproducibility of dose emissions (dosage 
uniformity) from each of the inhalers and average percentage of label claim 
emitted from each inhaler. For comparative purposes, the emitted percentage 
was calculated as the amount of drug extracted from the sampling apparatus 
expressed as a percentage of the product label claim. On the other hand, 
when the spacers were compared together, the amount of delivered drug was
expressed as a percentage of the product of the emitted dose. However, 
when the performance of the spacer with drug alone was compared, the 
amount of delivered drug was expressed as a percentage of the product 
nominal dose.
The variability of dose emissions from the pMDIs was found to be relatively 
high, particularly those with the CFC formulations, both within and between 
devices. The STDEV associated with the emitted doses from CFC-free 
formulations devices were significantly lower e.g. Qvar ®. Bisgard and co-
workers (2002) reported that the introduction of the CFC-free formulation has 
led to improve dosage uniformity from first to last with the new devices.
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Table 4.3 Average and ±STDEV of total emitted dose % (nominal dose) 
from different formulations of beclomethasone at 28.3 L/min.
Experiment (n=10) Delivered drug (%)
STDEV
(%)
Qvar 50 µg 2 doses 86.26 3.82
Qvar 100 µg Easi-Breathe ® 1 dose 101.33 4.83
Qvar 50 µg 1 dose  84.67 5.37
Beclazone 100 µg Easi-Breathe ® 2 doses 100.61 5.61
Clenil 100 µg 2 doses 97.42 7.73
Qvar 100 µg Easi-Breathe ® 2 doses 100.86 8.33
Clenil 250 µg 1 dose 95.73 9.49
Becloforte 2 doses 100.58 11.23
Beclazone 250 µg Easi-Breathe ® 2 doses 93.54 15.42
Becloforte 1 dose 101.02 18.95
Becotide 100 µg 2 doses washed 106.66 22.00
Becotide 100 µg 2 doses unwashed 116.53 27.01
STDEV= Standard Deviation
Cripps co-workers (2000) showed consistent performance for HFA134a
formulated pMDIs, and the overall STDEV per actuation was within 10%. 
Moreover, CFC inhalers are suspensions and usually, suspension 
formulations are sensitive to the effect of separation of the suspended drug 
within the valve on standing due to sedimentation or creaming. As a result the 
dosing characteristic of the inhaler may be affected. 
There is a significant difference between the unwashed and washed average 
emitted dose for Becotide (p< 0.05) and there is also a difference between the 
STDEV for unwashed and washed Becotide. Failure to wash the mouthpiece 
can lead to inconsistent dose and aerosol particle size (Terzano, 2001). 
Furthermore, Berlnski (2001) reported that actuators should be cleaned to 
avoid build up of drug in them. 
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4.1.3 Effect of number of doses
One of the factors which has been tested is the effect of number of doses on 
the total emitted dose. Since it is a common practice to give a patient two
doses and assume that the two doses deliver double the amount of drug 
compared to one dose. But, this may not be the case in practice, if there is 
build up of drug in the delivery unit or a variation in delivery from the inhaler. 
Table 4.4 Effect of number of doses (95% confidence interval) on 
percentage of delivered dose (% nominal dose).
Experiment (n=10) Delivereddose [%] STDEV
Mean
Difference
Qvar 50 µg 1 dose  84.67 5.37 -1.6
-9.8- 6.6Qvar 50 µg 2 doses 86.26 3.82
Qvar 100 µg Easi-Breathe ® 1 dose 101.33 4.83 0.5
-7.8-  8.7Qvar 100 µg  Easi-Breathe ® 2 doses 100.86 8.33
Becloforte 1 dose 101.02 18.95 0.4
-7.8-  8.7Becloforte 2 doses 100.58 11.23
Qvar 50 µg  1 dose aerosol APLUS 54.52 2.8 -6.6
-14.8-1.6Qvar 50 µg  2 doses aerosol APLUS 61.17 8.5
Qvar 1 dose Easi-Breathe®
100 µg APLUS 62.62 10.20
-1.5
-9.7-  6.8a
Qvar 100 µg  aerosol
1 dose optimiser 57.48 4.9 -10.8
-19.0 -2.6Qvar 100 µg  aerosol
2 doses optimiser 68.29 12.34
Beclazone Easi-Breathe®
250 µg  1 dose  optimiser 50.62 13.2 3.1
-5.1-11.3Beclazone Easi-Breathe®
250 µg 2 doses  optimiser 47.51 3.9
Becloforte 1 dose APLUS 29.88 3.86 5.1
-3.1-13.3Becloforte 2 doses  APLUS 24.76 3.61
a) Qvar 50 µg  2 doses aerosol APLUS versus Qvar 1 dose Easi-Breathe®
100 µg APLUS
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
However, as the results in Table 4.4 shows there is no significant difference in 
total emitted dose for the pMDI alone, Becloforte 1 dose and Becloforte 2 
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doses, Qvar 100 µg Easi-Breathe ® 1 dose and Qvar 100 µg Easi-Breathe® 
2 doses and Qvar 50 µg 1 dose and Qvar 50 µg 2 doses. When 2 doses were
required the patient leaflet instructions were followed (see appendix A). .
Furthermore, the effect of the number of actuations has been investigated on 
the delivered dose, using spacers. Four inhalers representing CFC and CFC-
free and two spacers which are prone to static have been examined. There is 
no significant difference between 1 and 2 doses Table 4.4. Also, the data 
showed no significant difference between Qvar 50 µg 2 doses aerosol APLUS 
and Qvar 1 dose Easi-Breathe 100 µg APLUS. 
4.1.4 Effect of spacers on delivered dose 
Tables 4.5 to 4.8 and Figures 4.4 to 4.7 show the summary of performance of 
the spacers with a different brand of beclomethasone. 
All the investigated spacers decrease the delivered dose compared to an 
pMDI alone. There are also strong statistical differences, which are often p <
0.001 and many studies show the same effect. Barry and co-workers (1996)
examined inhalation drug delivery from seven different spacers and found that 
they reduced the total amount of drug delivered from spacers.
Dose emission of  Beclomethasone pMDIs                                                      Chapter4
158
Table 4.5 Average and ±STDEV of delivered dose percentage (% nominal
dose) from different formulations of Qvar® with different spacers. Mean 
difference (95% confidence interval) for delivered dose of pMDI alone 
compared to delivered dose of pMDI+ spacers. (for Qvar alone data see Table 
4.3)
Experiment  (n=10) Delivereddose (%) STDEV Mean difference
Qvar 50 µg  1 dose 
APLUS 47.64 4.18
-37.0***
-46.6- -27.4
Qvar 50 µg  2 doses 
APLUS 50.72 5.16
-35.5***
-45.1- -26.0
Qvar 50 µg  2 doses 
AMAX 76.19 7.81
-10.1*
-19.6 - -.492
Qvar 100 µg  1 dose 
Optimiser ® 51.04 6.64
-50.3***
-59.9 - -40.7
Qvar 100 µg  2 doses 
Optimiser ® 64.12 18.92
-37.2***
-46.8 - -27.6
Qvar 100 µg  1 dose 
Easi-Breathe AMAX 93.98 11.89
-7.4
-16.9- 2.2
Qvar 100 µg  1 dose 
Easi-Breathe Optimizer 86.38 6.69
-15.0**
-24.5- -5.4
Qvar 100 µg  1 dose 
Easi-Breathe APLUS 63.32 11.13
-23.1***
-32.6- -13.5
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.4 Delivered dose (% nominal dose) from Qvar® different 
formulations attached to different spacers. 
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Table 4.6 Average and ±STDEV of delivered dose percentage (% nominal 
dose) from different formulations of Clenil® with different spacers. Mean 
difference (95% confidence interval) for delivered dose of pMDI alone 
compared to delivered dose of pMDI+ spacers. (for Clenil® alone data see 
Table 4.3)
Experiment (n=10) DeliveredDose (%) STDEV
Mean 
difference
Clenil 100 µg 2 doses 
APLUS 24.01 10.07
-73.4***
83.0- -63.8
Clenil 100 µg 2 doses 
AMAX 73.60 10.92
-23.8***
-33.4- -14.2
Clenil 250 µg 1 dose 
APLUS 31.99 3.51
-63.7***
-73.3- -54.1
Clenil 250 µg 1 dose 
AMAX 56.47 7.17
-39.3***
-48.8- -29.7
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.5 Total emitted dose (% nominal dose) from Clenil®, different 
concentration attached to different spacers. 
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Table 4.7 Average and ±STDEV of delivered dose percentage (% nominal 
dose) from different formulations of Beclazone® with different spacers. Mean 
difference (95% confidence interval) for delivered dose of pMDI alone 
compared to delivered dose of pMDI+ spacers. (for Beclazone® alone data 
see Table 4.3)
Experiment  (n=10) DeliveredDose (%) STDEV
Mean 
difference
Beclazone100 µg 2 doses  
APLUS 44.31 9.22
-56.3***
-65.9- -46.7
Beclazone100 µg 2 doses  
AMAX 71.03 6.73
-29.6***
39.15- -20.0
Beclazone Easi-Breathe® 
250 µg 2 doses  Optimizer 39.66 5.46
-53.9***
-63.5- -44.3
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.6 Total emitted dose (% nominal dose) from Beclazone®, different 
formulations attached to different spacers.
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Table 4.8 Average and ±STDEV of delivered dose percentage (% nominal 
dose) from different formulations of Becotide® and Becloforte® with different 
spacers. Mean difference (95% confidence interval) for delivered dose of 
pMDI alone compared to delivered dose of pMDI+ spacers. (for Becotide® and 
Becloforte®  alone data see Table 4.3)
Experiment (n=10) DeliveredDose (%) STDEV
Mean 
difference
Becotide100 µg 2 
doses AMAX 40.95 7.78
-57.1***
-66.7- -47.6
Becotide100 µg 2 
doses optimiser 59.36 6.84
-75.6***
-85.1- -66.0
Becloforte 1 dose 
APLUS 30.10 2.92
-70.9*
-80.5-61.4
Becloforte 2  doses  
APLUS 23.01 4.89
-77.6***
-87.1- -68.0
Becloforte 1 dose  
AMAX 59.49 18.82
-41.5***
-51.1- -32.0
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.7 Total emitted dose (% nominal dose) from Becotide® and 
Becloforte® different formulations attached to different spacers.
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Moreover, Nagel et al reported a reduction in the total delivered dose with 
fluticasone and salmeterol from 102.1 ug and 20 ug for pMDIs alone to 58.4 
ug and 10.8 ug with APLUS respectively (Nagel et al., 2002). Hardy et al 
examined optimizer performance with three Easi-Breath ® Beclazone
formulations. Using the impinger they demonstrated that the spacer removed 
27% - 39% of the total dose. Also, their data showed a mean of 55% of the 
dose was deposited in the spacer, which was assayed using an imaging 
technique (gamma camera, Transmission images with technetium-99m)
(Hardy et al., 1996).    
4.1.5 Effect of type of VHCs and spacer  
Electrostatic charge is created on discharging the aerosol, which can
influence deposition in the spacer. Moreover, different spacers have different
electrostatic properties. Non-electrostatic devices have been recommended 
for young children as these result in increased lung deposition (Devadason, 
2006).
Table 4.9 Effect of type of spacer (95% confidence interval) on 
percentage of delivered dose (%emitted dose) for Becloforte® and Becotide®
Experiment  (n=10) Delivereddose (%) STDEV
Mean difference
Becloforte 1 dose APLUS 29.88 3.86 -31.6***
-39.8 - -23.3Becloforte 1 dose AMAX 61.44 12.65
Becotide100 µg 2 doses 
AMAX 68.05 3.77 26.4***
18.2- 34.6Becotide100 µg 2 doses 
optimiser 41.66 4.46
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
Tables 4.9 to 4.12 and Figures 4.8 to 4.11 summarise the performance of the 
spacers with different formulations of beclomethasone. The data show 
statistically significant differences between spacer performances except in the 
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case of Qvar 100 µg Easi-Breathe ® with AMAX and Optimizer where the 
difference is not statistically significant. The AMAX spacers delivered the 
highest dose of all formulations, while the Optimizer performed better than 
APLUS.
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Figure 4.8 Percentage of delivered emitted dose of Becloforte® and 
Becotide® for different spacer devices.
Table 4.10 The effect of type of spacer (95% confidence interval) on 
percent of delivered dose (% emitted dose) for Qvar®. 
Experiment  (n=10) Delivereddose (%) STDEV
Mean difference
Qvar 50 µg  2 aerosol 
doses APLUS 61.17 8.50 -28.1***
-36.4- -19.9Qvar 50 µg  2 doses 
aerosol AMAX 89.31 4.57
Qvar 100 µg  1 dose 
Easi-Breathe AMAX 87.24 2.68
7.8 -0.4- -16.0a
24.6*** 16.4-32.9b
Qvar 100 µg  1 dose 
Easi-Breathe Optimizer 79.44 3.54
-7.8 -16.0-0.4c
16.8*** 8.6-25.1d
Qvar 100 µg  1 dose 
Easi-Breathe APLUS 62.62 10.20
-24.6*** -32.9- -16.4e
-16.8*** -25.1- -8.6e
a AMAX vs. optimizer, b AMAX vs. APLUS, c optimizer vs. AMAX d optimizer vs. 
APLUS, e APLUS vs. AMAX, f APLUS vs. optimizer. 
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* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.9 Percentage of delivered emitted dose of Qvar® for different 
spacer devices
Table 4.11 Effect of t ype  of spacer (95% confidence interval) on 
percentage of delivered dose (%emitted dose) for Clenil®
Experiment (n=10) DeliveredDose (%) STDEV
Mean
difference
Clenil 100 µg 2 doses APLUS 28.05 8.20 -49.5***
-57.7 -41.3Clenil 100 µg 2 doses AMAX 77.55 2.29
Clenil 250 µg 1 dose APLUS 37.25 5.50 -29.1***
-37.4- -20.9Clenil 250 µg 1 dose AMAX 66.41 3.57
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
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Figure 4.10 Percentage of delivered emitted dose of Clenil® for different 
spacer devices.
Table 4.12 Effect of type of spacer (95% confidence interval) on percentage
of delivered dose (emitted dose) for Beclazone®. 
Experiment (n=10) DeliveredDose (%) STDEV
Mean
difference
Beclazone100 µg 2 
doses  APLUS 52.47 8.63 -15.6***
-23.8- -7.4Beclazone100 µg 2 
doses  AMAX 68.05 3.57
* p<0.05, ** <0.01, ***<0.001, otherwise no significant difference.
It is proposed that the half life of the aerosol available for inhalation is reduced 
by electrostatic activity resulting in a reduction in the delivered dose. 
Furthermore, the aerosol half life is 10s with the plastic spacers, while it is 30s 
if the static charge is abolished (Bisgaard et al., 2002). This agrees with the 
work of Terzano who reported that antistatic spacers deliver a significantly 
higher lung dose than ordinary spacers (Terzano, 2001). In addition, Anhoj 
and co-workers (1999) examined the effect of electrostatic charges in-vivo on 
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the lung dose of salbutamol in children. The plasma level of salbutamol was 
measured before and 5, 10, 15 and 20 min after inhalation of four single 
doses of 100 g salbutamol. Cmax and Cav 5—20 (min) were used as a 
reflection of lung deposition The results show that the dose of salbutamol had 
to be halved when an ordinary plastic spacer was used compared with the 
same spacer after antistatic priming. 
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Figure 4.11 Percentage of delivered emitted dose of Beclazone® for different 
spacer devices.
Geller and co-workers (2006) tested the predicted lung delivery in infants of 
Flovent® CFC-free inhaler (fluticasone propionate) using the AMAX, Pari 
Vortex® (antistatic coating), and OptiChamber® Advantage (no antistatic
treatment) as significantly AMAX delivered more Flovent® than the other two 
chambers. Geller and co-workers (2006) suggested that the results could be 
due to the lower chamber static and better valve design for AMAX. Hardy and 
co-workers (1996) measured the drug amount deposited in an optimizer 
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spacer with Qvar 100 and 50 ug. The result shows that the spacer deposition 
was 27% and 34% for 50 and 100 ug respectively.  Iula and co-workers
(1996) tested the performance of four different spacers coupled with 
Azmacort® (triamcinolone acetonide) and found up to a fivefold differences in 
the amount of drug delivered when using different spacers. Barry and co-
workers (1996) demonstrated large variations in the lung dose delivered from 
different spacers and variations in the performance of spacers to deliver 
different drug.
4.1.6 Drug formulation
The reformulation of inhalers with HFA-based propellants has resulted in 
changes to the aerosol plume formulation characteristics.  
Table 4.13 Effect of drug formulation and concentration on percentage of 
delivered dose (emitted dose) using AMAX  
Formulation n=10) Spacer(%)
Delivered 
dose (%) STDEV
Qvar 50 ug 2 doses 10.69 89.31 4.33
Qvar 100 ug Easi-Breathe 12.76 87.24 2.55
Beclazone100 ug 2 doses 14.42 85.58 3.39
Clenil 100 ug 2 doses 22.45 77.55 2.17
Becotide100 ug 2 doses 31.95 68.05 3.58
Clenil 250 ug 1 dose 33.59 66.41 3.39
Becloforte ug 1dose 38.56 61.44 2.71
Drug formulation and drug concentration per actuation are important factors 
which influence drug delivery to the lung. Table 4.1 lists the excipients and 
alcohol content per actuation for each inhaler used in this study. The tested 
inhalers can be classified in three groups; first Qvar CFC-free containing 
alcohol and HFA; second, Clenil using Modulite® technology and it consists of 
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HFA, alcohol and glycerol. Modulite® technology uses the following variables
to adjust the particle size: the non-volatile components of a solution formula 
(glycerol), the volume of the metered solution, the actuator orifice size and the 
vapour pressure of the propellants. The aim of this formulation is to maintain 
the same particle size of the CFC formulation (Bousquet, 2002). Third is a 
formulation which comprises CFC (Becloforte, Becotide and Beclazone). 
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Figure 4.12 Effect of drug formulation and concentration on percent of 
delivered dose using AMAX.  
Table 4.14 Effect of drug formulation and concentration on percentage of 
delivered dose (emitted dose) using Optimizer spacer.  
Formulation Spacer(%)
Collecting 
tube (%) STDEV
Qvar 100 Easi-Breathe 20.56 79.44 3.54
Qvar 100 2 doses 31.72 68.29 12.34
Qvar 100  1 dose Aerosol 42.52 57.48 4.90
Beclazone Easi-Breathe® 
250 ug 1 dose 49.38 50.62 3.44
Beclazone Easi-Breathe® 
250 ug 2 doses 52.49 47.51 3.86
Becotide 100 ug 2 doses 58.34 41.66 7.13
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Figure 4.13 The effect of drug formulation and concentration on percentage
of delivered dose using optimizer spacer
Table 4.15 The effect of drug formulation and concentration on percent of 
delivered (emitted dose) dose using APLUS
Formulation (n=10) Spacer(%)
Delivered 
dose (%) STDEV
Qvar 100 ug Easi-Breathe 37.38 62.62 10.20
Qvar 50 ug 2 Doses 38.84 61.17 8.50
Qvar 50 ug  1 Dose 45.48 54.52 2.87
Beclazone100 ug 2 Doses 47.53 52.47 8.63
Clenil 250 ug 1 Dose 62.75 37.25 5.50
Becloforte 1 Dose 70.12 29.88 3.86
Clenil 100 ug 2 Doses 71.96 28.05 8.20
Becloforte 2 Doses 75.24 24.76 3.61
Tables 4.13 to 4.18 and Figures 4.12 to 4.14 illustrated the effect of drug 
formulation. The results of AMAX show that the highest delivered dose was 
89.31% with Qvar 50 ug and the lowest was 61.44% with Becloforte. On the 
other hand, the highest drug delivery with the optimizer spacer was 79.44%, 
with a Qvar 100 ug Easi-Breathe®, while the lowest was Becotide 100 ug with 
41.66%. Also, the APLUS results show superiority of Qvar over other 
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formulations where Qvar Easi-Breathe® delivered 62.62%. These differences 
were statistically significant (see Tables 4.16 to 4.18). 
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Figure 4.14 The effect of drug formulation and concentration on percentage
of delivered dose (emitted dose) using APLUS.
Bisgaard and co-workers (2002) reported that the micronised drug particles
are wet and surrounded by propellant which evaporates inside the VHC/ 
spacer. The superiority of Qvar can possibly be explained by its volatile 
content. Because it contains ethanol which easily evaporates and the amount 
of drug available for entrainment will therefore be more.
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CONCLUSION 
The phasing-out of CFC pMDIs has promoted introducing new formulations. 
As a result it is necessary to show that the new formulations do not alter the
quality, efficacy and safety profiles of the inhalers. This process begins by 
demonstrating that the alternative propellant does not adversely affect dosage 
uniformity or pulmonary deposition.
Establishing the performance of new products in these terms is essential to 
demonstrate that new CFC-free pMDIs meet the regulatory requirements. 
It is possible that the new formulations may affect the characteristic of the 
aerosol plume development by several factors which are formulation-
dependent, including propellant type, vapour pressure, type of excipients and 
actuator nozzle size. As a consequence, the interaction of the aerosol 
particles with spacers could result in a change of the drug deposition within 
spacers. There are also many other factors which may affect drug deposition 
within spacers, which are spacer dependent, including electrostatic charge, 
volume and the shape of the spacer, incorporated valves and the materials 
used to build the spacer.
This study results show that experiments with one spacer or drug cannot be 
extrapolated directly to other spacers or drugs, therefore it is necessary to test 
specific drugs and device combinations. The use of a universal spacer 
common to all inhalers, even if the pMDI adapter fits, will lead to arbitrary
dosing. Therefore, it is suggested that the regulatory authorities consider an 
pMDI to be used only with the spacer tested. In addition, the spacer leaflet 
should include the brand names of acceptable pMDIs with which it has been 
tested.
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CHAPTER 5
PERFORMANCE OF SEVERAL BRAND NAMES OF 
BECLOMETHASONE pMDIs WITH DIFFERENT 
SPACERS
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5 PERFORMANCE OF SEVERAL BRAND NAMES OF 
BECLOMETHASONE pMDIs WITH DIFFERENT SPACERS
OBJECTIVES 
The objective of this section of the research program is to compare the in-vitro
aerosol deposition characteristics from different beclomethasone pMDIs with 
three common spacers. Also, to evaluate how these spacers affect the dose 
of beclomethasone delivered to the lungs and the throat deposition. A 
secondary objective is to examine the hypothesis of whether the result of a 
specific spacer with a given drug/ brand name can be extrapolated to other 
pMDIs or brand names for the same drug.   
INTRODUCTION
As indicated earlier considerable formulation changes were needed when 
switching to HFA 134a. The new formulations were in solution rather than a 
micronised suspension as in the CFC pMDI. Also, design changes were 
needed within the HFAs, pMDI canister, valve and actuator. In conjunction 
with these changes, it was essential to evaluate the particle size distribution 
and performance of the new product.
As suggested at the beginning of this thesis, particle size is obviously a crucial 
factor in inhaled drugs, affecting both the lung dose and delivery location and 
therefore clinical efficacy. It has been proposed that the primary factor of drug 
deposition in the lung is its aerodynamic size. It characterises the particle’s 
inertial behaviour and its rate of sedimentation because particles range about 
some average size, they are generally expressed as a mass median 
aerodynamic diameter (MMAD) and sizes of 1 to 5 m are usually considered
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as suitable for pulmonary delivery. Particles at the high end of this range
would deposit centrally in the larger conducting airways whereas fine particles
would reach the pulmonary periphery. In many formulations, the fraction of the 
cloud in this size range is usually expressed as the fine particle dose (FPD),
i.e. the fraction of the label claim < 5 m (Ganderton et al., 2002). 
The phasing-out of CFC pMDIs led to the adoption of different strategies: first 
it is possible to generate clouds close to or having similar particle size and 
drug mass CFC formulations which lead to a seamless transition; second to 
use this opportunity to refine and produce a clinically useful product with 
defined particle size targeting specific lung areas (Bousquet, 2002). 
There are many brands of generic beclomethasone dipropionate pMDIs 
available in the UK. However, there has been controversy as to the in 
equivalence (Barnes et al., 1996).
Although, the local side effects of inhaled corticosteroids are considered minor 
problems. However, while not generally serious, they are clinically important, 
because they may hamper compliance with therapy. They include dysphonia, 
oropharyngeal candidiasis, thirst, cough, tongue hypertrophy and peri-oral 
dermatitis. On the other hand, the cold Freon effect, in which the cold high-
velocity aerosol impacts on the back of the throat, can cause patients to stop 
inhaling prematurely. The use of a spacer may reduce these effects or 
eliminate them. However, the spacer may cause peri-oral dermatitis,
especially when a mask is used (Roland et al., 2004).
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METHODOLOGY  
5.1.1 Instrumentation 
5.1.1.1 Equipment and inhalation device
The equipment used for the aerodynamic study is described in section 2.1
2.6.
The analytical HPLC method is detailed in section 2.6.
5.1.1.2 Instrumentation set-up
The initial work was to prepare the ACI. All its parts and stages were washed 
with acetone and dried. Furthermore, to ensure efficient capture of the
particles collection plates were sprayed with silicone (USP, 2005) and allowed 
to air dry. The ACI stages were then assembled as described in the 
manufacture manual which incorporates an after filter below the final stage to 
capture any fine particles which otherwise would escape from the apparatus. 
Figure 5.1 shows the positioning of the ACI, critical flow controller and 
vacuum pump. The pMDIs/spacer was connected to the mouthpiece adapter. 
Then they were attached to the end of the induction port. The flow control 
valve was adjusted to achieve a steady flow through the system at the 
required rate 28.3L/min (±5%) which was measured by an electronic digital 
flow meter Model (DFM). According to the pharmacopeial method 4L of air 
were drawn through the inhaler for each determination and the absolute 
pressure ratio P3/P2 < 0.5, was confirmed.
The pMDI/spacer was then prepared according to the patient leaflet 
instructions (see appendix A). The mean content of drug per actuation was 
tested at different points between the first and final actuation.
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Groups of a five doses were selected randomly using random schedules for 
studying the aerodynamic size over the entire set of inhalers. Each dose of 
five was separately discharged into the apparatus by opening the valve if the 
device was breath-actuated, otherwise it was done by pressing down on the 
inhaler to release its contents. The time 8.4 sec (±5%) was calculated 
according to equation 4-1. Determinations were made for each pMDI and for 
each pMDI attached to each of the three different spacers (n=5). The spacers 
were Optimizer®, Aerochamber® MAX® (AMAX) and Aerochamber® PLUS®
(APLUS). Table 5.1 summarises the experiments. The apparatus was then 
dismantled carefully to avoid any loss of material. The active ingredient was 
washed from the inner walls and the collection plate of each of the stages of 
the apparatus into an appropriate volume of washing solution (acetonitrile : 
water 70:30 v/v) Table 5.2. 
Table 5.1 List of experiments.
Experiment  (n=5)
Beclazone alone
Beclazone AMAX
Beclazone APLUS
Beclazone Optimizer
Becloforte alone
Becloforte AMAX
Becloforte APLUS
Becloforte Optimizer 
Clenil alone
Clenil AMAX
Clenil APLUS
Clenil Optimizer
Qvar alone
Qvar AMAX
Qvar APLUS
Qvar Optimizer
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The drug under test was extracted from the filter into the washing solution. In 
order to ensure complete extraction the filter was sonicated for three minutes 
in the washing solution. Also, the washing solution from the filter was further 
filtered through a 0.45 μm filter in order to remove any unwanted particles 
which might block the HPLC system. 
Table 5.2 The washing volume of 70% acetonitrile for ACI stages.
Stage Volume of washing (ml)pMDI pMDI with spacers
Spacer - 50
Induction port 50 25
0 10 10
1 25 25
2 25 25
3 25 25
4 25 25
5 10 10
6 10 10
7 10 10
Filter 10 10
The amount of drug was determined by HPLC using the previously validated 
method described in section 2.6. Spacer and each ACI stage content is
reported separately.
5.1.2 Fine particle analysis 
All the aerodynamic calculations were conducted using the Copley software 
(CITDAS version 2). 
5.1.3 Statistical analysis 
The one-way ANOVA with Bonferroni effect test was used to compare the 
aerodynamic particle size characterization of pMDIs and pMDIs with spacer
using SPSS V15.0 (SPSS Inc., Chicago, USA).
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RESULTS AND DISCUSSION
Four inhalers representing CFC and CFC-free, and two spacers which are
prone to static and an anti-static spacer have been examined. Beclazone®
and Becloforte® are CFC pMDIs whereas Clenil® Modulite® and Qvar® are 
CFC-free. In addition, the Optimizer® and APLUS prone to static and AMAX
anti-static spacer for more detail, see section 4.1. Table 3.1 shows stage cut 
size (µm) for ACI for 28.3L/min.
For comparative purposes, the throat deposition percentage was calculated 
as the amount of drug deposited in the induction port expressed as a 
percentage of the product label claim. Also, the FPD was expressed as a 
percentage of the nominal dose. Tables 5.3 to 5.10 and Figures 5.2 to 5.9
summarised the aerodynamic results while the Tables 5.11 to 5.18 and 
Figures 5.10 to 5.17 are comparisons of beclomethasone pMDIs aerodynamic 
characterisations.   
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Figure 5.2 Amount g) of beclomethasone deposited on each stage of the 
ACI from Clenil® alone and with different spacers.
Table 5.4 Cumulative mass percentage under size for Clenil® alone and with 
different spacers.
Stage ALONE AMAX OPTIMIZER APLUS 
Stage 0 [%] 100.00 100.00 100.00 100.00 
Stage 1 [%] 90.83 98.02 89.97 99.51 
Stage 2 [%] 86.02 90.86 85.04 94.75 
Stage 3 [%] 78.29 78.07 75.19 84.22 
Stage 4 [%] 54.75 45.42 50.37 52.41 
Stage 5 [%] 30.72 20.18 26.41 22.05 
Stage 6 [%] 10.25 4.76 6.28 4.71 
Stage 7 [%] 4.73 1.81 2.55 1.78 
Filter [%] 1.99 0.76 1.20 1.22 
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Figure 5.3 Cumulative mass percentage under size for beclomethasone 
deposited on each stage of the ACI from Clenil® alone and with different 
spacers.
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Figure 5.4 Amount (g) of beclomethasone deposited on each stage of the 
ACI from Becloforte® alone and with different spacers.
Table 5.6  Cumulative mass percentage under size for Becloforte® alone and 
with different spacers.
Stage ALONE AMAX OPTIMIZER APLUS 
Stage 0 [%] 100.00 100.00 100.00 100.00 
Stage 1 [%] 83.86 93.72 89.58 94.24 
Stage 2 [%] 61.55 73.10 67.64 76.24 
Stage 3 [%] 41.21 50.18 43.72 54.91 
Stage 4 [%] 9.82 15.50 12.39 15.74 
Stage 5 [%] 0.65 1.60 1.55 2.06 
Stage 6 [%] 0.01 0.09 0.19 0.07 
Stage 7 [%] 0.01 0.03 0.01 0.01 
Filter [%] 0.00 0.00 0.01 0.00 
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Figure 5.5 Cumulative mass percentage under size for beclomethasone 
deposited on each stage of the ACI from Becloforte® alone and with different 
spacers.
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Figure 5.6 Amount (g) of beclomethasone deposited on each stage of the 
ACI from Beclazone® alone and with different spacers.
Table 5.8 Cumulative mass percentage under size for Beclazone® alone and 
with different spacers.
Stage ALONE AMAX OPTIMIZER APLUS 
Stage 0  [%] 100.0 100.0 100.0 100.0
Stage 1  [%] 82.94 91.62 79.76 89.86
Stage 2  [%] 48.92 67.57 55.47 68.63
Stage 3  [%] 33.17 39.67 34.32 44.42
Stage 4  [%] 10.14 7.50 7.32 9.99
Stage 5  [%] 1.72 0.02 0.21 0.20
Stage 6  [%] 0.02 0.02 0.02 0.02
Stage 7  [%] 0.01 0.01 0.01 0.01
Filter  [%] 0.01 0.01 0.01 0.01
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Figure 5.7 Cumulative mass percentage under size for beclomethasone 
deposited on each stage of the ACI from Beclazone® alone and with different 
spacers.
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Figure 5.8  Amount (g) of beclomethasone deposited on each stage of the 
ACI from Qvar® alone and with different spacers.
Table 5.10 Cumulative mass percentage under size for Qvar® alone and with 
different spacers.
Stage ALONE AMAX OPTIMIZER APLUS 
Stage 0  [%] 100.0 100.0 100.0 100.0
Stage 1  [%] 98.92 95.81 99.58 98.67
Stage 2  [%] 98.66 95.62 99.41 98.56
Stage 3  [%] 98.16 93.90 98.81 98.41
Stage 4  [%] 96.41 89.81 97.67 97.87
Stage 5  [%] 84.14 74.42 89.41 92.38
Stage 6  [%] 36.30 33.71 45.15 48.89
Stage 7  [%] 14.18 12.53 17.58 23.57
Filter  [%] 5.55 5.21 6.87 12.59
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Figure 5.9 Cumulative mass percentage under size for beclomethasone 
deposited on each stage of the ACI from Qvar® alone and with different 
spacers.
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Figure 5.10 A comparison of the percentage of beclomethasone deposited on 
each stage of the ACI from the different pMDIs.
Table 5.12 A comparison of cumulative mass percentages under size of 
beclomethasone pMDIs alone deposited on each stage of the ACI.
Stage Clenil Becloforte Beclazone Qvar
Stage 0  [%] 100.00 100.00 100.00 100.00
Stage 1  [%] 90.83 83.86 82.94 98.92
Stage 2  [%] 86.02 61.55 48.92 98.66
Stage 3  [%] 78.29 41.21 33.17 98.16
Stage 4  [%] 54.75 9.82 10.14 96.41
Stage 5  [%] 30.72 0.65 1.72 84.14
Stage 6  [%] 10.25 0.01 0.02 36.30
Stage 7  [%] 4.73 0.01 0.01 14.18
Filter  [%] 1.99 0.00 0.01 5.55
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Figure 5.11 A comparison of cumulative mass percentages under size for 
beclomethasone pMDIs alone deposited on each stage of the ACI.
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Figure 5.12 A comparison of the percentage of beclomethasone deposited on 
each stage of the ACI from the different pMDIs with AMAX.
Table 5.14 A comparison of cumulative mass percentages under size of 
beclomethasone pMDIs with AMAX deposited on each stage of the ACI.
Stage Clenil Becloforte Beclazone Qvar
Stage 0  [%] 100.00 100.00 100.00 100.00
Stage 1  [%] 98.02 93.72 91.62 95.81
Stage 2  [%] 90.86 73.10 67.57 95.62
Stage 3  [%] 78.07 50.18 39.67 93.90
Stage 4  [%] 45.42 15.50 7.50 89.81
Stage 5  [%] 20.18 1.60 0.02 74.42
Stage 6  [%] 4.76 0.09 0.02 33.71
Stage 7  [%] 1.81 0.03 0.01 12.53
Filter  [%] 0.76 0.00 0.01 5.21
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Figure 5.13 A comparison of cumulative mass percentages under size for 
beclomethasone pMDIs with AMAX deposited on each stage of the ACI.
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Figure 5.14 A comparison of the percentage of beclomethasone deposited on 
each stage of the ACI from the pMDIs with Optimizer.
Table 5.16 A comparison of cumulative mass percentages under size of 
beclomethasone pMDIs with Optimizer deposited on each stage of the ACI.
Stage Clenil Becloforte Beclazone Qvar
Stage 0  [%] 100.00 100.00 100.00 100.00
Stage 1  [%] 89.97 89.58 79.76 99.58
Stage 2  [%] 85.04 67.64 55.47 99.41
Stage 3  [%] 75.19 43.72 34.32 98.81
Stage 4  [%] 50.37 12.39 7.32 97.67
Stage 5  [%] 26.41 1.55 0.21 89.41
Stage 6  [%] 6.28 0.19 0.02 45.15
Stage 7  [%] 2.55 0.01 0.01 17.58
Filter  [%] 1.20 0.01 0.01 6.87
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Figure 5.15 A comparison of cumulative mass percentages under size for 
beclomethasone from pMDIs with Optimizer deposited on each stage of the 
ACI.
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Figure 5.16 A comparison of the percentage of beclomethasone deposited on 
each stage of the ACI from the different pMDIs with APLUS.
Table 5.18  A comparison of cumulative mass percentages under size of 
beclomethasone pMDIs with APLUS deposited on each stage of the ACI.
Stage Clenil Becloforte Beclazone Qvar
Stage 0  [%] 100.00 100.00 100.00 100.00
Stage 1  [%] 99.51 94.24 89.86 98.67
Stage 2  [%] 94.75 76.24 68.63 98.56
Stage 3  [%] 84.22 54.91 44.42 98.41
Stage 4  [%] 52.41 15.74 9.99 97.87
Stage 5  [%] 22.05 2.06 0.20 92.38
Stage 6  [%] 4.71 0.07 0.02 48.89
Stage 7  [%] 1.78 0.01 0.01 23.57
Filter  [%] 1.22 0.00 0.01 12.59
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Figure 5.17 A comparison of cumulative mass percentages under size for 
beclomethasone pMDIs with APLUS deposited on each stage of the ACI.
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Table 5.19 and Figure 5.18 show the MMAD results. The largest MMAD was 
Beclazone alone 5.8 µm and the smallest Qvar with APLUS 1.1 µm. There 
were no statistically significant differences between the pMDIs alone and 
pMDIs with spacers apart from Beclazone with APLUS where the difference 
was statistically significant (p < 0.05) Table 5.20. However, the differences 
between brand names were statistically significant (p < 0.001) except in the 
case of Becloforte and Beclazone where the difference was not statistically 
significant Table 5.21. Also, the effect of spacer type was not statistically 
significant Tables 5.22, 5.23, 5.24. 
An important conclusion is that, the results of this study disagree with those 
reported by Barry and co-workers (1996) where they showed that, in most 
cases, a reduction in the size of drug particles delivered, which was 
demonstrated  by the decrease in MMAD of the aerosol from pMDIs with 
spacers. However, Rahmatalla and co-workers (2002) reported no significant 
difference (p < 0.1) in MMAD after cascade impactor measurements at an 
inhalation flow rate of 28.3 L/min with and without a spacer.
Another study, which compared many parameters including MMAD of 
Flovent® CFC delivered via APLUS or Easivent® spacers versus the pMDI 
alone has shown no difference in MMAD (Asmus et al., 2002). Also, Cripps 
and co-workers (2000) examined the effect of Volumatic® and Babyhaler®
spacers on the particle size distributions for the corresponding HFA 134a and 
CFC salbutamol and fluticasone propionate pMDIs and found no significant 
effect on MMAD.
The differences between brand names is influenced by a variety of factors, 
including chemical and physical characteristics of the propellant and the other 
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additives; pressure inside the canister; metering valve and actuator design;
drug concentration; delivered volume and actuator and delivery outlet 
cleanness (Terzano, 2001). Also, the addition of non-volatile co-solvent 
increases the MMAD, e.g.  polyethylene glycol (Ganderton et al., 2002). 
Furthermore, HFAs are delivered at a higher velocity than CFCs, due to a 
higher pressure inside its canister compared to CFCs. For this reason, 
metering valves using HFAs have been redesigned to separate a volume of 
25 l rather than 63 l when CFCs are used. This alteration can be the cause 
of differences in particle size distribution (Terzano, 2001).
Table 5.19 MMAD values (µm) interpolated from size distribution data for 
different brand names of beclomethasone alone and with different spacers.
SPACER ALONE AMAX OPTIMIZER APLUS 
Clenil 250 ug 3.01 3.48 3.25 3.18
Becloforte 250 ug 5.15 4.69 4.97 4.50
Beclazone Easi-Breath 250 ug 5.88 5.08 5.49 4.94
Qvar Esi-Breath 100 ug 1.31 1.43 1.17 1.11
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Figure 5.18 MMAD values (µm) for different brand names of beclomethasone 
alone and with different spacers.
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Table 5.20 Mean difference for MMAD (95% confidence interval) for pMDI 
compared to pMDI+ spacers
APLUS AMAX Optimize
Clenil® -0.15-0.7-0.4
-0.47
-1.0-0.1
-0.30
-0.90-0.31
Becloforte® 0.60.0- 1.2
0.4
-0.3- 1.0
0.2
-0.5- 0.8
Beclazone® 0.7*0.0- 1.4
0.6
0.0- 1.3
0.2
-0.5- 0.8
Qvar® 0.2-0.5- 0.8
-0.1
-0.8- 0.5
0.1
-0.5- 0.8
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.21 Mean difference for MMAD (95% confidence interval) between 
pMDIs alone.
Clenil® Becloforte® Beclazone® Qvar®
Clenil® _ _ _ _ 2.2***1.6- 2.8
2.732***
2.1- 3.3
-1.6***
-2.2- -1.0
Becloforte® -2.2***-2.8- -1.6 _ _ _ _
0.5
-0.1- 1.2
-3.8***
-4.5- -3.2
Beclazone® -2.7***-3.3- -2.1
-0.5
-1.2- 0.1 _ _ _ _
-4.4***
-5.0- -3.7
Qvar® 1.6***1.0- 2.2
3.8***
3.2- 4.5
4.4***
3.7- 5.0 _ _ _ _
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.22 Mean difference for MMAD (95% confidence interval) for pMDI 
+AMAX compared to the pMDI+ other spacers
APLUS Optimize
Clenil® 0.3-0.2- 0.8
0.2
-0.3- 0.8
Becloforte® 0.3-0.3- 0.9
-0.1
-0.7- 0.5
Beclazone® 0.1-0.5- 0.8
-0.4
-1.0- 0.2 
Qvar® 0.3-0.3- 0.9
0.3
-0.4- 0.9
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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Table 5.23 Mean difference for MMAD (95% confidence interval) for pMDI 
+Optimizer® compared to pMDI+ other spacers
AMAX APLUS
Clenil® -0.2-0.8- 0.3
0.1
-0.5- 0.7
Becloforte® 0.1-0.5- 0.7
0.4
-0.2- 1.1
Beclazone® 0.4-0.2- 1.0
0.5
-0.1- 1.2
Qvar® -0.3-0.9- 0.4
0.1
-0.6- 0.7
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.24 Mean difference for MMAD (95% confidence interval) for pMDI 
+APLUS compared to pMDI+ other spacers
AMAX Optimizer
Clenil® -0.3-0.8- 0.2
-0.1
-0.7- 0.5
Becloforte® -0.3-0.9- 0.3
-0.4
-1.1- 0.2
Beclazone® -0.1-0.8- 0.5
-0.5
-1.2- 0.1
Qvar® -0.3-0.9- 0.3
-0.1
-0.7- 0.6
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.25 and Figures 5.19 and 5.20 show the throat deposition results. The 
highest was Becloforte alone 81.68% and the lowest was Qvar with APLUS 0.
33%. The differences between the pMDIs alone and pMDIs with spacers were 
statistically significant (p < 0.001) Table 5.26. Also, there were statistically 
significant differences between the beclomethasone pMDIs (p < 0.001) except 
between Clenil and Beclazone Table 5.27. Furthermore, the highest throat 
depositions for pMDI with spacers were for AMAX with all pMADs except Qvar
Tables 5.25. Table 5.28 to Table 5.30 show the mean differences between 
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spacer types. The differences were statistically significant between AMAX and 
APLUS in case of Clenil and Beclazone and between AMAX and Optimizer in 
case of Becloforte and Beclazone.  These findings are consistent with 
previous studies. The average reduction caused by spacers is 54% with range
from 26% to 74%. The amount of drug deposited in the throat in this study 
was similar to several experiments.  Bisgaard and co-workers (2002) reported 
the deposition with the pMDI alone ranged from 30% to 70% compared with 
5% to 10% with spacers. Rahmtalla and co-workers (2002) examined the 
effect of spacer on the mouth-throat deposition of Qvar and found that adding 
the spacer reduced drug deposition in the throat. Asmus and co-workers
(2002) tested the performance of spacers with a fluticasone pMDI. Their 
results showed a decrease in quantity of drug deposited in the throat so they 
suggested the use of spacers may diminish the risk of topical adverse effects. 
Spacers reduce deposition in the mouth and throat, decreasing cough, and 
also may decrease oral candidiasis when oral inhaled corticosteroids are 
used. Furthermore, their use may decrease the systemic bioavailability and 
the risk of systemic side effects (Rabe et al., 2007). Also, radio-labelling data 
for Qvar showed an up to three time lower dose is deposited in the throat 
when the spacer is used (Bisgaard et al., 2002). In addition, Roland and co-
workers (2004) suggested the spacers use as a part of treatment to prevent 
local side effects recurring through reduction of throat deposition. However,
another study found that the spacer may increase the incidence of cough. 
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Table 5.25 Throat deposition (%) of nominal dose for different brand names of 
beclomethasone alone and with different spacers
ALONE AMAX Optimizer APLUS
Clenil® 67.52 10.10 3.87 3.21
Becloforte® 81.68 13.92 6.32 7.79
Beclazone® 64.96 12.80 3.48 4.34
Qvar® 28.67 2.72 3.61 0.33
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Figure 5.19 Throat deposition (%) of nominal dose for different brand names 
of beclomethasone alone and with different spacers.
T h ro a t d e p o s itio n %  fo r S p a cer
0
2
4
6
8
10
12
14
16
C lenil B ec lo forte B ec laz one Q var
A M A X O P TIM IZE R A P LUS  
Figure 5.20 Throat deposition (%) of nominal dose for different brand names 
of Beclomethasone with different spacers.
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Table 5.26 Mean difference for throat deposition (95% confidence interval) for 
pMDI compared to pMDI+ Spacers
APLUS AMAX Optimize
Clenil® 64.3***58.2- 70.5
57.4***
51.3- 63.6
63.7***
56.5- 70.8
Becloforte® 73.897***66.0- 81.8
67.763***
60.3- 75.2
75.363***
67.4- 83.3
Beclazone® 60.6***52.7- 68.6
52.2***
44.2- 60.1
61.5***
53.5- 69.4
Qvar® 28.3***20.4- 36.3
26.0***
17.8- 34.1
25.1***
16.9- 33.2
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.27 Mean difference for throat deposition (95% confidence interval) 
between pMDIs
Clenil® Becloforte® Beclazone® Qvar®
Clenil® _ _ _ _ 14.2***7.1- 21.3
-2.6
-9.7- 4.6
-38.9**
-46.0- -31.7
Becloforte® -14.2***-21.3- -7.1 _ _ _ _
-16.7***
-24.7- -8.8
-53.0***
-61.0- -45.1
Beclazone® 2.6-4.6- 9.7
16.7***
8.8- 24.7 _ _ _ _
-36.3***
-44.2- -28.4
Qvar® 38.9***31.7- 46.0
53.0***
45.1- 61.0
36.300***
28.4- 44.2 _ _ _ _
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.28 Mean difference for throat deposition (95% confidence interval) for 
pMDI +AMAX  compared to pMDI+ other spacers
APLUS Optimize
Clenil® 6.9*0.6- 13.2
7.0
-0.5- 14.6
Becloforte® 6.5-1.3- 14.3
8.0*
0.2- 15.7
Beclazone® 8.5*0.3- 16.6
9.3*
1.2- 17.5
Qvar® 2.4-5.8- 10.5
-0.9
-9.1- 7.3
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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Table 5.29 Mean difference for throat deposition (95% confidence interval) for 
pMDI +Optimizer®  compared to pMDI+ other spacers
AMAX APLUS
Clenil® -7.0-14.6- 0.5
-0.1
-7.7- 7.4
Becloforte® -8.0*-15.7- -0.2
-1.5
-9.6- 6.7
Beclazone® -9.3*-17.5- -1.2
-0.9
-9.0- 7.3
Qvar® 0.9-7.3- 9.1
3.3
-4.9- 11.4
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.30 Mean difference for throat deposition (95% confidence interval) for 
pMDI +APLUS compared to pMDI+ other spacers
AMAX Optimizer
Clenil® -6.9*-13.2- -0.6
0.1
-7.4- 7.7
Becloforte® -6.5-14.3- 1.3
1.5
-6.7- 9.6
Beclazone® -8.5*-16.6- -0.3
0.9
-7.3- 9.0
Qvar® -2.4-10.5- 5.8
-3.3
-11.4- 4.9
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5-31 and Figure 5-21 illustrates the FPD results. The highest FPD was 
Qvar with AMAX 64% while the lowest FPD was Beclazone alone. In addition,
the effect of spacers, on the FPD with CFC pMDIs; was not statistically 
significant however, in the case of CFC-free pMDIs, the effect of spacers 
depended on spacer type. The effect of APLUS on FPD was statistically 
significant, while the effect of the optimizer was not statistically significant. On 
the other hand, the effect of AMAX was significant only with Clenil (p < 0.001)
Table 5-32. Table 5-33 illustrates the differences among pMDIs. Qvar 
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delivered a statistically significant FPD comparing to other pMDIs. Tables 5.34 
– 5.36 summarise the statistical test result for differences between spacers for 
FPD. Since the spacers produced an FPD not significantly different from that 
of the pMDI alone for CFC pMDI.  It may suggest that any of these spacers 
would be equally effective for pMDI alone with an appropriate inhaler 
technique.
Rahmatalla and co-workers (2002) showed a selective effect for spacers, 
reducing the throat deposition while slightly increasing the lung deposition.
However there was no significant influence on the size distribution of FPD 
after examining the effect of a spacer on Qvar aerodynamic characterisation. 
Also, Leach and co-workers (1998) found no significant differences in lung 
deposition when a spacer was used in-vivo; however, there was a large 
variability in in-vivo results. In addition, Bisgard and co-workers (2002)
reported that the lung dose with intermediate and large volume spacers is 
about double the dose compared to pMDI alone; however, in other studies,
the large and small volume spacers delivered a lung dose similar to pMDI 
alone.
In contrast, Fink and co-workers (1998) compared the effect of several 
spacers on salbutamol pMDI. They found a significant variation in FPD when
compared to pMDI alone. FPD was similar for the Aerochamber®, but there 
was a 33%, 35% and 55% reduction for Optihaler®, Ace®, and Inspirease®,
respectively. Furthermore, another study compared Flovent® CFC delivery 
with APLUS and Optichamber® spacer to pMDI alone in terms of FPD and 
showed equivalent delivery (Asmus et al., 2002). 
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Use of ethanol to reformulate Qvar resulted in a an increase in the FPD which
led to a two-fold reduction in dosage with the Qvar compared with the CFC 
pMDI under certain conditions (Cripps et al., 2000). 
The spacers allow more time for the propellant to evaporate; this promotes 
the formation of small aerosol particles 1-5 µm which are more likely to be 
entrained by inspiration into small human airways (Asmus et al., 2004). In 
addition, the spacer acts as a settling chamber, allowing large particles to 
sediment or impact. Therefore the final size of drug particles depends on the 
time available for evaporation of propellant and distance from the actuator 
orifice (Bisgaard et al., 2002). Faarc and co-workers (2006) studied a 
nonelectrostatic versus a non-conducting spacer using Xopenex®
(Levalbuterol) HFA Inhalation, the FPD difference between AMAX and APLUS 
was statistically significant in their study. Furthermore, Rau and co-workers
(2006) reported that electrostatic charge is more prevalent with HFA 
formulations compared to CFC. Moreover, the half life of the aerosol inside
the spacer is reduced by electrostatic activity of the spacer (Bisgaard et al., 
2002). Terzano (2001) concluded that non-electrostatic spacers delivered a 
significantly higher dose than non-conducting; furthermore, a reduction in 
dose should be considered when CFC-free formulation is used with a spacer. 
Table 5.31 FPD (%) of nominal dose for different brand names of 
beclomethasone alone and with different spacers
ALONE AMAX OPTIMIZER APLUS
Clenil® 25.55 50.13 25.03 42.70
Becloforte® 18.71 26.95 18.84 24.33
Beclazone® 17.08 21.84 18.06 21.57
Qvar® 59.60 64.30 53.97 47.26
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Figure 5.21 FPD (%) of nominal dose for different brand names of 
Beclomethasone alone and with different spacers
Table 5.32 Mean difference for FPD (95% confidence interval) for pMDI alone 
compared to pMDI+ spacers
APLUS AMAX Optimize
Clenil® -17.2***-24.7- -9.6
-24.6***
-32.1- -17.1
0.5
-8.1- 9.2
Becloforte® -5.6-15.3- 4.1
-8.3
-17.3- 0.8
-0.1
-9.8- 9.6
Beclazone® -4.2-13.8- 5.5
-4.4
-14.1- 5.3
-0.6
-10.3- 9.1
Qvar® 12.5***2.8- 22.2
-4.5
-14.2- 5.2
5.4
-4.3- 15.1
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.33 Mean difference for FPD (95% confidence interval) between 
pMDIs
Clenil® Becloforte® Beclazone® Qvar®
Clenil® _ _ _ _ -6.8-15.5- 1.8
-8.1
-16.8- 0.5
34.0***
25.4- 42.7
Becloforte® 6.8-1.8- 15.5 _ _ _ _
-1.3
-11.0- 8.4
40.9***
31.2- 50.6
Beclazone® 8.1-0.5- 16.8
1.3
-8.4- 11.0 _ _ _ _
42.2***
32.5- 51.9
Qvar® -34.0***-42.7 -25.4
-40.9***
-50.6- -31.2
-42.2***
-51.9- -32.5 _ _ _ _
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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Table 5.34 Mean difference for FPD (95% confidence interval) for pMDI + 
AMAX compared to pMDI+ other spacers
APLUS Optimize
Clenil® 7.4-0.1- 14.9
25.1***
16.4- 33.8
Becloforte® 5.4-3.7- 14.4
8.1
-0.9- 17.2
Beclazone® -2.5-12.1- 7.2
3.8
-5.9- 13.5
Qvar® 17.0**7.3- 26.7
9.9*
0.2- 19.6
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.35 Mean difference for FPD (95% confidence interval) for pMDI + 
Optimizer® compared to pMDI+ other spacers
AMAX APLUS
Clenil® -25.1***-33.8- -16.4
-17.7***
-26.3- -9.0
Becloforte® -8.1-17.2- 0.9
-5.5
-15.2- 4.2
Beclazone® -3.8-13.5- 5.9
-3.5
-13.2- 6.2
Qvar® -9.9*-19.6- -0.2
7.1
-2.6- 16.7
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.36 Mean difference for FPD (95% confidence interval) for pMDI + 
APLUS compared to pMDI+ other spacers
AMAX Optimizer
Clenil® -7.4-14.9- 0.1
17.7***
9.0- 26.3
Becloforte® -2.7-11.7- 6.4
5.5
-4.2- 15.2
Beclazone® -0.3-10.0- 9.4
3.5
-6.2- 13.2
Qvar® -17.0**-26.7- -7.3
-7.1
-16.7- 2.6
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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Tables 5.37 and Figure 5.22 demonstrate the FPF results. The FPF is 
calculated by equation 3.1. The highest FPF was Qvar with APLUS and the 
lowest was with Becloforte alone. There were strong statistically significant 
differences between pMDIs alone and pMDIs with spacers (p < 0.001) Table 
5.38. As the spacer retains large particles and passes the small, the equation 
to calculate FPF is 
FPF =  A
R
Where ∑A is delivered dose, R is FPD
Therefore the FPF result with spacer is higher since the delivered dose is 
smaller than pMDI alone.
The differences among the pMDIs alone were statistically significant except 
between Beclazone and Becloforte Table 5.39. There were significant 
differences between APLUS and AMAX in Clenil, Becloforte and Beclazone, 
also between APLUS and Optimizer in Clenil, Becloforte and Beclazone, 
however the differences between the Optimizer and AMAX  were not 
statistically significant; this may be explained by the amount retained in the 
AMAX and Optimizer being smaller because AMAX is non-electrostatic and 
Optimizer is a small volume spacer (50 ml) while the APLUS is a non-
conducting spacer with a volume of 149 ml Tables 5.40 –5.42. 
Table 5.37 FPF for different brand names of beclomethasone alone and with 
different spacers.
ALONE AMAX OPTIMIZER APLUS
Clenil® 25.93 70.50 69.94 82.61
Becloforte® 15.45 42.05 43.28 51.29
Beclazone® 16.06 37.27 37.22 46.52
Qvar® 66.49 90.79 92.25 97.11
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Figure 5.22 FPF for different brand names of Beclomethasone alone and with
different spacers.
Table 5.38 Mean difference for FPF % (95% confidence interval) for pMDI 
alone compared to pMDI+ spacers
APLUS AMAX Optimize
Clenil® -56.7***-62.1- -51.3
-44.6***
-50.0- -39.1
-44.0***
-50.3- -37.8
Becloforte® -35.8***-42.8- -28.9
-26.6***
-33.1- -20.1
-27.8***
-34.8- -20.8
Beclazone® -30.5***-37.5- -23.5
-21.2***
-28.2- -14.2
-21.1***
-28.2- -14.2
Qvar® -30.6***-37.6- -23.6
-24.3***
-31.3- -17.3
-25.8***
-32.8- -18.8
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.39 Mean difference for FPD (95% confidence interval) between 
pMDIs
Clenil® Becloforte® Beclazone® Qvar®
Clenil® _ _ _ _ -10.5**-16.7- -4.2
-9.9**
-16.1- -3.6
40.6***
34.3- 46.8
Becloforte® 10.5**4.2-16.7 _ _ _ _
0.6
-6.4- 7.6
51.0***
44.0- 58.0
Beclazone® 9.9**3.6- 16.1
-0.6
-7.6- 6.4 _ _ _ _
50.4***
43.4- 57.4
Qvar® -40.6***-46.8- -34.3
-51.0***
-58.0- -44.0
-50.4***
-57.4- -43.4 _ _ _ _
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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Table 5.40 Mean difference for FPF (95% confidence interval) for pMDI + 
AMAX compared to pMDI+ other spacers
APLUS Optimize
Clenil® -12.1***-17.5 -6.7
0.6
-5.7- 6.8
Becloforte® -9.2*-15.8 -2.7
-1.2
-7.8- 5.3
Beclazone® -9.2*-16.2- -2.3
0.1
-6.9- 7.0
Qvar® -6.3-13.3- 0.7
-1.5
-8.5- 5.5
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.41  Mean difference for FPF (95% confidence interval) for pMDI +
Optimizer® compared to pMDI+ other spacers
AMAX APLUS
Clenil® -0.6-6.8- 5.7
-12.7***
-18.9- -6.4
Becloforte® 1.2-5.3- 7.8
-8.0*
-15.0- -1.0
Beclazone® -0.1-7.0- 6.9
-9.3*
-16.3- -2.3
Qvar® 1.5-5.5- 8.5
-4.9
-11.8- 2.1
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
Table 5.42 Mean difference for FPF (95% confidence interval) for pMDI + 
APLUS compared to pMDI+ other spacers.
AMAX Optimizer
Clenil® 12.1***6.7- 17.5
12.7***
6.4- 18.9
Becloforte® 9.2*2.7- 15.8
8.0*
1.0- 15.0
Beclazone® 9.3*2.3- 16.2
9.3*
2.3- 16.3
Qvar® 6.3-0.7- 13.3
4.9
-2.1- 11.8
* p<0.05, ** < 0.01, ***<0.001, otherwise no significant difference.
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CONCLUSION 
The MMAD is not affected when a spacer is used with the pMDI when 
compared to its use alone, but there are significant differences between 
pMDIs. In contrast with the pMDI alone, spacers, especially the APLUS, 
markedly reduces throat drug deposition. The reduction takes place because 
spacers have a size-selective function, retaining larger particles on the spacer 
and allowing smaller particles to pass. Therefore, a proportion of the particles
that would have been deposited in the throat is shifted to the spacer itself and 
thereby diminishes the risk of local adverse effects. In addition, compared with 
the pMDI alone, the FPD is generally either increased or unaffected by using 
spacers. Several factors can cause these variable findings, for instance the 
electrostatic charge present in the spacer, as well as the volume. There are 
strong statistically differences between pMDIs alone and pMDIs with spacers 
in FPF which can be explained by the reduction in total delivered dose since 
the spacer retains a part of the emitted dose.
Future works 
A principal limitation of the study is that the ACI is based on sampling the 
aerosol at a constant flow rate and does not reflect patient-specific variables 
such as lung volume, lung function and breathing pattern. Future works 
should include measurement of aerosol deposition under more physiological 
conditions, particularly those likely to be encountered in patients with asthma 
and COPD. Furthermore, a clinical study is needed to confirm if FPD 
differences among these pMDIs translate to significant clinical differences.
Another limitation is that the study results only reflect the performance of 
these spacers with the Beclomethasone pMDI formulations containing CFC 
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and CFC-free propellants. They may not be reflective of performance with 
other brands of the same drug or of different pMDIs. The study results 
suggest that it is inappropriate to use a drug with any device without 
evaluating the interaction between pMDIs and the spacer with which they are 
used.
The study showed a significant reduction in throat drug deposition with the 
pMDI alone, comparing to pMDI with spacer. It would be considerable 
advantage if spacer is tested with DPIs to reduce the throat deposition.
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APPENDICES
APPENDIX A  PATIENT INFORMATION LEAFLETS
How to prepare a new inhaler for use
Before you start using SYMBICORT TURBUHALER for the first time it is important that you 
read the instructions below and follow them carefully.
TURBUHALER is an inhaler from which very small amounts of powder are administered. 
When you breathe in through TURBUHALER the powder is delivered to the lungs. It is 
therefore important that you inhale forcefully and deeply through
the mouthpiece.
SYMBICORT TURBUHALER is very easy to use. If you follow the instructions below, you will 
receive the’ medication. 
Preparation before first use of new inhaler:
Before using your inhaler for the first time you need to prepare the inhaler for use. The 
preparation does not need to be repeated even if your inhaler is not used regularly.
1. Unscrew and lift off the cover. You may hear a rattling sound. This is normal.
2. Hold the inhaler upright with the red grip downwards Fig.1). Turn the red grip as far as it will 
go in one direction and then turn it back as far as it will go in the opposite direction. Perform 
this procedure twice.
Figure 1 Figure 2
B. Using the inhaler
To administer a dose, simply follow the instructions below. Unscrew and lift off the cover. A 
rattling sound may be heard. This is normal.
TURN 
Hold the inhaler upright with the red grip downwards Fig. 1). Do not hold the mouthpiece 
when turning the grip. To load the inhaler with a dose turn the grip as far as it will go in one 
direction and then turn it back again as far as it will go in the opposite direction You will hear a 
‘click’ some time during this procedure. The inhaler is now ready to use. Breathe out. Do not 
breathe out through the mouthpiece.
INHALE
Place the mouthpiece gently between your teeth. Close your lips and breathe in forcefully and 
deeply through your mouth Fig. 2). You may not taste or feel any medication when inhaling. 
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This is common. Do not chew or bite on the mouthpiece.
Remove the inhaler from your mouth before breathing out again.
If more than one dose has been prescribed, repeat the steps above.
Replace the cover.
If you accidentally drop, shake or breathe out into SYMBICORT TURBUHALER after it is 
loaded, you will lose your dose. If this happens, you should load a new dose and inhale it.
Note: Never breathe out through the mouthpiece. Always replace the cover properly after use. 
Do not try to remove the mouthpiece or to twist it unnecessarily; it is fixed to the inhaler and 
must not be taken off. As the amount of powder dispensed is very small, you may not be able 
to taste or feel it after inhalation. However, you can still be confident that the dose has been 
inhaled if you have followed the instructions.
Stopping SYMBICORT TURBUHALER
Talk to your doctor about how to gradually stop your medication if necessary. It is important 
that you do not suddenly stop taking SYMBICORT TURBUHALER as it may cause unwanted 
side effects.
Cleaning: Clean the outside of the mouthpiece once a week with a dry tissue. Never use 
water or any other fluid when cleaning the mouthpiece. If fluid enters the inhaler it may not 
work properly.
When to start a new inhaler: SYMBICORT TURBUHALER has a dose indicator. The dose 
indicator tells you how many doses are left in the inhaler. The dose indicator moves slowly 
each time you load a dose. Every 20th dose is marked with a number and every 10th dose is 
marked with a dash. When the "0" on the red background has reached the middle of the 
window you should discard your inhaler. The sound you hear when you shake the inhaler is 
produced by a drying agent, not the medication. SYMBICORT TURBUHALER cannot be re-
filled with drug and should be discarded.
Dose indicator shows that it is
time to start a new inhaler
Symbicort patient information leaflet
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Instructions for use:
It is important that you know how to use your inhaler properly. Your doctor, nurse or 
pharmacist will show you how to use your inhaler correctly and will check regularly that you 
are using your inhaler correctly. You must follow their instructions carefully, so that you know 
how, when and how many puffs to inhale and how often you must use your inhaler. The 
instructions should be on the pharmacist’s label and are given in this leaflet. If you are not 
sure what to do or have problems inhaling then ask your doctor, nurse or pharmacist for 
advice.
To remove the mouthpiece cover, hold between the thumb and forefinger, squeeze gently and 
pull apart as shown. Check inside and outside to make sure that the mouthpiece is clean, and 
that there are no foreign objects. Testing Your Inhaler: If the inhaler is new or if it has not 
been used for three days or more, one puff should be released into the air to make sure that it 
works.
Hold the inhaler upright as shown, with your thumb on the base, below the mouthpiece.
Breathe out as far as is comfortable, place the mouthpiece in your mouth between your teeth 
and close your lips around it but do not bite it.
Just after starting to breathe in through your mouth press down on the top of the inhaler to 
release a puff while still breathing in steadily and deeply.
Hold your breath; take the inhaler from your mouth and your finger from the top of the inhaler. 
Continue holding your breath for a few seconds or as long as is comfortable. Breathe out 
slowly.
If you are to take another puff, keep the inhaler upright and wait about half a minute before 
repeating steps 2 to 5.
After use always replace the mouthpiece cover to keep out dust and fluff. Replace firmly and 
snap into position.
Important: Do not rush steps 2, 3, 4 and 5.
Cleaning:
It is important to clean your inhaler at least once a week, to stop it blocking up.
Pull the metal canister out of the plastic case of the inhaler and remove the mouthpiece cover.
Rinse the plastic case and the mouthpiece cover in warm water. If you use a mild liquid 
detergent, rinse carefully with clean water before drying. Do not put the metal canister into 
water.
Leave to dry thoroughly in a warm place. Avoid excessive heat.
Replace the canister and mouthpiece cover.
It is important that you also read the Package leaflet which is supplied with your Volumatic 
spacer device and that you follow the instructions on how to use the Volumatic and on how to 
clean it, carefully.
Clenil Patient Information Leaflet 
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PATIENT'S INSTRUCTIONS
It is important that you read these instructions before using QVAR.
Correct and regular use of the inhaler will prevent or lessen the severity of asthma attacks.
Remove the plastic cap see Figure 1) and be sure there are no foreign objects in the 
mouthpiece.
Figure 1
As with all aerosol medications, it is recommended to prime the QVAR inhaler before using 
for the very first time after purchase, and in cases where the inhaler has not been used for 
more than ten days. Prime by releasing two actuations into the air, away from your eyes and 
face. Be sure the canister is firmly seated in the plastic mouthpiece adapter before each use.
BREATHE OUT AS FULLY AS YOU COMFORTABLY CAN. Hold the inhaler as shown in 
Figure 2. Close your lips around the mouthpiece, keeping your tongue below it.
Figure 2
WHILE BREATHING IN DEEPLY AND SLOWLY, PRESS DOWN ON THE CAN WITH YOUR 
FINGER. When you have finished breathing in, hold your breath as long as you comfortably 
can i.e., 5 – 10 seconds).
TAKE YOUR FINGER OFF THE CAN and remove the inhaler from your mouth. Breathe out 
gently.
IF YOUR PHYSICIAN HAS TOLD YOU TO TAKE MORE THAN ONE INHALATION PER 
TREATMENT REPEAT STEPS 3 THROUGH 5.
You should rinse your mouth with water after treatment.
For normal hygiene, the mouthpiece of your inhaler should be cleaned weekly with a clean, 
dry tissue or cloth. DO NOT WASH OR PUT ANY PART OF YOUR INHALER IN WATER.
Qvar aerosol Patient Information Leaflet 
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How to use your Beclazone Easi-Breathe Inhaler
Beclazone Easi-Breathe inhaler is designed to make it easier for you to take your medicine. It 
is a breath-actuated inhaler. This means that it only releases a actuation when you breathe in.
IMPORTANT:
Before you use your Inhaler, please read this leaflet carefully and follow the instructions,
TESTING YOUR INHALER
Test spray your inhaler before you use it for the first time and also if you have not used it for a 
week or more. Unscrew the top of your inhaler so that you can see the metal canister inside 
Open the cap, shake the Inhaler and spray the aerosol by pressing the canister with your 
finger or thumb, Close the cap and replace the top. Your inhaler is now ready for use.
This pack also contains a spacer called the Optimizer which can be used with your Beclazone 
Easi-Breathe inhaler,
Your doctor or pharmacist may have already advised you to use the Optimiser with your 
Inhaler. If you have been advised to use the Optimiser follow the instructions in ‘How to use 
your inhaler with the Optimiser’ B). If not, follow instructions A).
A) How to use your inhaler without the Optimiser
Shake the inhaler vigorously.
Hold the Inhaler uptight and open It by folding down the cap which fits over the mouthpiece.
Breathe out normally as Far as you comfortably can and then.
Place the mouthpiece in your mouth between your teeth and close your lips firmly around 
It, but do not bite it. Make sure that your hand is not blocking the airholes.
Breathe in slowly and deeply through mouthpiece. Don’t stop breathing when the inhaler 
actuates the dose into your mouth. Carry on until you have taken a deep breath.
Take the inhaler out of your mouth and hold your breath for 10 seconds or as Long as is 
comfortable. Then breathe out slowly.
After you have used your inhaler, hold it upright and close the cap immediately.
If you need to take a second actuation, it is important to re-prime your inhaler by closing the 
cap and waiting about one minute before starting again from step 1. If your inhaler is not re-
primed you will not receive a second actuation.
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B) How to use your inhaler with the Optimiser
Shake the inhaler vigorously.
Hold the inhaler upright and open it by folding down the cap which fits Over the mouthpiece.
Slot the Optimiser firmly onto the mouthpiece of the inhaler.
Breathe out normally as far as you comfortably can and then.
Place the mouthpiece of the Optimizer in your mouth between your teeth and close your lips 
firmly around it, but do not bite it. Make sure that your hand Is not blocking the airholes.
Breathe in slowly  and deeply through the Optimiser. Do not stop breathing when the inhaler 
actuates the dose into your mouth. Carry on until you have taken a deep breath.
Take the Optimiser out of your mouth and hold your breath for 10 seconds or as long as Is 
comfortable. Then breathe out slowly,
After you have used your inhaler, hold it upright, remove the Optimiser and close the cap 
immediately.
If you need to take a second actuation, It is important to re-prime your inhaler by closing the 
cap and waiting about one minute before starting again from step ‘1. if  your inhaler is not re-
primed you will not receive a second actuation.
You must keep your Inhaler clean, especially In the mouthpiece. This will prevent deposits 
from the aerosol building up. Wash your inhaler once a week.
in the unlikely event that your Inhaler does not work property, unscrew the top, open the cap 
and press the canister down, If your inhaler does not spray, It may be empty and should be 
replaced. If it sprays successfully, screw the top back on, close the cap and use as above.
Cleaning
Before cleaning make sure the cap is closed.
Unscrew the top of your inhaler. Keep this top dry at all times
Remove the metal canister Do not put this metal canister In water
Open the cap, rinse the inhaler body in warm water and dry it.
Put the canister back In. your inhaler, screw the top back on   and close the cap.
Do not wash the top part of the inhaler. 
Do not use any heat to dry the inhaler body.
Beclazone Easi-Breathe Patient Information Leaflet
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HOW TO USE YOUR INHALER
1) To remove the SNAP-ON mouthpiece cover from the 
inhaler, hold between the thumb and finger,. squeeze gently 
and pull apart as shown.  check inside and outside to make 
sure that the mouthpiece is clean and that there ,are no 
foreign objects.
TESTING YQUR INHALER.
If your ‘inhaler is new or if it has not been used for a week or more, shake it well and release 
one puff into the air to make sure that it works.
2) Shake the inhaler 
before use.
3) Hold the inhaler upright as 
shown above will, your thumb on 
the base, below the mouthpiece, 
Breathe out as far as is 
comfortable and then…..
4) Place the mouthpiece in 
your mouth between
your teeth arid close your 
lips around it but do not 
bite it,
5) Just after starting to breathe in through 
your mouth press down on the top of the 
inhaler to release a puff while still breathing 
in steadily and deeply.
6) Hold your breath, take the inhaler from 
your mouth and your finger from the top of 
the inhaler. Continue holding your
breath for a few seconds or as long as is 
comfortable
7) If you  are going to take another puff keep the inhaler upright and wait for about half a 
minute before repeating steps 2 to 6.
8) After use always replace the mouthpiece cover to keep out dust and fluff
REPLACE FIRMLY AND SNAP INTO POSITION. 
IMPORTANT
Do not rush stages 3,4 and 5.
It is important that you start to breathe in as slowly as possible ,just before operating your 
inhaler. Practise in front of a mirror for the first few times. If you see mist coming from top of 
inhaler or the sides of your mouth you should start again from stage 2.
Some people find it difficult to release a puff of medicine just after they start to breathe in. The 
Volumatic large-volume spacer device helps to overcome this problem your doctor or 
pharmacist will be able to 
advise you about this.
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People with weak hands may find it easier to hold the inhaler with both hands as shown. Put 
the two forefingers on top of the inhaler and both thumbs on the bottom below the 
mouthpiece.If this does not help, a special device called a HalersidTM., may make it easier 
your doctor, nurse or pharmacist will he able to advise you.)
If you have been given different instructions for using your inhaler, please fallow them 
carefully Tell your doctor, nurse or pharmacist If you, have my difficulties.
CLEANING
Your inhaler should lie cleaned at least once a week
I. Pull the metal canister out of the plastic case of the inhaler and remove the mouthpiece 
cover.
2. Rinse the plastic case and the mouthpiece cover in warm water. A mild detergent or a 
solution of the type used to clean babies feeding bottles may he added in the water your 
pharmacist will advise you). Then rinse thoroughly with clean water before drying. Do not put 
the metal canister into water
3. Leave to dry in a warns place Avoid excessive heat
4. Replace the canister and mouthpiece cover.
Becloforte and Becotide Patient Information Leaflet
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Appendix A                                                             Patient Information Leaflets
247
Aerochamber PLUS package leaflet: patient instructions for use.
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APPENDIX B ASTHMA TABLES
classifying severity in children who are not currently taking long-term control medication.
Classification of Asthma Severity Children 0-4 Years of Age)
Persistent
Components of Severity Intermittent Mild Moderate Severe
Impairment
Symptoms ≤2 days/week >2 days/ week but not daily Daily Throughout day
Night-time  awakenings 0 1-2x/month 3-4x/month > Ix/week
SABA use for symptom control 
not prevention  of EIB)
≤2 days/week >2 days’ week but not daily Daily Several times per day
Interference with normal activity None Minor limitation Some limitation Extremely limited
Risk Exacerbations requiring oral systemic corticosteroids
0-1 year ≥ 2 exacerbation in 6 months requiring oral corticosteroids or ≥ 4 wheezing 
episodes in 1 year lasting > 1day AND risk factors for persistent asthma
Consider severity and interval since last exacerbation.
Frequency and severity may fluctuate over time.
Exacerbations of any severity may occur in any patients in any severity category.
Level of severity is determined by both impairment and risk. Assess impairment domain by caregiver recall of previous 2-4 weeks. Assign severity 
to most severe category in which any feature occurs.
At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. For treatment purposes. 
patients who had ≥ 2 exacerbations requiring oral corticosteroids in the past 6 months, or ≥4 wheezing episodes in the past year. and who have
risk factors for persistent asthma may be considered the same as patients who have persistent asthma, even in the absence of impairment levels 
consistent with Persistent asthma.
Classifying severity in patients after asthma becomes well controlled, by lowest level of treatment required to maintain control.
ElB. exercise-induced bronchospam
SABA. short-acting inhaled β2-agonist
Classification of Asthma Severity
Persistent
Intermittent Moderate Mild Severe
Step 1 Step 2 Step 3 or 4 Step 5 
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Classifying severity in children who are not currently taking long-term control medication.
Classification of Asthma Severity Children 5-11 Years of Age)
Persistent
Components of Severity Intermittent Mild Moderate Severe
Impairment
Symptoms ≤2 days/week >2 days/ week but not daily Daily Throughout day
Night-time  awakenings ≤2x/month 3-4x/month >1 x/week but not 
nightly 
Often 7x/week
SABA use for symptom control 
not prevention  of EIB)
≤2 days/week >2 days’ week but not daily Daily Several times per day
Interference with normal activity None Minor limitation Some limitation Extremely limited
Lung function Normal FEV1
Between exacerbations
FEV1 >80% predicted
FEV1/FVC >85%
FEV1 >80% predicted
FEV1 /FVC >80%
FEV1 = 60%-80%
Predicted
FEV1 /FVC
75%-80%
FEV1 <60% predicted
FEV1 /FVC <75%
Risk Exacerbations requiring oral systemic corticosteroids
0-1 year ≥ 2 see note 
Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over 
time. Exacerbations of any severity may occur in any patients in any severity category.
Relative annual risk of exacerbations may be related to FEV1.
Level of severity is determined by both impairment and risk. Assess impairment domain by patient/caregivers recall of the previous 2-4 weeks and 
spirometry. Assign severity to the most severe category in which any feature occurs.
At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent 
and intense exacerbations e.g.. requiring urgent, unscheduled care, hospitalisation. or ICU admission indicate greater underlying disease severity. 
For treatment purposes. patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as 
patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma. 
Classifying severity in patients after asthma becomes well controlled, by lowest level of treatment required to maintain control.
EIB. exercise-induced bronchospasin; FEV1, 
forced expiratory volume in 1second: FVC. forced 
vital capacity ICU. intensive care unit. SABA. 
short-acting β2 agonist. 
Classification of Asthma Severity
Persistent
Intermittent Moderate Mild Severe
Step 1 Step 2 Step 3 or 4 Step 5 
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Classifying severity in children who are not currently taking long-term control medication.
Classification of Asthma Severity Children ≥ 12 Years of Age)
Persistent
Components of Severity Intermittent Mild Moderate Severe
Impairment
Symptoms ≤2 days/week >2 days/ week but not daily Daily Throughout day
Night-time  awakenings ≤2x/month 3-4x/month >1 x/week but not 
nightly 
Often 7x/week
SABA use for symptom control 
not prevention  of EIB)
≤2 days/week >2 days’ week but not > 
1x/day
Daily Several times per day
Interference with normal activity None Minor limitation Some limitation Extremely limited
Lung function Normal FEV1
between exacerbations
FEV1 >80% predicted
FEV1/FVC normal
FEV1 ≥80% predicted
FEV1 /FVC > normal 
FEV1 > 60% < 
80% predicted
FEV1 /FVC
reduced 5%
FEV1 <60% predicted
FEV1 /FVC  reduced 
> 5
Risk Exacerbations requiring oral systemic corticosteroids
0-1 year ≥ 2 see note 
Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over 
time. Exacerbations of any severity may occur in any patients in any severity category.
Relative annual risk of exacerbations may be related to FEV1.
Level of severity is determined by both impairment and risk. Assess impairment domain by patient/caregivers recall of the previous 2-4 weeks and 
spirometry. Assign severity to the most severe category in which any feature occurs.
At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma severity. In general, more frequent 
and intense exacerbations e.g.. requiring urgent, unscheduled care, hospitalisation. or ICU admission indicate greater underlying disease severity. 
For treatment purposes. patients who had ≥2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as 
patients who have persistent asthma, even in the absence of impairment levels consistent with persistent asthma. 
Classifying severity in patients after asthma becomes well controlled, by lowest level of treatment required to maintain control.
EIB. exercise-induced bronchospasin; FEV1, 
forced expiratory volume in 1second: FVC. forced 
vital capacity ICU. intensive care unit. SABA. 
short-acting β2 agonist. 
Classification of Asthma Severity
Persistent
Intermittent Moderate Mild Severe
Step 1 Step 2 Step 3 or 4 Step 5 
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Summary of stepwise management in adults  British Guideline on the Management 
of Asthma)
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Summary of stepwise management in children aged 5-12 years   British Guideline on 
the Management of Asthma)
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Summary of stepwise management in children aged less than 5years  British 
Guideline on the Management of Asthma)
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High performance liquid chromatography assay method for simultaneous quantitation of formoterol and the two epimers of 
budesonide
M. Almeziny and B. Clark
School of Pharmacy, Bradford, BD7 1DP, UK. E-mail: M.A.Almeziny@bradford.ac.uk
Objective The aim of this study was to develop a sensitive and a simultaneous HPLC method for the analysis of formoterol and the two epimers 
of budesonide hence it is required by European pharmacopoeia to keep a fixed ratio between the
two epimers.
Method This method used a Capital ODS2 Spherisorb 5 micrometer 250 mm 4.6 mm i.d. with a mobile phase consisting of acetonitrile phosphate 
buffer (pH 3.0; 7.5 mM) (40:60, v:v) and a flow rate of 1.0 mL/min; two wave lengths were used to analyse the pharmaceutical preparations, the 
first wave length was 214 nm for formoterol and the second was 240 nm for budesonide.
Result Validation studies demonstrated that the method possessed a linear UV response, high system precision and accuracy, high sensitivity and 
specificity for formatrol and two epimers of budesonide. The limit of detection (LOD) and the limit of quantitation (LOQ) for formoterol assay 
method were 5.401 mcg/L and 18.003 mcg/L respectively. In addition, the LOD and LOQ for budesonide A assay method were 134.525mcg/L 
and 448.416mcg/L, respectively. Finally, The LOD and LOQ for Budesonide B assay method were 62.27mcg/L and 207.566mcg/L, respectively.
Conclusion An isocratic liquid chromatographic method has been described, optimised and validated for simultaneous qualitative and quantitative 
determination of formoterol fumarate and budesonide epimers. Acceptable assay precision and accuracy and excellent linearity was achieved. In 
addition to its high sensitivity and robustness, the proposed HPLC method proved reliable determination of the budesonide and formoterol 
delivered from the Symbicort Turbuhaler. As result this method can substitute the two separate methods, and the single method for budesonide 
and formoterol since it can determine both budesonide epimers. For that reason, this method will save both cost and time.
